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Summary 
Arousal disturbances are common and disabling complaints among patients with 
various neurological disorders. The term arousal disturbances refers to a group of symptoms 
with quantitative reduction or qualitative alteration of normal wakefulness, encompassing, 
among others, hypersomnia, excessive daytime sleepiness and fatigue. Hypersomnia means 
increased sleep need per 24 hours, often but not necessarily accompanied by daytime 
sleepiness. Excessive daytime sleepiness despite adequate nighttime sleep implies 
increased sleep pressure due to impairment of the normal arousal system in the brain. 
Fatigue, eventually, represents an ill-defined, subjective experience characterized by a loss 
of energy, rapid exhaustion and physical and/or mental tiredness. The collection of papers 
included in this habilitation treatise (I) illustrates the challenges in the clinical and diagnostic 
assessment of arousal disturbances, (II) discusses recent neuropathological contributions, 
and (III) presents different therapeutic approaches. 
 
1. Diagnostic approach to a frequent and disabling clinical problem 
Despite the increased awareness of the high prevalence and clinical relevance of 
arousal disturbances in neurological disorders, clinicians still struggle with many diagnostic 
difficulties. First, objective measurement of arousal disturbances is often challenging. This is 
particularly true in the case of fatigue, which is a subjective experience that currently can be 
assessed only in a semi-quantitative manner by questionnaires. Second, different arousal 
disturbances may coexist in the same patient, making it difficult for the treating physicians to 
differentiate them. Third, clinicians need a high degree of suspicion to diagnose arousal 
disturbances, because patients may not be aware of and thus not report them. Indeed, the 
regular use of objective tools such as the mean sleep latency test (MSLT) or actigraphy have 
revealed a considerable discrepancy between subjective and objective measures of arousal 
disturbances. Finally, different neurological disorders may produce similar results in sleep lab 
examinations (e.g. similar mean sleep latency in the MSLT), making the definition of 
additional features for differentiation necessary. 
In the first part, we present four papers exemplifying the above-mentioned diagnostic 
difficulties. In the first paper, we translated and validated the Fatigue Severity Scale (FSS) in 
a large sample (n = 1306) and for different neurological disorders, thereby providing a 
reliable, valid and very useful tool for detecting and monitoring fatigue, both for clinical and 
research purposes.1 In the second paper, we demonstrated in patients with idiopathic 
Parkinson’s disease that fatigue and excessive daytime sleepiness are often overlapping yet 
in many aspects distinct arousal disturbances, as suggested by disparities of their correlation 
to severity of motor symptoms, disease duration, depression, and dopaminergic treatment.2 
In the third paper, we assessed sleep need following traumatic brain injury (TBI) and 
compared subjective estimates with actigraphic measures, thereby identifying a significant 
underestimation of effective sleep need by TBI patients.3 In addition, we found that the 
combination of hypersomnia and underestimation of posttraumatic sleep-wake disturbances 
may increase the risk of secondary sleep deprivation with excessive daytime sleepiness. 
Eventually, in the fourth paper, we compared two patient groups with EDS – patients with 
narcolepsy with cataplexy and patients with behaviourally induced insufficient sleep 
syndrome (BIISS) – and showed that analyzing the specific sequence of sleep stages in the 
MSLT may help differentiating these two conditions.4 Specifically, we found that the sleep 
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stage sequence non rapid eye movement sleep (NREM)1 – REM – NREM2 may serve as 
additional diagnostic parameter for narcolepsy, while the sequence NREM1 – NREM2 – 
REM was more common in BIISS patients. 
 
2. A neuropathological perspective 
Narcolepsy is a neurological disorder characterized by severe sleepiness, cataplexy, 
sleep paralysis, hypnagogic hallucinations and fragmented night-time sleep. The study of 
narcolepsy has proved crucial for our understanding of arousal disturbances in other 
neurological disturbances and continues to promote substantial advances in the field. 
Narcolepsy is caused by an extensive loss of the hypothalamic neurons producing the 
hypocretin (also called orexin) neuropeptides. Subsequently, several groups examined the 
integrity of these neurons in different neurological disorders commonly associated with 
chronic daytime sleepiness, and found partial hypocretin cell loss in postmortem brains of 
patients with idiopathic Parkinson’s disease, Alzheimer’s disease and Huntington’s disease. 
Arousal disturbances are also very common among TBI survivors, but whether head trauma 
causes hypocretin cell loss or not was uncertain at that moment. On the other hand, we do 
not really know whether extensive hypocretin deficiency is solely responsible for all 
symptoms in narcolepsy with cataplexy. 
Thus, in the first paper of the second part of this habilitation treatise we examined 
brains of deceased TBI patients and compared the number of various hypothalamic neurons, 
including cells producing hypocretin and melanin-concentrating hormone (MCH), between 
TBI patients and non-neurological control brains. Our pilot study indicated a significant injury 
to the hypothalamus, as indicated by reactive gliosis throughout the hypothalamus and loss 
of several neuronal systems, including cells producing hypocretin and MCH.5 Trauma-
induced decrease of hypocretin signaling may thus contribute to the frequently observed 
posttraumatic arousal disturbances. In the second paper, we investigated a potential 
involvement of the histamine system in the neurobiology of narcolepsy.6 Histamine neurons 
play an important role in promoting and maintaining wakefulness, are located in the 
tuberomammillary nucleus in the posterior hypothalamus, and receive intense excitatory 
input from hypocretin neurons. Comparing 7 narcolepsy and 12 control brains, we found a 
striking 94% increase of histamine neurons in narcolepsy patients, and the gain in histamine 
neurons was higher in those narcolepsy patients who had the greatest loss of hypocretin 
neurons. We speculate this increment may reflect an effort to compensate for the reduction 
of excitatory hypocretin signaling. 
 
3. Therapeutic challenge 
In the last part of this habilitation treatise, we discuss different treatment strategies for 
arousal disturbances in neurological disorders. Considering the heterogeneous 
pathophysiology of arousal disturbances, opportunities of effective therapy may emerge from 
distinct approaches. Certainly the best way would be to prevent the disease, which is 
producing the arousal disturbance. We discuss this possibility in the first paper concerning 
the effect of intravenous immunoglobulins (IVIg) in patients with narcolepsy with cataplexy.7 
Since current understanding suggests that narcolepsy represents an autoimmune disease, 
two groups recently treated narcolepsy patients with IVIg and reported a sustained effect on 
both cataplexy and sleepiness. However, we did not obtain a persistent improvement of 
narcoleptic symptoms, although temporary (placebo?) effects could be observed. Other 
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researchers similarly failed to observe any sustained effect of immunosuppressive treatment 
in narcolepsy. The next two papers demonstrate that arousal disturbances can either be 
treated by improving the quality of nocturnal sleep by using hypnotics such as sodium 
oxybate,8 or by reinforcing the activity of certain components of the ascending arousal 
system, e.g. with stimulants such as modafinil.9 Finally, arousal disturbances may emerge 
not only as a direct consequence of impaired wake-promoting brain circuitries, but also by 
comorbidities that are associated with the underlying neurological disorder. In this line, in the 
last paper we discuss the relationship between sleep-disordered breathing and fatigue in 
patients with multiple sclerosis and whether treatment by continuous positive airway pressure 
(CPAP) significantly reduces fatigue severity.10 
 
Significance of the results 
 The importance of arousal disturbances in neurological disorders is represented by 
the unfavorable discrepancy between the high prevalence and arduous impact on quality of 
life on one hand, and the currently still marginal insights into the underlying neurobiology and 
our limited treatment options on the other hand. The first part is dedicated to the clinical and 
diagnostic assessment of arousal disturbances. The validation of the Fatigue Severity Scale 
in a large sample size provides a reliable and useful tool for fatigue management, and an 
ideal addition to the German version of the Epworth Sleepiness Scale, which has also been 
validated in Zurich (by K. Bloch and colleagues). Additional studies exemplified different and 
highly characteristic challenges in the diagnosis of arousal disturbances, including overlap of 
distinct symptoms, discrepancy between subjective and objective measures, and 
differentiation of neurological disorders producing identical arousal disturbances. The two 
papers presented in the second part provide a significant contribution to the neurobiological 
understanding of arousal disturbances. Massive increase of histamine neurons in narcolepsy 
suggests the capability of the adult human brain to compensate for loss of a specific 
neuronal population. Finally, the four papers of the third part indicate multiple approaches to 
improve arousal disturbances. Our single-center study on modafinil in TBI patients provides 
Class I evidence that modafinil is significantly superior compared to placebo in treating 
posttraumatic EDS but not fatigue. Nevertheless, our findings emphasize at the same time 
the necessity of further basic research to produce new and targeted treatment, which is 
based on neurobiological evidence. Combining clinical perspective and basic neuroscience, 
the results of the studies are of considerable relevance for both practicing neurologists and 
fundamental researchers. 
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1. Introduction 
Wakefulness continuously alternates with sleep. While these two behavioral states 
may be regarded as mutually exclusive, they are at the same time closely interconnected 
and affect each other in a reciprocal way. Yet even after normal amount of consolidated 
sleep, any healthy individual experiences fluctuations in her or his wakefulness, 
encompassing moments when she or he enjoys full alertness, feels fatigued after sustained 
effort or struggles with drowsiness and increasing sleepiness. In other words, there is a 
continuous fluctuation among different states of vigilance, and in this cycle, periods of 
decreased arousal states can be regarded as physiological.    
We take for granted the ability to be fully awake for about two-thirds of a 24-hour day. 
However, clinical practice conspicuously illustrates that impairment of normal wakefulness 
occurs in many disorders of the brain. In this context, decreased arousal states in the 
absence of sleep deprivation become pathological symptoms, as they are persistent, 
disabling and significantly impair quality of life. 
Over the last two decades, neurologists have increasingly recognized the high 
prevalence, medicolegal consequences and considerable burden of arousal disturbances in 
neurological disorders. Despite this advanced awareness, arousal disturbances often remain 
underdiagnosed or inadequately assessed. The field remains a major challenge for both 
clinicians and researchers, because our understanding of the underlying neurobiology is still 
very limited, and – as a consequence – helping affected patients is frustrating due to a lack 
of treatment options targeting known neurophysiological deficits. 
 
 
2. Diagnostic approach to a frequent and disabling clinical problem 
As mentioned, recognition of arousal disturbances is compromised by multiple 
diagnostic difficulties. Several aspects highlight this problem and explain why arousal 
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disturbances continue to be underrecognized in many neurological disorders. First, the lack 
of biomarkers or appropriate clinical features often hampers the objective assessment of 
arousal disturbances. This is particularly challenging for the problem of fatigue, which is a 
subjective experience that currently can be assessed only in a semi-quantitative manner by 
questionnaires. Second, different arousal disturbances may coexist in the same patient (e.g. 
sleepiness and fatigue), making it difficult for the treating physicians to differentiate them. 
Third, clinicians need a high degree of suspicion to diagnose arousal disturbances, because 
patients may not be aware of and thus not report them. Indeed, the regular use of objective 
tools such as the mean sleep latency test (MSLT) or actigraphy have revealed a 
considerable discrepancy between subjective and objective measures of arousal 
disturbances.1 Finally, different neurological disorders may produce similar results in sleep 
lab examinations (e.g. similar mean sleep latency in the MSLT), making the definition of 
additional features for differentiation necessary. 
The following collection of papers illustrates the above-mentioned difficulties and 
provides potential approaches. In the first paper, we translated and validated the Fatigue 
Severity Scale (FSS), to offer both clinicians and researchers a tool for identification and 
quantification of fatigue. In the second paper, we demonstrated in patients with idiopathic 
Parkinson’s disease that fatigue and excessive daytime sleepiness (EDS) are often 
overlapping yet in many aspects distinct arousal disturbances. In the third paper, we 
assessed sleep need following traumatic brain injury (TBI) and compared subjective 
estimates with actigraphic measures, thereby identifying a significant underestimation of 
effective sleep need by TBI patients. Eventually, in the fourth paper, we compared two 
patient groups with EDS – patients with narcolepsy and patients with behaviourally induced 
insufficient sleep syndrome (BIISS), which is the official term for chronic sleep deprivation – 
and showed that analyzing the specific sequence of sleep stages in the MSLT may help 
differentiating these two conditions. 
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2.1. Validation of the Fatigue Severity Scale in a Swiss cohort 
(Valko PO, Bassetti CL, Bloch KE, Held U, Baumann CR. Validation of the Fatigue Severity 
Scale in a Swiss Cohort. Sleep 2008; 31:1601-1607) 
Fatigue is a very common symptom in a large number of neurological disorders.2 It is 
a subjective experience that lacks a clear-cut definition but can be described as loss of 
energy, rapid exhaustion and physical and/or mental tiredness. While fatigue has been 
increasingly identified as a major cause for impaired health-related quality of life, the 
condition is nevertheless often underrecognized. A possible explanation is the lack of 
adequate tools to examine fatigue. Although several fatigue questionnaires have been 
introduced, they have been validated only in few disorders with inclusion of small patient 
numbers.3 Thus, in this study we aimed at validating the German version of the Fatigue 
Severity Scale, which is the most frequently used fatigue questionnaire. The FSS is a self-
administered questionnaire that contains 9 items and patients need to indicate on a Likert 
scale from 1 to 7 whether they agree or disagree with the statement. The final score is the 
mean value of the 9 items.  
We obtained and compared complete FSS questionnaires of 454 healthy subjects 
and various patient groups, including 188 patients with multiple sclerosis, 235 patients who 
have suffered an ischemic stroke and 429 patients with different sleep-wake disorders. 
Linear regression analysis showed significantly lower values for healthy controls than each 
patient group: mean FSS scores were 3.00 ± 1.08 in healthy subjects, 4.66 ± 1.64 in patients 
with multiple sclerosis, 3.90 ± 1.85 in patients with previous ischemic stroke, and 4.34 ± 1.64 
in patients with sleep-wake disorders (Figure 1). Considering the range of FSS scores in 
healthy controls and patients, we concluded that a value ≥ 4.00 should be regarded as cut-off 
for the presence of fatigue. Using this cut-off, fatigue was present in 18% of healthy subjects, 
in 69% of patients with multiple sclerosis, in 49% of patients with previous ischemic stroke, 
and in 62% of patients with sleep-wake disorders. 
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To explore the reliability of our German translation of the FSS, we performed an item 
analysis, examined the internal consistency, and assessed the test-retest variability.4,5 
Cronbach’s analysis exhibited a coefficient α of 0.93 for the entire sample, which reflects a 
high degree of internal consistency of the questionnaire. The lowest internal consistencies 
were found for items 1 and 2, but the internal consistency of the FSS did not improve when 
these two items were deleted. We assessed the test-retest variability in 104 healthy subjects 
and found no difference when repeating the testing after 21 days: FSS scores were 2.94 ± 
0.90 and 2.90 ± 0.74 (p = 0.27). 
 
 
 
 
 
 
Figure 1 
Boxplots demonstrating the median and 
interquartile range of FSS scores in 
healthy control subjects (n = 454), 
patients with multiple sclerosis (n = 188), 
patients with a history of ischemic stroke 
(n = 235), and patients with various 
sleep-wake disturbances (n = 429). 
 
 
In conclusion, this was the first state-of-the-art validation of a fatigue scale in a large 
sample size (n = 1306) and for different neurological disorders. We demonstrated that the 
FSS is a valid instrument for detecting and monitoring fatigue and thus can be applied for 
both clinical and research purposes. 
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2.2. Fatigue and excessive daytime sleepiness in idiopathic Parkinson’s disease 
differently correlate with motor symptoms, depression and dopaminergic 
treatment 
(Valko PO, Waldvogel D, Weller M, Bassetti CL, Held U, Baumann CR. Fatigue and 
excessive daytime sleepiness in idiopathic Parkinson’s disease differently correlate with 
motor symptoms, depression and dopaminergic treatment. Eur J Neurol 2010; 17:1428-
1436) 
 Fatigue and EDS are both very common complaints in patients with idiopathic 
Parkinson’s disease, and the reported prevalence ranges between 50-75% and 40-60%, 
respectively.6-8 Many patients who suffer from EDS also feel fatigued, suggesting a high 
degree of clinical but also pathophysiological overlap of the two arousal disturbances.9 To 
explore the frequency of coexisting fatigue and EDS in Parkinson’s disease and to identify 
potential differences in their association with other disease-related features, we set out to 
prospectively assess fatigue, EDS, depression, motor severity, disease duration, and 
dopaminergic treatment. 
              We included 88 consecutive patients with 
idiopathic Parkinson’s disease from our Movement 
Disorders outpatient clinic. Using the Fatigue Severity 
Scale (FSS) and the Epworth Sleepiness Scale (ESS) with 
cut-off values of ≥ 4.00 and ≥ 10 for fatigue and EDS, 
respectively, we diagnosed fatigue in 59% and EDS in 48% 
of all patients, while an overlap of fatigue and EDS was 
observed in 35%. FSS and ESS scores significantly 
correlated (r = 0.48, p < 0.001), but the two arousal 
disturbances revealed different associations with other 
disease-related features. Fatigue significantly correlated 
with disease severity and motor disability, but also with the 
presence of autonomic disturbances and depression.  
 
Figure 2 
Correlation analysis between 
Parkinson’s disease duration and 
scores of the Fatigue Severity 
Scale (FSS) and Epworth 
Sleepiness Scale (ESS). 
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Conversely, EDS – but not fatigue – 
significantly increased with longer disease 
duration (Figure 2).  
Furthermore, dopaminergic treatment, 
namely the use of dopamine agonists, 
appeared to have a significant impact on 
the severity of EDS, but not on fatigue. 
Finally, using a multinomial regression 
model, we compared the frequency of 
depression between patients with fatigue 
alone, EDS alone, and co-occurrence of 
fatigue and EDS. As shown in Figure 3, 
only fatigue alone – as opposed to fatigue 
with EDS or EDS alone – was associated 
with a significant effect on depression. 
 
 
 
Figure 3 
Multinomial regression model was used to 
assess the impact of depression on the odds 
ratio of only excessive daytime sleepiness 
(EDS; without fatigue), only fatigue (without 
EDS), and both symptoms. The graph 
illustrates the respective odds ratios and 
corresponding 95% confidence intervals (CI).  
In conclusion, our study indicates that fatigue and EDS represent different constructs, 
as suggested by the observed disparities of their correlation to severity of motor symptoms, 
disease duration, depression, and dopaminergic treatment. The findings highlight the 
complex etiology especially of fatigue, which is probably influenced by a combination of 
primary and secondary factors, such as neurodegeneration of arousal-promoting brainstem 
and diencephalic structures, depression, sleep-wake disturbances including EDS and motor 
disability.   
 
 
 
2.3. Excessive sleep need following traumatic brain injury: a case-control of 36 
patients 
(Sommerauer M, Valko PO, Werth E, Baumann CR. Excessive sleep need following 
traumatic brain injury: a case-control study of 36 patients. J Sleep Res 2013; 22:634-639)  
 Arousal disturbances represent a major consequence in survivors of TBI. In a 
prospective study, posttraumatic EDS and increased sleep need (pleiosomnia) were 
identified as the most common sleep-wake disturbances.1 Posttraumatic hypersomnia is 
diagnosed if the patient persistently complains about increased sleep need of at least 2 
hours per 24 hours as compared to the time prior TBI. The clinical impact and therapeutic 
implications of posttraumatic hypersomnia have not yet been elucidated, and thus represent 
the aim of this paper. 
 We conducted a case-control study of 36 TBI patients with posttraumatic pleiosomnia 
and compared the findings to 36 age- and sex-matched control subjects. We assessed 
subjective measures including fatigue, EDS and estimated sleep need per 24 hours by 
questionnaires and sleep logs. In addition, patients underwent also sleep laboratory 
recordings including 14-day actigraphy, polysomnography and MSLT.  
 Sleep increase after TBI ranged from 2.0 hours to 6.5 hours. Subjectively, TBI 
patients estimated their sleep need as 9.4 hours, but actigraphy revealed a significantly more 
pronounced sleep need of 10.8 hours (p = 0.02). Conversely, subjective estimation and 
actigraphic measurement of sleep need did not differ in control subjects (7.5 hours vs. 7.3 
hours, respectively). In addition, 10 TBI patients had an actigraphic pattern suggestive for 
chronic sleep deprivation, as indicated by longer sleep times of ≥ 2 hours during weekend 
compared to weekday. All 10 TBI patients returned to work.  
Polysomnography demonstrated more slow-wave sleep in TBI patients than in control 
subjects (20.4% vs. 13.8%, p = 0.009), while all other parameters were similar. Finally, MSLT 
findings showed shorter mean sleep latency in TBI patients than in control subjects (8.7 min 
vs. 12.4 min, p < 0.001).  
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Thus, this paper suggests that posttraumatic pleiosomnia may be even more common 
than previously appreciated, because affected patients often do not estimate their actual 
sleep need correctly. The combination of pleiosomnia and underestimation or anosognosia of 
their posttraumatic sleep-wake disturbances may lead to an increased risk of secondary 
chronic sleep deprivation and excessive daytime sleepiness, particularly in TBI survivors 
returning to work. This finding should be considered when counseling and treating TBI 
patients, and must not be forgotten when dealing with the question whether a patient is able 
to drive motor vehicles.  
 
2.4. Multiple sleep latency measures in narcolepsy and behaviourally induced 
insufficient sleep syndrome 
(Marti I, Valko PO, Khatami R, Bassetti CL, Baumann CR. Multiple sleep latency measures in 
narcolepsy and behaviourally induced insufficient sleep syndrome. Sleep Med 2009; 
10:1146-1150) 
EDS is the mandatory symptom of narcolepsy.10,11 When narcolepsy patients do not 
present typical cataplexy, brief episodes of loss of postural muscle tone triggered by strong 
emotions, differentiating narcolepsy from other disorders with EDS may be difficult. 
Diagnostic criteria for narcolepsy include typical findings of the MSLT, such as a mean sleep 
latency of ≤ 8 min and the presence of ≥ 2 sleep onset rapid eye movement (SOREM) 
periods.12 However, these MSLT markers are not specific and may also be present in 
patients with non-narcoleptic EDS, for instance due to sleep-disordered breathing or BIISS.13-
17 To improve the diagnostic value of the MSLT in differentiating narcolepsy from patients 
with non-narcoleptic EDS, we analyzed MSLT data including sleep latencies to and between 
different sleep stages of 20 patients with narcolepsy with cataplexy, 20 BIISS patients and 20 
age-, sex- and body mass index -matched control subjects. 
We found that mean sleep latency to non-rapid eye movement (NREM) 1 was 
significantly shorter in narcolepsy (1.8 ± 1.5 min) compared to BIISS (4.7 ± 2.1 min; p < 
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0.001), but mean sleep latency to NREM2 was similar in narcolepsy and BIISS (8.6 ± 4.7 min 
vs. 8.1 ± 2.7 min). Three BIISS patients fulfilled the MSLT criteria for narcolepsy, and three 
narcolepsy patients had ≤ 1 SOREM period. When analyzing only MSLT naps with SOREM 
periods, mean sleep latency from lights off 
to NREM1 were similar in narcolepsy and 
BIISS (1.9 ± 2.3 min vs. 1.8± 1.3 min, 
respectively; p = 0.96). Conversely, mean 
sleep latency from lights off to REM sleep 
was significantly shorter in narcolepsy 
than in BIISS (5.4 ± 3.8 vs. 10.0 ± 4.0 min, 
respectively; p < 0.001). The reason for 
this discrepancy is that in narcolepsy the 
most common sleep stage sequence was 
NREM1 – REM – NREM2, while in BIISS it 
was NREM1 – NREM2 – REM (Figure 4). 
 
Figure 4 
Group comparison of mean sleep 
latencies to different sleep stage.
The clinical presentation of narcolepsy and BIISS may show substantial overlap, and 
in the absence of typical cataplexy the differentiation of narcolepsy and BIISS can be difficult. 
A minority of BIISS patients (15% in this paper) even fulfill the MSLT criteria for narcolepsy. 
For these diagnostic challenges, our study demonstrates that the sleep stage sequence 
NREM1 – REM – NREM2 may serve as additional discriminating factor (Figure 5). 
 
 
Figure 5 
Analysis of sleep stage 
sequence in MSLT naps with 
SOREMs (narcolepsy with 
cataplexy (NC): n = 62/85 
naps; BIISS: n = 13/89 naps) 
reveals significant differences 
between NC and BIISS.  
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3. A neuropathological perspective 
One of the first clinico-anatomical studies that aimed at correlating specific sleep-
wake disturbances with structural lesions in the brain was done during the epidemic of 
encephalitis lethargica around the time of World War I. Von Economo reported that patients 
with lesions in the posterior part of the hypothalamus demonstrated profound EDS and 
increased sleep need.18 He was probably the first to speculate that narcolepsy might 
represent a neurological disorder originating from the posterior hypothalamus. Seven 
decades later, when researchers discovered that narcolepsy is caused by an extensive loss 
of the hypothalamic neurons producing the hypocretin (also called orexin) neuropeptides, it 
became clear that von Economo was right.19-21  
People with narcolepsy suffer from severe EDS, along with cataplexy, sleep paralysis, 
hypnagogic hallucinations and fragmented night-time sleep. The study of narcolepsy has 
proved crucial for our understanding of arousal disturbances in other neurological 
disturbances and continues to promote substantial advances in the field. Several groups 
examined the integrity of the neurons producing hypocretin in different neurological disorders 
commonly associated with chronic EDS, and found partial loss of these hypothalamic cells in 
postmortem brains of patients with idiopathic Parkinson’s disease,22,23 Alzheimer’s disease24 
and Huntington’s disease.25 These papers clearly represent an important contribution to our 
understanding why sleep-wake disturbances occur so frequently in neurodegenerative 
disorders. However, further studies are warranted to elucidate whether partial hypocretin 
deficiency is the principle etiology of arousal disturbances in neurodegenerative disorders – 
which is probably not the case – and whether extensive hypocretin deficiency is solely 
responsible for all symptoms in narcolepsy with cataplexy. 
As mentioned earlier, arousal disturbances represent a major and disabling symptom 
for a majority of patients surviving traumatic brain injury. A study in 1971 reported frequent 
hypothalamic lesions following closed head injury,26 but the hypothalamic arousal-promoting 
system including the neurons producing hypocretin was not known at that time and has not 
been investigated since. Thus, in the first paper of the second part of this habilitation treatise 
we compared the number of various hypothalamic neurons, including cells producing 
hypocretin and melanin-concentrating hormone (MCH), between patients with fatal TBI and 
non-neurological control brains. In the second paper, we investigated the integrity of 
histamine neurons in narcolepsy brains. The histamine neurons are located in the 
tuberomammillary nucleus in the posterior hypothalamus, and they receive intense excitatory 
input from hypocretin neurons.27,28 The histaminergic system plays an important role in 
promoting wakefulness, but has not been examined yet in narcoleptic brains. 
 
3.1. Loss of hypocretin (orexin) neurons with traumatic brain injury 
(Baumann CR, Bassetti CL, Valko PO, Haybaeck J, Keller M, Clark E, Stocker R, Tolnay M, 
Scammell TE. Loss of hypocretin (orexin) neurons with traumatic brain injury. Ann Neurol 
2009; 66:555-559) 
 Arousal disturbances such as EDS or increased sleep need (pleiosomnia) are 
common after traumatic brain injury (TBI) and may persist for many years.29-32 Roughly 1 in 4 
TBI patients suffer from chronic EDS, as documented by several studies. Considering the 
common occurrence yet unclear etiology of posttraumatic sleepiness, we examined the 
hypothalami of 4 patients, who died after severe TBI. Previous studies had shown strongly 
reduced cerebrospinal fluid (CSF) concentration of hypocretin during the acute period after 
TBI, possibly reflecting functional down-regulation during coma or marked obtundation.33 
Subsequently, however, this hypocretin deficiency was followed by recovery of CSF levels of 
hypocretin at 6 months after TBI.1 Interestingly, however, CSF levels of hypocretin did not 
return to normal values in all TBI patients, but remained reduced in some of them.1 Thus, we 
hypothesized that head trauma may cause damage to the hypothalamus, including partial 
loss of neurons producing hypocretin. 
 To test our hypothesis, we used immunohistochemistry for hypocretin-1 (orexin-A) 
and MCH, counted the numbers of immunoreactive cells and performed quantitative 
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comparison between 4 hypothalami from 
patients with fatal TBI and 4 control brains. 
As shown in Figure 6, we found a 27% 
reduction of neurons producing hypocretin 
in TBI brains compared to control brains 
(23’655 ± 5’035 vs. 32’318 ± 3’060; p = 
0.001). The number of MCH neurons also 
appeared to be lower in TBI brains than in 
control brains (39’540 ± 10’900 vs. 57’176 
± 24’016), without however reaching 
statistical significance (p = 0.06). Finally, 
immunostaining of glial fibrillary acidic 
protein (GFAP), a marker of astrocytes 
and reactive gliosis, revealed a higher 
density of reactivated astrocytes in TBI 
than control brains (21 ± 12 /mm2 vs. 7 ± 2 
/mm2), including dense perivascular 
immunoreactivity (Figure 7). 
 
Figure 6 
Quantitative comparison of neurons producing 
hypocretin and MCH in controls and TBI patients. 
 
  
Figure 7 
Immunostaining for hypocretin in a TBI brain, 
revealing dense perivascular immunoreactivity 
within the hypothalamic hypocretin field (A, B), 
but not in adjacent areas (C). 
 
This pilot study confirmed that head trauma is associated with a significant impact on 
the hypothalamus, as indicated by the reactive gliosis seen throughout the hypothalamus. 
Furthermore, hypothalamic injury involves a loss of several neuronal systems, including cells 
producing hypocretin and MCH. Trauma-induced decrease of hypocretin signaling may thus 
contribute to the frequently observed posttraumatic arousal disturbances. Use of arousal-
stimulating drugs – ideally including hypocretin agonists – might represent a promising and 
tailored treatment option in patients with persistent posttraumatic arousal disturbances. 
 
3.2. Increase of histaminergic tuberomammillary neurons in narcolepsy 
 (Valko PO, Gavrilov YV, Yamamoto M, Reddy H, Haybaeck J, Mignot E, Baumann CR, 
Scammell TE. Increase of histaminergic tuberomammillary neurons in narcolepsy. Ann 
Neurol 2013; 74:794-804) 
 In the year 2000, two groups discovered a > 90% loss of the number of hypothalamic 
neurons producing hypocretin in narcoleptic brains.19-21 It is assumed that the pathogenic 
attack to these cells occurs in a highly selective way, because the integrity of MCH-producing 
neurons – the closest neighbors of the hypocretin neurons – appeared to be unaffected. 
However, other cell populations involved in the regulation of sleep and wakefulness have not 
been examined yet, and both cause and consequences of the hypocretin neuron loss in 
narcolepsy remain unknown.  
 Among the targets of the excitatory hypocretin neurons, the histaminergic 
tuberomammillary nucleus (TMN) in the posterior hypothalamus is considered to have a 
major role in maintaining normal wakefulness, as suggested by the fact that TMN neurons 
generally fire only after wakefulness is established.34-37 A large body of evidence suggests 
that the histamine system might play an important role in the neurobiology of narcolepsy. The 
TMN is the only brain structure producing histamine, receives strong excitatory innervation 
from hypocretin neurons,38-40 and histamine CSF levels have recently been reported to be 
decreased in narcolepsy and other conditions with excessive daytime sleepiness.41-43 In 
humans, centrally-acting antihistamines are known to elicit drowsiness.44 Eventually, while 
mice lacking histidine decarboxylase (HDC), a marker of the histaminergic TMN neurons, 
have less wakefulness at the beginning of their active period and sleep more in a novel 
environment, mice lacking histamine H1 receptors are not able anymore to show a normal 
arousal reaction to hypocretin. 
 To explore a potential involvement of the histamine system in the neurobiology of 
narcolepsy, we examined TMN neurons in human narcoleptic brains and in two mouse 
models of narcolepsy. In the human part, we included 7 brains of narcolepsy patients and 12 
control brains, immunostained for hypocretin-1 (orexin-A), HDC and MCH, and used 
unbiased stereology for quantification of positively labeled cells. For the rodent part we used 
6 wild-type (WT) C57BL/6J mice, 5 prepro-orexin ligand knockout (KO) mice, and 6 
orexin/ataxin-3 (Atx) transgenic mice. The latter express ataxin-3, which is a toxic transgene 
that selectively kills most of the hypocretin neurons by around 12 weeks of age.        
 We found a 94% increase of 
histaminergic TMN neurons in 
narcolepsy patients compared to 
controls, and the gain in histamine 
neurons was higher in those narcolepsy 
patients who had the greatest loss of 
neurons producing hypocretin (Figures 
8+9). The pattern of rostro-caudal 
distributions of histaminergic neurons 
was similar in control subjects and 
narcolepsy patients (Figure 10). 
 
Figure 8 
Histidine decarboxylase (HDC) immunostaining in 
control and narcolepsy subjects, showing 
approximately 60% more HDC-immunoreactive 
neurons in this section through the medial 
mammillary nucleus.  
 
 
 
 
Figure 9  
Patients with narcolepsy with cataplexy had 86% fewer hypocretin neurons ( ***  p < 0.001) and 94%  
more histamine neurons ( ***  p < 0.001) than control subjects, while the number of MCH neurons was  
similar. 
 
Likewise, hypocretin KO mice had 53% more histaminergic TMN neurons, and Atx mice had 
28% more histaminergic TMN neurons than WT mice (Figure 11). 
24 
 
  
 
Figure 10 
Similar pattern of rostro-caudal distributions 
of histaminergic tuberomammillary neurons 
in control subjects and narcolepsy patients. 
Our discovery was surprising and raised several questions. Although our study does 
not provide a pathophysiologic explanation for the striking increase of histaminergic TMN 
neurons, we speculate this increment may reflect an effort to compensate for the reduction of 
excitatory hypocretin signaling. Furthermore, as not all symptoms occurring in the course of 
narcolepsy may be satisfactorily attributed to the loss of hypocretin neurons, the increase of 
histaminergic TMN neurons may account for the gradual decline of hypersomnia a few 
weeks or months after the onset of the disease, and the progressive sleep fragmentation, 
which usually develops later in the disease course than the appearance of sleepiness or 
cataplexy. Finally, drugs enhancing the histamine signaling may constitute an alternative 
treatment option for patients with narcolepsy or other neurological disorders with arousal 
disturbances.  
 
Figure 11 
Cell counts in two mouse models of narcolepsy. Orexin-ligand knockout mice have no orexin 
immunoreactivity and 53% more histaminergic tuberomammillary nucleus (TMN) neurons than wild-
type mice. Orexin/ataxin-3 transgenic mice have an 85% loss of orexin neurons and 28% more 
histaminergic neurons than wild-type mice. The cell counts of neurons producing melanin-
concentrating hormone (MCH) is similar in all groups.   
4. Therapeutic challenge 
In the last part of this habilitation treatise, I discuss different treatment strategies for 
arousal disturbances in neurological disorders. Considering the heterogeneous 
pathophysiology of arousal disturbances, opportunities of effective therapy may emerge from 
distinct approaches. Understanding of the underlying neurobiology of arousal disturbances 
should determine the choice of treatment. The best way, obviously, would be to prevent or 
treat the pathological process which is producing the arousal disturbance. We discuss this 
possibility in the first paper concerning the effect of intravenous immunoglobulins in patients 
with narcolepsy with cataplexy. The next two papers illustrate the common effort to alleviate 
arousal disturbances by the use of drugs that increase wakefulness. We demonstrate that 
this goal can be achieved in different manner, either by improving the quality of nocturnal 
sleep by using hypnotics such as sodium oxybate, or by reinforcing the activity of certain 
components of the ascending arousal system (although the precise mechanism of action 
remains uncertain, but the effect of modafinil might result from stimulation of wake-promoting 
histaminergic tuberomammillary neurons45). Finally, arousal disturbances may emerge not 
only as a direct consequence of impaired wake-promoting brain circuitries, but also by 
comorbidities that are associated with the underlying neurological disorder (e.g. depression 
or sleep disorders in multiple sclerosis). In the last paper, we discuss the relationship 
between sleep-disordered breathing and fatigue in patients with multiple sclerosis and 
whether treatment by continuous positive airway pressure (CPAP) significantly reduces 
fatigue severity. 
 
4.1. No persistent effect of intravenous immunoglobulins in patients with 
narcolepsy with cataplexy 
(Valko PO, Khatami R, Baumann CR, Bassetti CL. No persistent effect of intravenous 
immunoglobulins in patients with narcolepsy with cataplexy. J Neurol 2008; 255:1900-1903) 
The cause of the hypocretin deficiency in narcolepsy is not understood, but several 
findings suggest an autoimmune etiology. First of all, there is no other neurological disorder 
exhibiting a similarly tight linkage to the human leukocyte antigen (HLA) system. Specifically, 
the HLA DQB1*0602 haplotype can be identified in 85-95% of all narcolepsy patients, 
whereas fewer than 25% of Caucasian American controls present this subtype allele.46,47 
Furthermore, the impact of environmental factors, as demonstrated by the recent endemic 
increase of narcolepsy cases following the vaccination for the H1N1 influenza A virus, 
additionally favor the autoimmune hypothesis.48,49 
Although the exact dynamics of the underlying pathogenic mechanism is poorly 
known, we currently assume injury to hypocretin neurons occurs over weeks to a few years.11 
Obviously, the best treatment of narcolepsy would be to prevent it or, once the cardinal 
symptoms are emerging, to hamper full breakout by arresting the presumed and hopefully 
still incomplete attack to the hypocretin neurons. This is exactly what two groups claimed to 
have successfully accomplished by administering high-dose intravenous immunoglobulins 
(IVIg) to narcolepsy patients with hypocretin deficiency.50-52 The present study was 
undertaken to further evaluate the potential role of IVIg in the treatment of patients with 
narcolepsy with cataplexy. 
Four patients with narcolepsy with cataplexy, aged 39-51 years, were treated with 
IVIg therapy. All patients had undetectable cerebrospinal fluid (CSF) hypocretin levels, and 
HLA-typing was positive for DQB1*0602. In two patients, the latency between narcolepsy 
onset and IVIg trial was relatively short (4 and 11 months), while the other two patients have 
had narcolepsy for already 4 and 17 years. The IVIg trial consisted of three cycles at 5-week 
intervals, with a dose of 1g/kg/day administered over 2 days. At baseline and after each IVIg 
administration, we performed assessments of subjective and objective sleepiness using 
ESS, MSLT and maintenance of wakefulness test (MWT). In addition, the patients kept a 
diary on the frequency of cataplectic attacks. 
In conclusion and in agreement with findings from other groups, we could not confirm 
persistent improvements of narcoleptic symptoms, although temporary effects could be 
observed. Thus, our report does not support the results of the first observations. We 
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speculate that IVIg-related improvements may in part reflect a placebo effect, as suggested 
by the discrepant responses between objective measurements (MSLT, MWT) and subjective 
ratings (ESS score, cataplexy diary). Indeed, lack of difference between placebo and IVIg 
treatment was recently reported in a narcoleptic patient who underwent a double-blind, 
placebo-controlled IVIg trial.53 
 
4.2. Sodium oxybate in narcolepsy with cataplexy: Zurich sleep center experience 
(Poryazova R, Tartarotti S, Khatami R, Baumann CR, Valko P, Kallweit U, Werth E, Bassetti 
CL. Sodium oxybate in narcolepsy with cataplexy: Zurich sleep center experience. Eur 
Neurol 2011; 65:175-182) 
 The high clinical burden of narcolepsy is mainly defined by the severity of EDS and 
the frequency of cataplexy. However, disrupted night-time sleep, sleep paralysis and 
hypnagogic hallucinations may also be very annoying, unpleasant and frightening symptoms. 
In the absence of any definite cure, the current clinical management of narcolepsy patients 
relies on symptomatic treatment, usually combining stimulants (modafinil or amphetamine 
analogs) for EDS with tricyclic antidepressants for cataplexy. Sodium oxybate (Xyrem®) is the 
only drug that potentially improves all narcoleptic symptoms, including not only EDS and 
cataplexy but also disturbed nocturnal sleep.54,55 Sodium oxybate is the sodium salt of γ-
hydroxybutyrate and its action is believed to be mediated through GABA-B receptors. Large, 
randomized, double-blind, placebo-controlled studies confirmed the beneficial effects on all 
narcoleptic symptoms, mainly on cataplexy but also on EDS, albeit with higher dosages.56 
The present work was undertaken to analyze our own experiences with sodium oxybate with 
regard to treatment effects and potential adverse events.  
 Overall, we included 18 HLA-DQB1*0602 positive patients with narcolepsy with 
cataplexy. Hypocretin deficiency was confirmed in 17/17 patients. The presence of both EDS 
and frequent cataplectic attacks constituted the indication for sodium oxybate therapy in all of 
them. To monitor the treatment effects, we compared ESS scores, frequency of cataplexy, 
sleep paralysis, hallucinations and nightmares, actigraphic sleep/rest efficiency, and the 
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findings of polysomnography, MLST, MWT and steer-clear vigilance test before and after 
therapy with sodium oxybate. Mean dosage of sodium oxybate was 6.4 ± 1.2g, and mean 
treatment duration was 26 ± 13 months.  
 We observed an improvement of all narcoleptic symptoms. Specifically, significant 
effects were found for ESS score (17.8 ± 1 before and 13.9 ± 1.2 after treatment, p = 0.001), 
number of cataplexy (20 vs. 1, p = 0.001), number of sleep paralyses (4.1 ± 8.3 vs. 0, p = 
0.01), number of hallucinations (7.6 ± 9.5 vs. 0.4 ± 1.1, p = 0.005), sleep/rest efficiency in 
actigraphy (60.5 ± 19.7 vs. 76 ± 4, p = 0.012), mean sleep latency in MWT (5.5 ± 4.5 vs. 17.4 
± 8.9, p < 0.001), and error% in SCVT (10.8 ±12.5 vs. 2.1 ± 2.1, p = 0.02). On the other 
hand, sodium oxybate was rather well tolerated. Nighttime confusion represented the most 
common adverse effect (33%), followed by nausea (11%), enuresis (11%), diffuse muscle 
pain (6%), headache (6%), flatulence (6%), and disturbance in attention and forgetfulness 
(6%).  
 In conclusion, we confirmed that sodium oxybate effectively improves all narcoleptic 
symptoms. Since the drug is generally well tolerated, monotherapy with sodium oxybate 
should be considered as first-choice alternative to the combination of stimulants and tricyclic 
antidepressants.  
  
 
4.3. Modafinil ameliorates excessive daytime sleepiness after traumatic brain injury 
(Kaiser PR, Valko PO, Werth E, Thomann J, Meier J, Stocker R, Bassetti CL, Baumann CR. 
Modafinil ameliorates excessive daytime sleepiness after traumatic brain injury. Neurology 
2010; 75:1780-1785) 
Posttraumatic arousal disturbances are common, but specific treatment options for 
affected patients don’t exist. A prospective study conducted in our department revealed a 
prevalence of fatigue and EDS of 17% and 38%, respectively, among 65 consecutive TBI 
patients.1 In the present study, we set out to explore the effect of daily modafinil on 
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posttraumatic fatigue and EDS. Modafinil is a wake-promoting drug approved by the US 
Food and Drug Administration for therapy of EDS occurring in narcolepsy, obstructive sleep 
apnea and shift work sleep disorder, but not yet in TBI patients complaining about chronic 
arousal disturbances. 
We included 20 consecutive TBI patients with fatigue, EDS or both, and conducted a 
prospective, double-blind, randomized, placebo-controlled study (Figure 12, flow diagram).  
 
 
 
Figure 12    Flow diagram illustrating the passage of the participants through this trial. 
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During 6 weeks, half of the TBI patients were treated with 100 to 200mg modafinil 
every morning, while the remaining half received placebo. We investigated the patients at 
baseline and after the treatment period as follows: fatigue and sleepiness were assessed by 
means of the FSS and ESS questionnaires, for evaluation of mood disturbances we applied 
the Beck Depression and Anxiety Inventory, and sleep laboratory examinations included 2-
week actigraphy, polysomnography, MWT, and psychomotor vigilance test.  
Compared to the placebo group, ESS scores decreased and mean sleep latency on
MWT increased to a significantly larger extent in the modafinil group (Figure 13). 
Improvement in ESS scores remained significant after correction for sex, age, TBI severity, 
and Beck Depression and Anxiety scale values. Conversely, multiple regression analysis 
revealed that the decrease in FSS score was not significantly higher in the modafinil group 
than in the placebo group. 
In this trial, we showed that treatment with modafinil is effective in improving both 
subjective and objective posttraumatic EDS. The lack of significant effect on posttraumatic 
fatigue might be the result of underdosing, as modafinil is routinely given up to 400mg daily, 
or reflect distinct pathophysiology between sleepiness and fatigue. 
 
Figure 13 Changes from baseline in ESS and FSS scores, and in mean sleep latencies on 
MWT, between the modafinil and placebo groups.  
 
 
4.4. Fatigue and sleep-disordered breathing in multiple sclerosis: a clinically 
relevant association? 
(Kallweit U, Baumann CR, Harzheim M, Hidalgo H, Pöhlau D, Bassetti CL, Linnebank M, 
Valko PO. Fatigue and sleep-disordered breathing in multiple sclerosis: a clinically relevant 
association? Mult Scler Int 2013:286581) 
 Fatigue is a very common complaint in patients with multiple sclerosis (MS) affecting 
up to 76-92%, and is often perceived as one of the worst symptom.57,58 The etiology of 
fatigue in MS patients remains unclear. Presumably, the most important contributors to 
fatigue are disease-inherent features, i.e. the underlying neuroimmunological and 
neurodegenerative processes. While these factors are still poorly understood, additional and 
potentially treatable comorbidities such as depression, pain, anemia or sleep-wake 
disturbances must be identified.59,60 
 Among these comorbidities, sleep-disordered breathing has recently been considered 
as a significant associate of fatigue in MS patients.61,62 In the present study we aimed at 
exploring whether respirography should be routinely conducted in MS patients with fatigue 
and whether treatment with continuous positive airway pressure (CPAP) reduced fatigue 
severity. 
 We prospectively screened 258 consecutive MS patients and diagnosed severe 
fatigue (FSS score ≥ 5.0) in 97 (38%) patients. Respirography was eventually performed in 
69/97 patients (71%). SDB was diagnosed in 28 MS patients (41%) and was mild (apnea-
hypopnea index 5-15/h) in 18 patients (26%), moderate (apnea-hypopnea index 15-30/h) in 3 
patients (4%), and severe (apnea-hypopnea index ≥ 30/h) in 7 patients (10%). CPAP therapy 
was recommended to 14 patients with and apnea-hypopnea index ≥ 10/h, but only 6 patients 
consented and tolerated the device. As shown in Figure 14, after 6 months of CPAP 
treatment, we observed a mild yet significant reduction in FSS scores, while ESS scores 
remained unchanged. 
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Figure 14 Follow-up after six months of CPAP treatment shows significant reduction of fatigue 
severity but not of sleepiness. 
 
 
In conclusion, respirography should be considered in MS patients with fatigue, 
because the prevalence of sleep-disordered breathing is rather high. In addition, our study 
confirms previous reports of a significant reduction of fatigue after CPAP therapy, but the 
clinical relevance of this finding remains unclear, as (I) our treated group was very small, (II) 
not placebo-controlled, and (III) the impact on quality of life was not monitored.  
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5. Significance of the results 
 The papers presented in this habilitation treatise highlight the significance of arousal 
disturbances in clinical practice of the neurologist. The importance of the topic relies on the 
unfavorable discrepancy between its high prevalence and arduous and far-reaching impact 
on quality of life on one hand, and the currently still marginal insights into the underlying 
neurobiology and our limited treatment options on the other hand. Combining clinical 
perspective and basic neuroscience, the results of the studies are of considerable relevance 
for both practicing neurologists and fundamental researchers.  
 In the first part, the author and his coworkers addressed common difficulties in the 
clinical and diagnostic assessment of arousal disturbances. The first validation study of the 
Fatigue Severity Scale in a large sample size now offers both clinicians and researchers a 
reliable, valid and very useful tool for detecting and monitoring fatigue. The remaining three 
studies exemplified different and highly characteristic challenges in the diagnosis of arousal 
disturbances, including overlap of distinct symptoms, discrepancy between subjective and 
objective measures, and differentiation of neurological disorders producing identical arousal 
disturbances. 
 The second part represents the centerpiece of our research, and illustrates how 
clinical observation has the potential to impact basic research. The discovery of quantitative 
changes in various components of the arousal-promoting system provides a significant 
contribution to our neurobiological understanding of arousal disturbances. Our report of a 
massive increase of histamine neurons in narcolepsy suggests the capability of the adult 
human brain to compensate for loss of a specific neuronal population. In addition to shedding 
light on the etiology of various sleep-wake disturbances, the implications of this result go 
beyond the mere study of arousal disturbances, as they give hope for the development of 
new treatment strategies in neurodegenerative disorders. 
 Finally, all coworkers of these studies hope that their neuroscientific research 
eventually contributes in turn to a better clinical and therapeutic management of affected 
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patients. While the four studies of the third part indicate multiple approaches to improve 
arousal disturbances, they emphasize at the same time the necessity of further basic 
research to produce new and targeted treatment, which is based on neurobiological 
evidence. 
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FATIGUE CAN BE DEFINED AS A SUBJECTIVE EXPE-
RIENCE, AND INCLUDES SUCH SYMPTOMS AS RAPID 
INANITION, PERSISTING LACK OF ENERGY, EXHAUS-
TION, physical and mental tiredness, and apathy.1 It can be a 
consequence of many sleep-wake disorders, but also of a large 
variety of other disorders including multiple sclerosis (MS) 
(present in as many as 76% to 92%; experienced as worst symp-
tom by 50% to 60% of patients), and stroke (poststroke fatigue, 
up to 68%).2-10 Fatigue represents one of the most frequent com-
plaints of primary care patients (6% to 45%).6
The large number of publications on fatigue in the last de-
cade reflects the increasing awareness and the substantial role 
it has gained in clinical practice and research. In spite of this 
increasing interest in fatigue, as well as its prevalence and clini-
cal significance, fatigue is underrecognized, possibly because 
of the lack of sufficiently validated and widespread instruments 
to quantify fatigue. Numerous fatigue scales have been intro-
duced; only few of them have been validated, mostly in small 
studies and for specific disorders.11,12 Hence, the availability of 
an appropriate tool for assessment and quantification of fatigue, 
which can be used in different disorders, is important for clini-
cal and research purposes.
A recent bibliographic study of fatigue measurement scales 
has shown that the FSS is the most commonly used fatigue 
specific questionnaire.13 The Fatigue Severity Scale (FSS) is a 
9-item self-report questionnaire scale developed in 1989; it was 
applied in 25 MS patients, 29 patients with systemic lupus ery-
thematosus, and in 20 healthy controls.11 The simple and time-
saving application of the FSS is probably the main reason for 
its high general acceptance. However, its use has been mainly 
limited to MS patients; large studies including patients with 
other sleep-wake and neurological disorders are lacking. These 
limitations may be the reason that there is no clearly defined 
FSS cut-off to discriminate normal from pathological results.1
Our aim in this study was to validate the FSS for the first 
time in a large sample size, by applying it to healthy controls 
and selected disorders frequently associated with fatigue.
MATERIAL AND METHODS
The study was conducted at the Neurology and Pulmonary 
Departments of the University Hospital of Zurich, Switzerland, 
between December 2005 and April 2007. The study protocol 
was approved by the local ethics committee.
German Translation of the FSS
The FSS is a self-administered questionnaire with 9 items 
(questions) investigating the severity of fatigue in different 
situations during the past week. Grading of each item ranges 
from 1 to 7, where 1 indicates strong disagreement and 7 strong 
agreement, and the final score represents the mean value of the 
9 items. We initially translated the 9 items of the FSS from Eng-
lish into German. Thereafter, a bilingual neurologist who was 
blinded with respect to the original version translated it back-
wards into English. Finally, the German version was adapted 
according to this procedure (Figure 1).
Subjects
We included 3 different patient groups (MS, ischemic stroke, 
and sleep-wake disorders), in which the prevalence of fatigue is 
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Fatigue Severity Scale (FSS, English version)* 
                                                                                   strongly    strongly 
       disagree          agree 
       ◄─────────────────► 
 1 2 3 4 5 6 7 
 
1. My motivation is lower when I am fatigued.  O  O  O  O  O  O  O  
2. Exercise brings on my fatigue.  O  O  O  O  O  O  O  
3. I am easily fatigued.  O  O  O  O  O  O  O  
4. Fatigue interferes with my physical functioning.  O  O  O  O  O  O  O  
5. Fatigue causes frequent problems for me.  O  O  O  O  O  O  O  
6. My fatigue prevents sustained physical functioning.  O  O  O  O  O  O  O  
7. Fatigue interferes with carrying out certain duties  O  O  O  O  O  O  O  
    and responsibilities.            
8. Fatigue is among my three most disabling symptoms.  O  O  O  O  O  O  O  
9. Fatigue interferes with my work, family, or social life.  O  O  O  O  O  O  O  
 
*Patients are instructed to choose a number from 1 to 7 that indicates their degree of agreement with each 
statement where 1 indicates strongly disagree and 7, strongly agree. [Krupp et al, Arch Neurol 1989]  
 
 
Fatigue Severity Scale (FSS, German version) 
 
Ich finde, dass während der vergangenen Stimme gar    Stimme voll- 
Woche folgendes zutraf: nicht zu           kommen zu            
  
 ◄─────────────────► 
 1 2 3 4 5 6 7 
 
1. Ich bin weniger motiviert, wenn ich müde bin.  O  O  O  O  O  O  O  
2. Körperliche Bewegung macht mich müde.  O  O  O  O  O  O  O  
3. Ich ermüde rasch.  O  O  O  O  O  O  O  
4. Meine Müdigkeit beeinträchtigt meine körperliche  O  O  O  O  O  O  O  
    Leistungsfähigkeit.  
5. Meine Müdigkeit bereitet mir oft Probleme.    O  O  O  O  O  O  O  
6. Meine Müdigkeit verhindert längerdauernde  O  O  O  O  O  O  O  
    körperliche Tätigkeiten.  
7. Meine Müdigkeit beeinträchtigt mich, gewisse  O  O  O  O  O  O  O  
    Pflichten und Verantwortungen zu erfüllen.               
8. Meine Müdigkeit gehört zu den drei Beschwerden,  O  O  O  O  O  O  O  
    die mich am meisten behindern.  
9. Meine Müdigkeit beeinträchtigt meine Arbeit,  O  O  O  O  O  O  O  
  meine Familie oder mein soziales Leben.  
Figure 1—The original English and the German version of the Fatigue Severity Scale (FSS).
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known to be high. We sent the FSS by postal service to 314 pa-
tients with clinically definite MS and to 490 patients with previ-
ous ischemic stroke; these consecutive patients were examined 
in our neurological clinic between January 2005 and January 
2007. A total of 188 patients (60%) with MS and 235 patients 
(48%) with ischemic stroke filled in and returned the question-
naire. The intervals between disease onset and the completion 
of this study were 11.1 ± 9.8 (mean ± SD, range 0.5-58) years 
for MS patients and 1.2 ± 0.6 (range 0.33–2) years for stroke 
patients. In addition, we prospectively included 429 consecu-
tive sleep-wake disordered patients referred to our neurological 
(n = 345) and pulmonary (n = 84) sleep clinics since December 
2005. These patients were diagnosed with narcolepsy with cata-
plexy (n = 22), RLS (n = 79), sleep apnea (n = 108), insomnia 
(n = 62), parasomnia (n = 25), EDS/hypersomnia of other origin 
(n = 84), and other sleep-wake disorders (n = 49).
The FSS was also administered to 454 healthy control sub-
jects recruited by the authors among relatives and friends. We 
attempted to obtain a control group that was representative of 
the general population with an equal distribution of different 
age categories and educational status (defined as highest educa-
tional degree attained). Subjects with a diagnosed sleep-wake 
disorder, previous sleep studies, or other diseases known to 
cause fatigue (e.g., advanced cancer, HIV infection, heart fail-
ure, rheumatic disorders and depression) were excluded.
Questionnaire
Apart from the FSS, all subjects had to quantify their fatigue 
on a Visual Analog Scale (VAS), where 0 indicates “very alert” 
and 10 “extremely fatigued.” Furthermore, the German version 
of the Epworth Sleepiness Scale (ESS) and questions regarding 
bedtime were simultaneously administered.14
Statistical Methods
We used SPSS (version 12.0), STATA (version 9), and R 
(version 2.4.1) for statistical analysis. Group data are described 
by means and standard deviations (SD). We calculated com-
parisons between patient groups by means of a linear regression 
model, including thorough residual analysis. We performed 
correlation analyses between FSS and continuous demographic 
variables with the Pearson correlation coefficient; for binary 
comparisons we used the t-test. We considered statistical test 
results to be significant at a level of P < 0.05. Reliability was 
estimated through stability (test-retest) and internal consistency 
assessment. The test-retest variability of the scale was evaluated 
by Lin’s correlation coefficient of concordance,15 which takes 
departures from the 45o angle bisector into account, and which 
is typically lower than the corresponding correlation coefficient 
of Pearson. Internal consistency of the FSS was assessed by 
calculating the item to total correlation and the Cronbach α 
statistics.16 Cronbach α measures how well a set of items (or 
variables) measures a single unidimensional latent construct. In 
our case, α reflected how the 9 items of the FSS scale measured 
overall fatigue in patients or healthy subjects.
RESuLTS
Subjects
The demographic and clinical characteristics of the patient 
groups and the control group are listed in Table 1.
FSS: comparison between Groups
Mean FSS scores were 4.66 ± 1.64 in MS patients (≥ 4.0 
in 69%), 3.90 ± 1.85 in patients with previous ischemic stroke 
(≥ 4.0 in 49%), 4.34 ± 1.64 in patients with sleep-wake disor-
ders (≥ 4.0 in 62%), and 3.00 ± 1.08 in healthy controls (≥ 4.0 in 
18%). The values for 95% confidence intervals (CI) are shown 
in Table 1. The results of the linear regression analysis showed 
a significantly higher FSS score for each of the 3 patient groups 
than healthy controls; the effects of each of the 4 groups on 
mean FSS can be found in Table 2. The residual analysis re-
vealed symmetrically distributed residuals around zero, and 
Table 1—Demographic and Clinical Characteristics of Healthy Subjects and Patients in this Study
  Healthy subjects Multiple sclerosis Previous ischemic stroke Sleep-wake disorders
  (n = 454) (n = 188) (n = 235) (n = 429)
Age (years, mean ± SD, range) 47 ± 18 (13-94) 45 ± 13 (20-79) 63 ± 14 (21-87) 52 ± 15 (16-86)
Gender: female (%) 60 67 31 35
Education status, n (%)
 Primary school degree 43 (10) 63 (36) 59 (28) 80 (28)
 Second school degree 128 (29) 57 (32) 105 (49) 113 (40)
 College degree 93 (21) 26 (15) 21 (10) 34 (12)
 University degree 183 (41) 30 (17) 29 (14) 59 (21)
Duration since disease onset  11.07 ± 9.79 1.21 ± 0.62
  (years, mean ± SD, range)  (0.5-58) (0.33-2)
EDSS (mean ± SD)  3.61 ± 2.26
VAS fatigue (mean ± SD) 3.47 ± 2.24 4.83 ± 2.49 4.65 ± 2.55 5.12 ± 2.45
FSS score, mean ± SD 3.00 ± 1.08 4.66 ± 1.64 3.90 ± 1.85 4.34 ± 1.64
95% CI 2.90-3.10 4.42-4.89 3.66-4.14 4.19-4.50
FSS score ≥4.0 18% 69% 49% 62%
SD: Standard Deviation, EDSS: Expanded Disability Status Scale, VAS: Visual Analog Scale, FSS: Fatigue Severity Scale, CI: Confidence 
Interval
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Patients with Sleep-Wake Disorders (n = 429)
FSS and ESS values for specific sleep-wake disorders are 
shown in Table 3. There are significant differences of mean 
FSS scores between sleep diagnoses (P = 0.04); patients with 
insomnia and narcolepsy had the highest scores (4.78 ± 1.51 
and 4.75 ± 1.47, respectively), and patients with restless legs 
syndrome had the lowest FSS scores (4.02 ± 1.75). Overall, 
we observed a modest yet significant correlation between 
FSS and ESS (r = 0.34, P < 0.01). In the subgroup of patients 
with narcolepsy with cataplexy and sleep apnea we found the 
highest correlation (r = 0.71 and 0.48, respectively, P < 0.01), 
whereas the correlation was lowest for patients with insomnia 
(r = 0.21, P = 0.11).
Healthy Subjects (n = 454)
We found no significant associations of FSS scores with age 
or education. There was a weak association between FSS score 
and gender: the mean difference of FSS in females compared to 
males was 0.21 (P = 0.04). Differences in bedtime of ≥ 2 hours 
between weekday and weekend—suggestive of behaviorally in-
duced insufficient sleep syndrome (BIISS)—had no influence on 
the FSS score (BIISS: n = 97, FSS 3.07 ± 0.97; non-BIISS: n = 
357, FSS 2.98 ± 1.11; P = 0.3). ESS scores, however, differed be-
tween the 2 groups (BIISS: 6.79 ± 3.53, non-BIISS: 5.93 ± 3.58, 
P = 0.04). In healthy subjects, there was a modest but significant 
correlation between FSS and ESS (r = 0.28, P < 0.01).
correlation Between FSS and vAS
We observed a highly significant correlation (r = 0.69, P < 
0.01) between FSS scores and fatigue as indicated on the VAS. 
This correlation was higher in patients (MS: r = 0.79, ischemic 
stroke: r = 0.70, sleep-wake disorders: r = 0.71) than in healthy 
subjects (r = 0.52).
Item Analysis, Internal consistency, and Test-Retest variability 
of the FSS
Cronbach coefficient α for the entire sample was 0.93, show-
ing a high degree of internal consistency of the FSS (Table 4). 
only a minor departure from the model assumptions, as the dis-
tribution of the residuals showed a small ceiling and bottom 
effect. This means that slightly more observations lie in the far 
left and far right side of the histogram of the residuals than one 
would expect under a strict Gaussian distribution.
Normal Range and cutoff of the FSS
Mean ± 2 SD of FSS scores in healthy controls ranged from 
0.8-5.2. When using 5.2 as the cutoff for the presence of fatigue, 
we found the following frequencies of fatigue: 3.5% in healthy 
controls, 45% in MS, 31% in patients with previous ischemic 
stroke, and 36% in patients with sleep-wake disorders. When 
using a cutoff of 4 (as suggested by some authors17,21), we found 
fatigue in 18% of healthy controls, 69% of MS patients, 49% of 
stroke patients, and 62% of patients with sleep-wake disorders.
MS Patients (n = 188)
We observed a tendency towards higher FSS scores with in-
creasing age (Pearson r = 0.18, P = 0.01). FSS scores were sig-
nificantly correlated with physical disability (expanded disabil-
ity status scale, EDSS) (r = 0.34, P < 0.01), but not with disease 
duration (r = 0.11, P = 0.13), gender (P = 0.86), or educational 
status (r = –0.05, P = 0.50).
Patients with Previous Ischemic Stroke (n = 235)
No correlation was found between FSS scores and age (P = 
0.95), duration from disease onset (P = 0.91), gender (P = 0.82), 
or educational status (P = 0.96).
Table 2—Results of the Linear Regression Model: Estimated 
Effects and Standard Errors of the 4 groups (Healthy Subjects, 
Patients with Sleep-Wake Disorder, MS, and Previous Ischemic 
Stroke) on the Mean FSS Score
Coefficient	 Estimate	 Standard	Error	 P-value
Healthy subjects 3.00 0.07 < 0.01
Sleep-wake disorder 4.34 0.07 < 0.01
Multiple sclerosis 4.66 0.11 < 0.01
Ischemic stroke 3.90 0.10 < 0.01
Table 3—Correlation Between Epworth Sleepiness Scale (ESS) and Fatigue Severity Scale (FSS) Values in Different Sleep-Wake Disorders 
(Mean ± SD)
Sleep-wake	disorder	 n	 ESS	 FSS	 	 Pearson**
  mean ± SD mean ± SD r P-value
Narcolepsy with cataplexy 22 15.00 ± 5.23 4.75 ± 1.47 0.71 <0.01
RLS 79 8.59 ± 5.54 4.02 ± 1.75 0.28 0.01
Sleep apnea 108 10.76 ± 5.81 4.11 ± 1.64 0.48 <0.01
Insomnia 62 7.39 ± 5.18 4.78 ± 1.51 0.21 0.11
Parasomnia 25 7.32 ± 3.96 4.64 ± 1.45 0.31 0.14
EDS/hypersomnia of other origin 84 10.47 ± 4.95 4.55 ± 1.70 0.33 <0.01
Other sleep-wake disorders* 49 8.85 ± 4.79 4.18 ± 1.56 0.45 <0.01
RLS: restless legs syndrome, EDS: excessive daytime sleepiness.
*sleep related headache, nocturnal epilepsy, circadian rhythm disorders.
**Correlation between ESS and FSS.
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DIScuSSION
We show for the first time in a large sample size study that 
the FSS is a valuable tool to assess and quantify fatigue, as 
it differentiates between patients with various diseases and 
healthy subjects. Our data obtained in healthy subjects provide 
normal reference values with an upper limit of the normal range 
of 3.10. The FSS shows an excellent internal consistency, dem-
onstrated by a Cronbach α coefficient of 0.93, which is higher 
than in the earlier small sample size studies in MS patients.11,13,17 
The reliability of the FSS is further reflected by the high test-
retest reliability. Based on our data, the minimal difference in 
FSS scores that can be reliably detected is 0.15. In addition, a 
high degree of correlation of FSS scores and VAS results could 
be demonstrated.
We found that the FSS is useful to distinguish frequency and 
severity of fatigue between healthy subjects and patients with 
MS, different sleep-wake disorders, and ischemic stroke.
Based on our findings and on previous reports on the preva-
lence of fatigue, we suggest that a FSS score ≥ 4 be interpreted 
as indicative of fatigue.2-5,11,13,17 When using 5.2 (mean + 2 SD) 
as the cutoff for the presence of fatigue, we obtained fatigue 
prevalences that were clearly lower than previously published 
prevalences of fatigue. In MS for instance, the prevalence of 
fatigue is well documented and ranges from 76% to 92%,2-5 
suggesting that a cutoff of 4 (obtained fatigue prevalence: 69%) 
would be more appropriate than 5.2 (obtained fatigue preva-
lence: 45%). Similarly, item 5 of the FSS (“Fatigue causes 
frequent problems for me”) indicates the presence of fatigue 
in tested subjects. The score of this item was ≥ 5 (affirmative 
answer) in 16% of healthy controls, 55% of MS patients, 36% 
of patients with previous ischemic stroke, and 51% of patients 
with sleep-wake disorders. This finding again is in favor of a 
Specific item analysis showed the lowest internal consisten-
cies for items 1 and 2. A total of 104 healthy subjects filled 
in the FSS a second time after 21 days. Initial values (2.94 ± 
0.90) did not differ from subsequent testing (2.90 ± 0.74) (P = 
0.27). Lin’s concordance measure rho was 0.88 (95% CI: 0.84 
to 0.92). In 87 normal controls (84%) the difference of the total 
score was ≤0.5. The mean difference between test and retest 
was 0.04 ± 0.41.
Table 4—Item Analysis of the FSS in Patients with MS, Ischemic 
Stroke, and Sleep-Wake Disorders, and in Healthy Controls
Item	number	 mean±SD	 corrected	item	to	 Cronbach	α
   total correlation if item deleted
a) multiple sclerosis (n = 188)
 1 5.28 ± 1.58 0.48 0.95
 2 4.93 ± 1.91 0.72 0.93
 3 4.69 ± 2.02 0.82 0.93
 4 5.04 ± 1.91 0.82 0.93
 5 4.45 ± 1.98 0.85 0.93
 6 4.85 ± 2.06 0.85 0.93
 7 3.99 ± 2.05 0.77 0.93
 8 4.52 ± 2.20 0.79 0.93
 9 4.19 ± 2.21 0.78 0.93
 Total 4.66 ± 1.64  0.94
b) ischemic stroke (n = 235)
 1 4.65 ± 1.98 0.70 0.96
 2 4.11 ± 2.00 0.77 0.96
 3 4.03 ± 2.12 0.85 0.95
 4 4.28 ± 2.13 0.86 0.95
 5 3.69 ± 2.21 0.86 0.95
 6 3.98 ± 2.26 0.85 0.95
 7 3.53 ± 2.19 0.84 0.95
 8 3.68 ± 2.34 0.85 0.95
 9 3.51 ± 2.23 0.86 0.95
 Total 3.90 ± 1.85  0.96
c) sleep-wake disorders (n = 429)
 1 5.07 ± 1.80 0.60 0.94
 2 4.23 ± 1.90 0.60 0.94
 3 4.28 ± 1.99 0.79 0.93
 4 4.61 ± 1.92 0.83 0.92
 5 4.41 ± 2.10 0.83 0.92
 6 4.06 ± 2.05 0.77 0.93
 7 3.90 ± 2.06 0.80 0.93
 8 4.44 ± 2.21 0.79 0.93
 9 4.16 ± 2.22 0.81 0.93
 Total 4.34 ± 1.64  0.94
d) healthy controls (n = 454)
 1 5.09 ± 1.60 0.32 0.86
 2 3.11 ± 1.66 0.41 0.85
 3 2.75 ± 1.44 0.63 0.83
 4 3.94 ± 1.71 0.50 0.84
 5 2.66 ± 1.58 0.67 0.82
 6 2.50 ± 1.57 0.66 0.83
 7 2.41 ± 1.55 0.65 0.83
 8 2.30 ± 1.73 0.65 0.83
 9 2.16 ± 1.55 0.68 0.82
 Total 3.00 ± 1.08  0.85
entire sample (n = 1306)
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Figure 2—Boxplots showing the median and interquartile range 
of FSS scores in healthy controls and patients with MS, previous 
ischemic stroke, and sleep-wake disorders.
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ous antidepressants. At the moment, however, fatigue remains 
an underrecognized problem, which may show negative inter-
action with performance levels and outcome measures (such as 
EDSS in MS patients, or Barthel Index in stroke patients for 
assessment of stroke-related disability), and therefore needs to 
be taken into consideration when caring for these patients. The 
scale allows detection and monitoring of disease-related fatigue 
and may indicate the need of appropriate interventions. In ad-
dition, reliable determination of fatigue severity and its varia-
tion during the time course of a disease are the prerequisite to 
develop future therapies to alleviate this troublesome symptom. 
The FSS constitutes a valid instrument to assess and quantify 
fatigue for such clinical and research purposes.
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Background and purpose: A comprehensive study of both fatigue and excessive
daytime sleepiness (EDS) in association with Parkinsons disease (PD)-related symp-
toms and treatment has not been performed yet. To assess the frequency and severity
of fatigue and EDS in patients with idiopathic PD and to study their relation to motor
and non-motor symptoms and dopaminergic treatment.
Methods: We prospectively assessed Fatigue Severity Scale (FSS) scores, Epworth
Sleepiness Scale (ESS) scores, Beck Depression Inventory (BDI) scores, severity
(Uniﬁed PD Rating Scale, UPDRS, part III; Hoehn & Yahr staging) and duration of
the disease, and the current dopaminergic treatment in 88 consecutive patients with
idiopathic PD.
Results: Fatigue was found in 52 (59%), EDS in 42 (48%), and both complaints in 31
(35%) patients. Fatigued patients had higher UPDRS III scores (23.5 ± 11.1 vs.
18.6 ± 7.6, P = 0.03), higher Hoehn & Yahr staging (2.4 ± 0.9 vs. 2.1 ± 0.7,
P = 0.03), and higher BDI scores (13.4 ± 7.1 vs. 9.1 ± 5.8, P = 0.004) than non-
fatigued patients. In contrast, UPDRS III, Hoehn&Yahr, and BDI scores did not diﬀer
between patients with or without EDS. However, the type of dopaminergic treatment
(levodopa monotherapy versus combination of levodopa/dopamine agonists) was
associated with signiﬁcant diﬀerences in ESS (8.5 ± 5.2 vs. 10.8 ± 4.3, P = 0.04), but
not FSS scores (4.1 ± 1.5 vs. 4.3 ± 1.5, P = 0.55). Disease duration correlated with
ESS scores (r = 0.32, P = 0.003), but not with FSS scores (r = )0.02, P = 0.82).
Conclusions: In PD, there is a signiﬁcant overlap of fatigue and EDS, but the two
symptoms are diﬀerently correlated with the severity of motor symptoms, disease
duration, depression, and dopaminergic treatment.
Introduction
Sleep-wake disturbances including fatigue and excessive
daytime sleepiness (EDS) are important non-motor
features of idiopathic Parkinsons disease (PD). EDS is
present in up to 50–75% of patients with PD, thereby
signiﬁcantly surpassing the frequency of EDS in other
brain disorders, e.g. multiple sclerosis, ischemic stroke,
traumatic brain injury [1–6]. Recently, the issues of
EDS and sleep attacks deﬁned as episodes of EDS-
triggered short involuntary sleep at inappropriate situ-
ations, and their association with the use of dopami-
nergic agents, have received increasing attention [7–10].
Fatigue, on the other hand, often remains unrecog-
nized, despite its high prevalence (40–60%) [1,11–13].
Moreover, the association between fatigue, treatment
and severity of motor symptoms and depression in PD
is still under debate [14–18]. Alves et al. [19] found a
signiﬁcant correlation between fatigue and EDS in PD.
The etiology of fatigue and EDS in PD has remained
controversial. Some authors attributed impaired vigi-
lance in PD to the high prevalence of sleep abnormal-
ities, including insomnia, sleep apnea, fragmented sleep
architecture, and reduced slow wave and REM sleep
[20–23].
So far, however, there is no comprehensive study that
systematically and prospectively assessed both fatigue
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and EDS in PD, and their relation to PD symptoms. We
therefore aimed at characterizing fatigue and EDS in
PD, ascertaining the extent of overlap between the two
symptoms, and associating them to other motor and
non-motor symptoms, and to dopaminergic medication.
Methods
This prospective study was conducted at the Depart-
ment of Neurology of the University Hospital of
Zurich, Switzerland, between August 2007 and May
2008. The study protocol was approved by the Ethics
Committee of the Canton of Zurich, specialized sub-
committee for Psychiatry, Neurology, Neurosurgery.
Subjects
We included 88 consecutive patients with PD from our
Movement Disorders outpatient clinic. The diagnosis of
PD was made according to international diagnostic
criteria [24,25]. Patients with other extrapyramidal or
neurodegenerative disorders were excluded.
Clinical assessments
We rated motor symptoms according to the motor
subset of the Uniﬁed Parkinsons Disease Rating Scale
(UPDRS III) in oﬀ condition [26]. PD severity was
determined by Hoehn & Yahr staging [27]. A detailed,
structured interview and clinical examination allowed
assessing the presence of the following motor and
non-motor symptoms: rapid eye movement (REM)
sleep behavior disorder (RBD), insomnia deﬁned as
deterioration of nighttime sleep compared to prior
disease onset, hallucinations, autonomic disturbances
including orthostatic hypotension, constipation,
impotence, paroxysmal sweating, and inadequate
bladder emptying. Patients were considered to suﬀer
from PD-related insomnia, if they judged their ability
to fall asleep and to sleep through as signiﬁcantly
worse than before disease onset. Information on pre-
dominantly aﬀected body side at disease onset, and
type of PD (tremor-dominant versus akinetic-rigid)
was also obtained. Overnight video-polysomnography
was performed in 26 patients (30%). Video-polysom-
nography was performed in patients with suspected
RBD.
Questionnaire for the assessment of fatigue, EDS, and
mean bedtimes
The Fatigue Severity Scale (FSS) was used to assess the
presence and severity of fatigue. The FSS represents the
most commonly used self-report questionnaire to
measure fatigue and has recently been validated for a
variety of neurological disorders in a large sample size
study (n = 1304), showing an excellent internal con-
sistency and reliability [28]. Several studies have used
the FSS in patients with PD, although the scale has not
yet been validated for PD [29]. We performed a reli-
ability statistic in this study sample, ﬁnding a high
internal consistency (Cronbachs a = 0.94) and good
item consistencies. For the assessment of EDS, we used
the validated Epworth Sleepiness Scale (ESS), where a
score ‡10 indicates EDS [30]. The questionnaire also
included questions on mean time in bed per 24 h. The
term increased sleep duration was used in patients with
PD with mean times in bed ‡10 h per day. Further-
more, the Beck Depression Inventory (BDI) was used
for evaluation of depression with a cut-oﬀ of ‡12 for the
presence of depression [31].
Dopaminergic medication
To compare diﬀerent dopaminergic medications at
doses of equivalent eﬃcacy, we converted all dosages to
levodopa dosage equivalents (LDE) according to the
following formula [10,32]: LDE = (regular levodopa
dose · 1) + (levodopa controlled release dose ·
0.75) + (pramipexole dose · 67) + (ropinirole dose
· 16.67) + (pergolide dose · 100) + (cabergoline dose
· 50) + (levodopa/entacapone dose · 1.25).
Data analysis and statistics
Data analyses include a synopsis of the demographic
and clinical characteristics of our study population, the
calculation of the prevalences of the diﬀerent vigilance
disturbances as well as their interactions, and their
association with other PD-related motor and non-
motor symptoms. For this purpose, we used SPSS (ver-
sion 16.0; Pearson Education Deutschland GmbH,
Mu¨nchen, Germany), STATA version 9.2 (Stata Corp
LP, College Station, TX, USA), and R version 2.10
(R Foundation for Statistical Computing, Vienna,
Austria, http://www.R-project.org). for statistical
analyses. Group data are described by means and
standard deviations (SD). For univariate analysis, we
used Students t-test for numerical scale variables and
v2-test for nominal scale variables. Correlation analyses
were performed using the Pearsons coeﬃcient. We used
multinomial regression to assess the inﬂuence of
depression (BDI) and motor symptoms (UPDRS III)
on the odds ratio (OR) of only EDS (without fatigue),
only fatigue (without EDS), and both symptoms. The
reference category in both regression models was the
group of patients with no EDS and no fatigue. Signif-
icance was accepted at P < 0.05. Internal consistency
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of the FSS in this study sample was assessed by calcu-
lating the item to total correlation and the Cronbachs a
statistics [33].
Results
Subjects and treatment
The demographic and clinical characteristics of our 88
patients are shown in Table 1. The majority of patients
received a combination of levodopa with a dopamine
agonist (DA; 44 patients, 50%), whereas 33 patients
(38%) had levodopa monotherapy and nine patients
(10%) had DA monotherapy. No patients were on
rasagiline or selegiline treatment.
Prevalence of fatigue, EDS, and increased sleep
duration
Fatigue (FSS ‡4.0) was present in 52 patients (59%);
mean FSS for all patients was 4.2 ± 1.6. EDS (ESS
‡10) was reported by 42 patients (48%); mean ESS was
9.7 ± 5.0. Thirty-one patients (35%) suﬀered from
both fatigue and EDS, whereas 11 patients (13%) had
only EDS and 21 patients (24%) had only fatigue.
Twenty-ﬁve patients (28%) indicated neither fatigue
nor EDS. Increased sleep duration was found in 15
patients (17%); mean time in bed was 8.4 ± 1.5 h. The
distribution of these sleep-wake disturbances was
independent of age and gender. However, the preva-
lence and severity of EDS but not of fatigue or
increased sleep duration became higher with longer
disease duration. Disease duration correlated with ESS
scores (r = 0.32, P = 0.003), but not with FSS scores
Table 1 Demographic and clinical characteristics of 88 patients with
idiopathic Parkinsons disease. To describe dopaminergic treatment,
the numbers and percentages of patients with a respective dopami-
nergic treatment are provided
Demographic data
Age (years) 67.5 ± 9.7 (38–84)
Gender, male 61 (69%)
Parkinson-related data
Disease duration (years) 9.8 ± 5.4 (2–28)
UPDRS III 21.5 ± 10.1 (4–59)
Hoehn & Yahr 2.3 ± 0.8 (1–5)
Affected side, left 50 (57%)
Type, tremor-dominant 23 (26%)
Type, akinetic-rigid 51 (58%)
Autonomic disturbances 31 (35%)
Neuropsychiatric symptoms
Hallucinations 21 (24%)
History of REM sleep behavior disorder 24 (27%)
BDI 11.6 ± 6.9 (0–35)
Depression (BDI ‡12) 37 (42%)
Sleep-wake disturbances
FSS 4.2 ± 1.6 (1.1–7)
Fatigue (FSS ‡4.0) 52 (59%)
ESS 9.7 ± 5.0 (2–24)
EDS (ESS ‡10) 42 (48%)
Time in bed (h) 8.4 ± 1.5 (4–13.5)
Increased sleep duration (bedtime ‡10 h) 15 (17%)
Insomnia 59 (67%)
Dopaminergic treatment
Levodopa 46 (52%)
Only levodopa 33 (38%)
DA 53 (60%)
Non-ergot DA 46 (52%)
Ergot DA 8 (9%)
Only DA 9 (10%)
Both levodopa and DA 44 (50%)
Levodopa + entacapone 32 (36%)
No dopaminergic drugs 2 (2%)
LDE (mg/day) 681 ± 402 (0–1581)
UPDRS, Uniﬁed Parkinsons Disease Rating Scale (part III = motor
score); BDI, Beck Depression Inventory; REM sleep, rapid eye
movement sleep; FSS, Fatigue Severity Scale; ESS, Epworth Sleepiness
Scale; DA, dopamine agonist; LDE, levodopa dosage equivalent.
r = –0.02
r = 0.32 
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Figure 1 Association of fatigue and excessive daytime sleepiness
(EDS) with disease duration. Individual scores for Fatigue
Severity Scale (FSS) or Epworth Sleepiness Scale (ESS) were
plotted against disease duration.
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(r = )0.02, P = 0.82) or mean time in bed (r = )0.17,
P = 0.12) (Fig. 1).
Polysomnographic data (n = 26)
Patients with a high arousal index, i.e. with frequent
electroencephalographic arousals at night, had lower
FSS scores (r = )0.48, P = 0.03). Similarly, a higher
periodic leg movements in sleep (PLMS) index was
found in non-fatigued than in fatigued patients
(37 ± 49 vs. 6 ± 21, P = 0.04). Fourteen patients
(54%) were diagnosed with moderate (apnea hypopnea
index, AHI = 20–30/h) to severe (AHI ‡30/h) sleep
apnea; no correlation was found between AHI and FSS
(r = 0.07, P = 0.74) or ESS scores (r = 0.23, P =
0.27). Other associations between polysomnographic
ﬁndings and the FSS, ESS, or mean bedtimes were not
found (data not shown).
The relation of fatigue to other PD-related symptoms
Fatigued patients with PD had more severe motor
symptoms than patients with PD without fatigue
(UPDRS III: 23.5 ± 11.1 vs. 18.6 ± 7.6, P = 0.03,
Hoehn & Yahr: 2.4 ± 0.9 vs. 2.1 ± 0.7, P = 0.03)
(Table 2). Our multinomial regression model conﬁrmed
this result: For motor symptoms (UPDRS III), we
found a positive association for the comparison of fa-
tigue alone versus the reference category: patients with
PD with a 10 point higher value on the UPDRS scale
have an estimated OR of 2.69 (P = 0.005) to suﬀer
from fatigue.
Fatigued patients with PD more often reported
PD-related insomnia (77% vs. 53% respectively,
P = 0.02) and autonomic disturbances (46% vs. 19%,
P = 0.008). On the other hand, the presence of fatigue
was not associated with PD features such as predomi-
nantly aﬀected body side, disease type (tremor-domi-
nant versus akinetic-rigid), or hallucinations. Fatigued
patients with PD more often were depressed (52% vs.
28%, P = 0.02) and had higher BDI scores
(13.4 ± 7.1 vs. 9.1 ± 5.8, P = 0.004).
The relation of EDS to other PD-related symptoms and
treatment
Comparing patients with PD with and without EDS, we
found no diﬀerences concerning severity of motor
symptoms, conﬁrmed in the multinomial regression
model, predominantly aﬀected body side, disease type
(tremor-dominant versus akinetic-rigid), hallucinations,
autonomic disturbances, or frequency, and severity of
Table 2 Comparison of patients with Parkinsons disease with and without fatigue (FSS ‡4.0), and with and without EDS (ESS ‡10)
Fatigued patients Non-fatigued patients P Patients with EDS Patients without EDS P
n 52 (59%) 36 (41%) 42 (48%) 46 (52%)
Age 67.2 ± 10.5 67.8 ± 8.6 0.77 68.2 ± 9.2 66.8 ± 10.2 0.52
Gender (m/f) 39/13 22/14 0.13 31/11 30/16 0.26
Disease duration 9.4 ± 4.6 10.3 ± 6.5 0.47 10.3 ± 4.5 9.4 ± 6.1 0.44
UPDRS III 23.5 ± 11.1 18.6 ± 7.6 0.03 22.3 ± 10.5 20.8 ± 9.8 0.50
Hoehn & Yahr 2.4 ± 0.9 2.1 ± 0.7 0.03 2.3 ± 0.8 2.3 ± 0.8 0.91
Autonomic disturbances 24/52 (46%) 7/36 (19%) 0.008 16/42 (38%) 15/46 (33%) 0.38
ESS 11.1 ± 5.1 7.6 ± 4.2 0.001
EDS (ESS ‡10) 31/52 (60%) 11/36 (31%) 0.007
FSS 4.8 ± 1.4 3.7 ± 1.5 <0.001
Fatigue (FSS ‡4.0) 31/42 (74%) 21/46 (46%) 0.007
Time in bed (h) 8.7 ± 1.7 8.1 ± 1.2 0.12 8.5 ± 1.7 8.4 ± 1.4 0.90
Insomnia 40/52 (77%) 19/36 (53%) 0.02 33/42 (79%) 26/46 (57%) 0.04
BDI 13.4 ± 7.1 9.1 ± 5.8 0.004 10.9 ± 5.5 12.3 ± 8.0 0.36
Depression (BDI ‡12) 27/52 (52%) 10/36 (28%) 0.02 16/42 (38%) 21/46 (46%) 0.31
LDE (mg/day) 732 ± 417 609 ± 375 0.16 729 ± 372 638 ± 427 0.29
PSG
Latency NREM2 (min) 21.7 ± 30.2 41.3 ± 38.4 0.17 33.2 ± 44.4 25.6 ± 20.0 0.59
Latency REM (min) 101.4 ± 43.2 92.5 ± 31.0 0.58 83.4 ± 25.7 113.5 ± 44.4 0.05
Arousal index 11.9 ± 9.0 24.0 ± 30.2 0.16 10.0 ± 5.4 24.1 ± 28.0 0.09
Sleep efﬁciency (%) 68.8 ± 21.5 81.3 ± 17.4 0.14 71.8 ± 23.9 75.7 ± 16.7 0.64
PLMS index 6.0 ± 21.2 36.6 ± 49.1 0.04 20.9 ± 44.9 14.2 ± 26.4 0.65
Wake (%) 31.2 ± 21.5 18.7 ± 17.4 0.14 28.2 ± 23.9 24.3 ± 16.7 0.64
Bold values indicate signiﬁcance.
UPDRS, Uniﬁed Parkinsons Disease Rating Scale (part III = motor score); BDI, Beck Depression Inventory; REM sleep, rapid eye movement
sleep; FSS, Fatigue Severity Scale; ESS, Epworth Sleepiness Scale; EDS, excessive daytime sleepiness; LDE, levodopa dosage equivalent; PSG,
polysomnography; NREM, non-rapid eye movement sleep; PLMS, periodic leg movements in sleep.
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depression (Table 2). Insomnia was more prevalent in
patients with PD with EDS (79% vs. 57%, P = 0.04).
The relation of increased sleep duration to other PD-
related symptoms
Patients with PD with increased sleep duration (n = 15)
were more severely aﬀected by motor symptoms
(UPDRS III: 27.3 ± 9.4 vs. 20.3 ± 9.9, P = 0.02)
compared to patients with PD with mean time in bed
<10 h (n = 73). There were no associations of the
presence or severity of increased sleep duration with
other PD symptoms such as autonomic disturbances,
disease type, and predominantly aﬀected body side.
The relations between fatigue, EDS, and increased
sleep duration in PD
FSS scores signiﬁcantly correlated with ESS scores
(r = 0.48, P < 0.001). EDS was almost twice as fre-
quent amongst fatigued patients compared to non-
fatigued patients (60% vs. 31%, P = 0.007). Similarly,
patients with PD with EDS had signiﬁcantly higher FSS
scores (4.8 ± 1.4 vs. 3.7 ± 1.5, P < 0.001). Patients
with PD with increased sleep duration (n = 15) were
more fatigued (FSS: 5.1 ± 1.2 vs. 4.0 ± 1.6, P = 0.02;
prevalence of FSS ‡4.0: 87% vs. 53%, P = 0.02). On
the other hand, there were no associations between
increased sleep duration and EDS.
The relation of fatigue, EDS, and increased sleep
duration to dopaminergic treatment
Presence and severity of fatigue were independent of
LDE or daily doses of levodopa or ergot DA. However,
patients with non-ergot DA had higher FSS scores
(4.5 ± 1.5) than patients with PD that were not treated
with non-ergot DA (3.9 ± 1.5, P = 0.049). The pres-
ence of EDS and increased sleep duration was inde-
pendent of whether patients were treated with levodopa
or ergot DA. However, total LDE correlated mildly
with the severity of EDS as assessed with the ESS
(r = 0.22, P = 0.04). Again, patients with non-ergot
DA had higher ESS scores (10.9 ± 5.1) than patients
without non-ergot DA (8.4 ± 4.7, P = 0.02).
A comparison of patients under levodopa mono-
therapy (n = 33) and patients receiving both levodopa/
DA (n = 44) revealed no diﬀerences for FSS score and
mean time in bed, but signiﬁcantly higher ESS scores in
patients taking both levodopa/DA (10.9 ± 4.3 vs.
8.4 ± 5.0, P = 0.02) (Table 3). Patients with levodopa
monotherapy slept almost 1 h more per night than
patients with both levodopa/DA (8.9 ± 1.2 vs.
8.0 ± 1.6, P = 0.006), and suﬀered less frequently
from insomnia (52% vs. 80%, P = 0.01). There was a
trend toward longer disease duration in the patient
group with both levodopa/DA (8.9 ± 5.3 vs.
11.0 ± 5.0, P = 0.08). Analyzing the dose-dependent
eﬀect (LDE) of speciﬁc dopaminergic drugs on FSS/
ESS scores, we found no correlation for levodopa (FSS:
r = 0.10, P = 0.50; ESS: r = 0.16, P = 0.37), ergot
DA (FSS: r = 0.11, P = 0.80; ESS: r = )0.28,
P = 0.50), and non-ergot DA (FSS: r = 0.24,
P = 0.11; ESS: r = 0.26, P = 0.08). For levo-
dopa + entacapone, however, we found a signiﬁcant
dose-dependent increase of the FSS score (r = 0.51,
P = 0.003), but not of the ESS score (r = 0.16,
P = 0.37).
Depression and vigilance impairment
Thirty-seven patients with PD (42%) fulﬁlled the cri-
teria for depression (BDI ‡12). BDI scores were not
associated with motor symptoms as assessed by
UPDRS III. Mean FSS was signiﬁcantly higher in
depressed (4.8 ± 1.2) than in non-depressed patients
with PD (3.8 ± 1.7, P = 0.004), and BDI scores
correlated with FSS scores (r = 0.33, P = 0.002).
Similarly, in the multinomial regression model, only
fatigue alone was associated with a signiﬁcantly
increased OR of depression (OR = 7.92, 95% CI (2.12;
29.67), P = 0.002), whereas no signiﬁcant eﬀects of
Table 3 Dopaminergic treatment: patients with only levodopa versus
patients with both levodopa and DA
Only
levodopa
Both
levodopa + DA P
n 33 44
Sex (male/female) 21/12 34/10 0.19
Age 70.4 ± 10.0 66.5 ± 9.1 0.08
Disease duration 8.9 ± 5.3 11.0 ± 5.0 0.08
UPDRS III 22.6 ± 9.9 20.9 ± 8.9 0.43
Hoehn & Yahr 2.3 ± 0.8 2.4 ± 0.8 0.86
FSS 4.0 ± 1.5 4.3 ± 1.6 0.43
ESS 8.4 ± 5.0 10.9 ± 4.3 0.02
Time in bed 8.9 ± 1.2 8.0 ± 1.6 0.01
Insomnia 17/33 (52%) 35/44 (80%) 0.01
BDI 13.6 ± 8.2 11.1 ± 6.0 0.13
PSG
Latency NREM2 (min) 40.9 ± 37.6 24.1 ± 35.4 0.32
Latency REM (min) 100.0 ± 42.0 97.7 ± 39.1 0.90
Arousal index 9.3 ± 5.2 19.4 ± 25.7 0.32
Sleep efﬁciency (%) 74.5 ± 27.3 72.3 ± 19.0 0.82
PLMS index 30.4 ± 39.5 12.7 ± 38.3 0.32
Wake (%) 25.5 ± 27.3 27.8 ± 19.0 0.82
Bold values indicate signiﬁcance.
UPDRS, Uniﬁed Parkinsons Disease Rating Scale (part III = motor
score); FSS, Fatigue Severity Scale; ESS, Epworth Sleepiness Scale;
BDI, Beck Depression Inventory; DA, dopamine agonist; LDE,
levodopa dosage equivalent; PSG, polysomnography; NREM, non-
rapid eye movement sleep; PLMS, periodic leg movements in sleep.
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depression were found for the contrasts of EDS alone
or both fatigue and EDS (Fig. 2). Twenty-seven
patients (31%) suﬀered from both fatigue and depres-
sion, but the frequency of fatigue without concomitant
depression was similarly high (25 patients, 28%).
Similarly, depressed patients had longer mean time in
bed than non-depressed patients (8.8 ± 1.4 h vs.
8.2 ± 1.6 h, P = 0.04). On the other hand, there was
no association between ESS and BDI.
Discussion
This study conﬁrms that fatigue (59%) and EDS (48%)
are frequent complaints in idiopathic PD. The indicated
frequencies are comparable to other reports on fatigue
(reported prevalences: 40–60% [1,11–13]) and EDS
(reported prevalences: 33–75% [10,34–37]) in PD.
Although we found a signiﬁcant overlap between
fatigue and EDS (35%), the two complaints appeared
to be diﬀerently associated with other clinical features
of PD and with the dopaminergic medication.
Fatigue, but not EDS, correlated with the severity of
motor symptoms (UPDRS III) and disease disability
(Hoehn & Yahr). In multiple sclerosis and ischemic
stroke, a similar correlation between fatigue and phys-
ical disability as measured by the expanded disability
status scale (EDSS), and by the National Institutes of
Health Stroke Scale, NIHSS, respectively, has been
found by various groups [4,28,38–40]. In PD, however,
Lou et al. [15] failed to establish a relationship between
motor disability and the presence of fatigue. In this
particular study, however, the sample size was low
(n = 39), fatigue was assessed with another question-
naire (Multidimensional Fatigue Inventory), and
disease severity was estimated only by the Hoehn &
Yahr staging. Karlsen et al. [13] found an association
between fatigue and disease severity that was not
conﬁrmed by multiple regression analysis. Conversely,
and in agreement with our own ﬁndings, Alves et al.
[19] showed in a prospective longitudinal study that
fatigue correlates with PD severity.
Longer disease duration was associated with higher
ESS but not higher FSS scores. A weak yet signiﬁcant
correlation between daytime sleepiness and longer dis-
ease duration was reported also by other groups
[10,36,41,42]. On the other hand, little is known about
the natural course of fatigue during progression of PD.
Friedman et al. [1] found that the prevalence of fatigue
remained stable over 9 years, although fatigue severity
worsened in aﬀected patients. Conversely, Alves et al.
[19] prospectively assessed the prevalence of fatigue
every 4 years and found an increase from 36% to 43%
and then to 56%. In this study, however, fatigue was
assessed with diﬀerent measurement tools at diﬀerent
time points, using the FSS only during the last assess-
ment. The lack of correlation between fatigue and
disease duration in our study might be explained by the
high prevalence of fatigue already during the ﬁrst years
after disease onset, whereas the prevalence of EDS
increased only later. In summary, the ﬁnding of a
diﬀerent evolution of fatigue and EDS during PD
progression corroborates the concept of two distinct
symptoms with diﬀerent pathomechanisms. We
suppose that EDS in PD is directly inﬂuenced by the
underlying neuropathology, which includes a disrupt-
ion of wake-promoting dopaminergic and hypocretin-
ergic structures in the upper brainstem and the
diencephalon [43–45]. It is conceivable that the increase
in EDS with longer disease duration reﬂects the
progression of neuropathological processes that
supposedly start in the caudal brainstem and thereafter
aﬀect other areas in the upper brainstem, diencephalon,
and cortex in an ascending pattern [43].
It may appear confusing that the UPDRS III scores
were not diﬀerent between patients with PD with and
without EDS, considering that both EDS and motor
disability signiﬁcantly worsen with disease duration.
We believe that the lack of such a diﬀerence could be
because of distinct mechanisms, by which the neuro-
degenerative progression leads to a deterioration of
motor symptoms on one hand and to an increase of
sleepiness on the other hand. The neuroanatomical
structures, which are involved in mediating the wors-
ening of the two symptoms, are diﬀerent and may be
aﬀected diﬀerently in an individual patient. Sleepiness is
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Figure 2 Multinomial regression model for depression against
excessive daytime sleepiness (EDS) alone, fatigue alone or both,
showing the respective odds ratios and corresponding 95%
conﬁdence intervals (CI).
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not directly caused by motor disability – as we suspect it
is in part the case with fatigue – but rather by a dis-
ruption of wake-promoting brainstem structures.
Fatigue, on the other hand, is characterized by its
multidimensionality encompassing cognitive, physical
and psychosocial aspects, and seems to be inﬂuenced by
a multitude of factors including motor symptoms,
depression, and EDS. This diﬀuse and complex overlap
with many other disease features probably explains,
why fatigue – conversely to the more speciﬁc symptom
of EDS – is present in many patients at an early disease
stage. Multiple sclerosis is another disorder, in which a
high prevalence of fatigue already at disease onset and a
lack of correlation with disease duration were reported
[28].
The presence of depression was signiﬁcantly associ-
ated with fatigue, but no relationship between
depression and EDS was established. Using a regres-
sion model, fatigue appeared to be correlated with
depression only in the patient group with fatigue but
without EDS (OR = 7.92, P = 0.002). The overall
prevalence of depression (42%) in our study sample is
comparable to other reports [46,47]. However,
depression does not primarily account for the high
frequency of fatigue in PD, as fatigue was similarly
prevalent also in the non-depressed patients with PD
of our study sample. The regression model found no
correlation for depression and fatigue in the patient
group suﬀering from both fatigue and EDS. This
ﬁnding might be explained by diﬀerent degrees of
comorbidity between depression, fatigue, and EDS: In
patients with both fatigue and EDS, fatigue could to
some extent be primarily related to EDS, whereas
fatigue in the absence of EDS is more probably to be
related to depression. The complex interaction and
overlaps of fatigue with other PD symptoms may
reﬂect the sparse knowledge of the pathophysiology of
fatigue, but also the low speciﬁcity in the assessment of
this ill-deﬁned symptom.
There is increasing literature dealing with the
relationship between dopaminergic drugs and EDS
[7–10,34], but the eﬀects on fatigue have been largely
neglected. Our data suggest that dopaminergic treat-
ment exerts a stronger eﬀect on EDS than on fatigue.
We found a weak yet signiﬁcant correlation between the
levodopa equivalent daily dose and ESS scores
(r = 0.22, P = 0.04), which is in line with the ﬁnding
of the Canadian Movement Disorder group in 638
patients with PD with various dopaminergic drugs
(r = 0.16, P < 0.001) [10]. In contrast, we found no
signiﬁcant correlation between levodopa equivalent
daily dose and FSS scores. Comparing patients with
levodopa monotherapy with patients under combina-
tion of levodopa with a DA, namely pramipexole or
ropinirole, the two groups diﬀered signiﬁcantly for ESS,
but not FSS scores. Similarly, Paus et al. [34] reported a
higher risk of sleep attacks in patients with PD with a
combination therapy of levodopa/DA compared to
patients with levodopa monotherapy. In this study,
however, ESS scores were not diﬀerent between patients
on levodopa monotherapy compared to levodopa/DA.
As our two groups diﬀered signiﬁcantly concerning
LDE, it remains unclear whether the diﬀerences in ESS
scores are caused by the diﬀerent dopaminergic treat-
ment, particularly the use of DA in the second group,
or simply by the higher LDE. Furthermore, the disease
duration was longer in the patient group with both
levodopa/DA, which may also account for the diﬀer-
ences of ESS scores. This diﬀerence might have
achieved statistical signiﬁcance if the included patient
number had been higher.
We did not assess detailed PD-related nighttime
disturbances by means of a validated tool such as the
Pittsburgh sleep questionnaire, which constitutes a
major limitation of our study. However, Fabbrini
et al. [48] found no correlation between the items of
the Pittsburgh sleep questionnaire and the ESS in
patients with PD, suggesting that EDS is not primarily
caused by sleep insuﬃciency but rather by neurode-
generation, e.g. EDS of central origin. Our ﬁnding
that PD-related fatigue was not associated with fre-
quent arousals during nocturnal sleep nor with a
higher PLMS index is also in line with this assump-
tion. A further limitation of this study is the low
number of performed polysomnographies that does
not allow estimating the inﬂuence of sleep apnea on
PD-related fatigue and EDS. We found no association
between AHI and fatigue or EDS, but the prevalence
of moderate to severe sleep apnea was high (54%).
Earlier studies reported prevalences of sleep apnea in
PD that ranged between 20–55% [49–53]. Recently,
Monaca et al. [53] could not establish any correlation
between AHI and mean sleep latency in the multiple
sleep latency test (MSLT).
In conclusion, our ﬁndings suggest that fatigue and
EDS, although often coexisting, are diﬀerently related
to severity of motor symptoms, disease duration,
depression, and dopaminergic treatment. Fatigue, EDS,
and depression all represent frequent non-motor
symptoms in PD, which may substantially overlap, in
particular fatigue-depression and fatigue-EDS. We
assume that – depending on the underlying patho-
physiology – fatigue in PD may be inﬂuenced by a
multitude of factors including vigilance impairment and
EDS, depression, and motor symptoms themselves,
which probably reﬂects the coexistent physical and
mental dimension of this symptom. Fatigue and EDS
should be separately assessed in PD in order to improve
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our understanding of their distinct but overlapping
pathophysiology.
References
1. Friedman JH, Friedman H. Fatigue in Parkinsons
disease: a nine-year follow-up. Mov Disord 2001; 16:
1120–1122.
2. Bran˜as P, Jordan R, Fry-Smith A, et al. Treatments for
fatigue in multiple sclerosis: a rapid and systematic review.
Health Technol Assess 2000; 4: 1–61.
3. Zifko UA. Management of fatigue in patients with mul-
tiple sclerosis. Drugs 2004; 64: 1295–1304.
4. Choi-Kwon S, Han SW, Kwon SU, et al. Poststroke
fatigue: characteristics and related factors. Cerebrovasc
Dis 2005; 19: 84–90.
5. Staub F, Bogousslavsky J. Fatigue after stroke: a major
but neglected issue. Cerebrovasc Dis 2001; 12: 75–
81.
6. Baumann CR, Werth E, Stocker R, Ludwig S, Bassetti
CL. Sleep-wake disturbances 6 months after traumatic
brain injury: a prospective study. Brain 2007; 130:
1873–1883.
7. Frucht S, Rogers JD, Greene PE, Gordon MF, Fahn S.
Falling asleep at the wheel: motor vehicle mishaps in
persons taking pramipexole and ropinirole. Neurology
1999; 52: 1908–1910.
8. Schapira AH. Sleep attacks (sleep episodes) with pergo-
lide. Lancet 2000; 355: 1332–1333.
9. Hauser RA, Gauger L, Anderson WM, Zesiewicz TA.
Pramipexole-induced somnolence and episodes of daytime
sleep. Mov Disord 2000; 15: 658–663.
10. Hobson DE, Lang AE, Martin WRW, Razmy A, Rivest
J, Fleming J. Excessive daytime sleepiness and sudden-
onset sleep in Parkinson Disease. JAMA 2002; 287:
455–463.
11. Schenkman M, Wei Zhu C, Cutson TM, Whetten-Gold-
stein K. Longitudinal evaluation of economic and physi-
cal impact of Parkinsons disease. Parkinsonism Relat
Disord 2001; 8: 41–50.
12. Shulman LM, Taback RL, Bean J, Weiner WJ. Comor-
bidity of the nonmotor symptoms of Parkinsons disease.
Mov Disord 2001; 16: 507–510.
13. Karlsen K, Larsen JP, Tandberg E, Jørgensen K. Fatigue
in patients with Parkinsons disease.Mov Disord 1999; 14:
237–241.
14. Friedman J, Friedman H. Fatigue in Parkinsons disease.
Neurology 1993; 43: 2016–2018.
15. Lou JS, Kearns G, Oken B, Sexton G, Nutt J. Exacer-
bated physical fatigue and mental fatigue in Parkinsons
disease. Mov Disord 2001; 16: 190–196.
16. Herlofson K, Larsen JP. Measuring fatigue in patients
with Parkinsons disease – the Fatigue Severity Scale. Eur
J Neurol 2002; 9: 595–600.
17. Abe K, Takanashi M, Yanagihara T. Fatigue in
patients with Parkinsons disease. Behav Neurol 2000; 12:
103–106.
18. Hagell P, Brundin L. Towards an understanding of fati-
gue in Parkinson disease. J Neurol Neurosurg Psychiatry
2009; 80: 489–493.
19. Alves G, Wentzel-Larsen T, Larsen JP. Is fatigue an
independent and persistent symptom in patients with
Parkinson disease? Neurology 2004; 63: 1908–1911.
20. Rye DB, Bliwise DL, Dihenia B, Gurecki P. Daytime
sleepiness in Parkinsons disease. J Sleep Res 2000; 9:
63–69.
21. Tandberg E, Larsen JP, Karlsen K. Excessive daytime
sleepiness and sleep beneﬁt in Parkinsons disease: a
community-based study. Mov Disord 1999; 14: 922–927.
22. Adler CH, Thorpy MJ. Sleep issues in Parkinsons disease.
Neurology 2005; 64(Suppl.): 12–20.
23. Friedman JH, Chou KL. Sleep and fatigue in Parkinsons
disease. Parkinsonism Relat Disord 2004; 10(Suppl.): 27–
35.
24. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for
Parkinson disease. Arch Neurol 1999; 56: 33–39.
25. Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ. What
features improve the accuracy of clinical diagnosis in
Parkinsons disease: a clinicopathologic study. Neurology
1992; 42: 1142–1146.
26. Fahn S, Elton RL and the members of the UPDRS
Development Committee. Uniﬁed Parkinsons Disease
Rating Scale. In: Fahn S, Marsden CD, Calne DB, Lie-
bermann A, eds. Recent Development in Parkinsons Dis-
ease. Florham Park, NJ: MacMillan Health Care
Information, 1987: 153–163.
27. Hoehn MH, Yahr MD. Parkinsonism: onset, progression
and mortality. Neurology 1967; 17: 427–442.
28. Valko PO, Bassetti CL, Bloch KE, Held U, Baumann CR.
Validation of the Fatigue Severity Scale in a Swiss cohort.
Sleep 2008; 31: 1601–1607.
29. Friedman JH, Brown RG, Comella C, et al; as the
Working Group on Fatigue in Parkinsons Disease.
Fatigue in Parkinsons disease: a review.Mov Disord 2007;
22: 297–308.
30. Bloch KE, Schoch OD, Zhang JN, Russi EW. German
version of the Epworth Sleepiness Scale. Respiration 1999;
66: 440–447.
31. Beck AT, Ward CH, Mendelson M, Mock M, Erbaugh J.
An inventory for measuring depression. Arch Gen Psy-
chiatry 1961; 4: 561–571.
32. Razmy A, Lang AE, Shapiro CM. Predictors of impaired
daytime sleep and wakefulness in patients with Parkinson
Disease treated with older (ergot) vs newer (nonergot)
dopamine agonists. Arch Neurol 2004; 61: 97–102.
33. Cronbach LJ. Coefﬁcient alpha and the internal structure
of test. Psychometrika 1951; 16: 297–334.
34. Paus S, Brecht HM, Ko¨ster J, Seeger G, Klockgether T,
Wu¨llner U. Sleep attacks, dayime sleepiness, and dopa-
mine agonists in Parkinsons disease. Mov Disord 2003;
18: 659–667.
35. Brodsky MA, Godbold J, Roth T, Olanow CW. Sleepi-
ness in Parkinsons disease: a controlled study. Mov Dis-
ord 2003; 18: 668–672.
36. Ondo WG, Dat Vuong K, Khan H, Atassi F, Kwak C,
Jankovic J. Daytime sleepiness and other sleep disorders in
Parkinsons disease. Neurology 2001; 57: 1392–1396.
37. Ho¨gl B, Seppi K, Brandauer E, et al. Increased daytime
sleepiness in Parkinsons disease: a questionnaire survey.
Mov Disord 2003; 18: 319–323.
38. Pittion-Vouyovitch S, Debouverie M, Guillemin F, Van-
denberghe N, Anxionnat R, Vespignani H. Fatigue in
multiple sclerosis is related to disability, depression and
quality of life. J Neurol Sci 2006; 243: 39–45.
39. Bergamaschi R, Romani A, Versino M, Poli R, Cosi V.
Clinical aspects of fatigue in multiple sclerosis. Funct
Neurol 1997; 12: 247–251.
Fatigue and EDS in idiopathic PD 1435
 2010 The Author(s)
European Journal of Neurology  2010 EFNS European Journal of Neurology 17, 1428–1436
40. Flachenecker P, Ku¨mpfel T, Kallmann B, et al. Fatigue in
multiple sclerosis: a comparison of different rating scales
and correlation to clinical parameters. Mult Scler 2002; 8:
523–526.
41. Gjerstad MD, Aarsland D, Larsen JP. Development of
daytime somnolence over time in Parkinsons disease.
Neurology 2002; 58: 1544–1546.
42. Del Dotto P, Gambaccini G, Caneparo D, Berti C, Ber-
nardini S, Bonuccelli U. Bedtime cabergoline in Parkin-
sons disease patients with excessive daytime sleepiness
induced by dopamine agonists. Neurol Sci 2003; 24: 170–
171.
43. Braak H, Del Tredici K, Ru¨b U, de Vos RAI, Jansen
Steur ENH, Braak E. Staging of brain pathology related
to sporadic Parkinsons disease. Neurobiol Aging 2003; 24:
197–211.
44. Fronczek R, Overeem S, Lee SY, et al. Hypocretin
(orexin) loss in Parkinsons disease. Brain 2007; 130: 1577–
1585.
45. Thannickal TC, Lai YY, Siegel JM. Hypocretin (orexin)
cell loss in Parkinsons disease. Brain 2007; 130: 1586–
1595.
46. Marsh L, McDonald WM, Cummings J, Ravina B. Pro-
visional diagnostic criteria for depression in Parkinsons
Disease: a report of an NINDS/NIMH Work Group.
Mov Disord 2006; 21: 148–158.
47. Dooneief G, Mirabello E, Bell K, Marder K, Stern Y,
Mayeux R. An estimate of the incidence of depression in
idiopathic Parkinsons disease. Arch Neurol 1992; 49: 305–
307.
48. Fabbrini G, Barbanti P, Aurilia C, Vanacore N, Pauletti
C, Meco G. Excessive daytime sleepiness in de novo
and treated Parkinsons disease. Mov Disord 2002; 17:
1026–1030.
49. Comella CL. Sleep disorders in Parkinsons disease: an
overview. Mov Disord 2007; 17(Suppl.): 367–373.
50. Maria B, Sophia S, Michalis M, et al. Sleep breathing
disorders in patients with idiopathic Parkinsons disease.
Respir Med 2003; 97: 1151–1157.
51. Arnulf I, Konofal E, Merino-Andreu M, et al. Parkin-
sons disease and sleepiness: an integral part of PD.
Neurology 2002; 58: 1019–1024.
52. Ferini-Strambi L, Franceschi M, Pinto P, Zucconi M,
Smirne S. Respiration and heart rate variability during
sleep in untreated Parkinson patients. Gerontology 1992;
38: 92–98.
53. Monaca C, Duhamel A, Jacquesson JM, et al. Vigilance
trouble in Parkinsons disease: a subjective and objective
polysomnographic study. Sleep Med 2006; 7: 448–453.
1436 P. O. Valko et al.
 2010 The Author(s)
European Journal of Neurology  2010 EFNS European Journal of Neurology 17, 1428–1436
Excessive sleep need following traumatic brain injury:
a case–control study of 36 patients
M ICHAEL SOMMERAUER , PH I L I P P O . VA LKO , ESTHER WERTH
and CHR I S T I AN R . BAUMANN
Department of Neurology, University Hospital Zurich, Zurich, Switzerland
Keywords
excessive daytime sleepiness, hypersomnia,
raumatic brain injury
Correspondence
Michael Sommerauer, Department of
Neurology, University Hospital Zurich,
Frauenklinikstrasse 26, 8091 Zurich,
Switzerland.
Tel.: +41-44-255-55-11;
fax: +41-44-255-43-80;
e-mail: michael.sommerauer@rwth-aachen.de
Accepted in revised form 1 June 2013; received
21 February 2013
DOI: 10.1111/jsr.12068
SUMMARY
Increased sleep need following traumatic brain injury, referred to in this
study as post-traumatic pleiosomnia, is common, but so far its clinical
impact and therapeutic implications have not been characterized. We
present a case–control study of 36 patients with post-traumatic pleio-
somnia, deﬁned by an increased sleep need of at least 2 h per 24 h after
traumatic brain injury, compared to 36 controls. We assessed detailed
history, sleep-activity patterns with sleep logs and actigraphy, nocturnal
sleep with polysomnography and daytime sleep propensity with multiple
sleep latency tests. Actigraphy recordings revealed that traumatic brain
injury (TBI) patients had longer estimated sleep durations than controls
(10.8 h per 24 h, compared to 7.3 h). When using sleep logs, TBI
patients underestimated their sleep need. During nocturnal sleep,
patients had higher amounts of slow-wave sleep than controls (20
versus 13.8%). Multiple sleep latency tests revealed excessive daytime
sleepiness in 15 patients (42%), and 10 of them had signs of chronic
sleep deprivation. We conclude that post-traumatic pleiosomnia may be
even more frequent than reported previously, because affected patients
often underestimate their actual sleep need. Furthermore, these patients
exhibit an increase in slow-wave sleep which may reﬂect recovery
mechanisms, intrinsic consequences of diffuse brain damage or relative
sleep deprivation.
INTRODUCTION
Traumatic brain injury (TBI) is a highly prevalent medical
condition, particularly in younger people. In the United States,
more than 1.5 million people incur TBI every year (Rutland-
Brown et al., 2006). The available epidemiological data from
Europe are in the same range (Bruns and Hauser, 2003;
Tagliaferri et al., 2006). Traumatic damage to the brain
causes prolonged impairment in many TBI survivors. Sleep–
wake disturbances are frequent even after mild TBI, and may
persist for years (Baumann et al., 2007; Castriotta et al.,
2007; Kempf et al., 2010). Six months after trauma, post-
traumatic sleep–wake disturbances occur in up to three of
four TBI patients (Baumann et al., 2007). Prospective studies
in consecutive patients suggest that the most prevalent post-
traumatic sleep–wake disturbances are excessive daytime
sleepiness (EDS, in 25%) and excessive sleep need after TBI
(in 22%) (Baumann et al., 2007; Castriotta et al., 2007). The
prevalence of insomnia and sleep apnea after TBI needs to
be assessed systematically in future studies, but other sleep–
wake disturbances, including circadian sleep–wake distur-
bances and parasomnias, are probably less frequent after
TBI (Verma et al., 2007). Although recognized as a common
complaint, so far the clinical impact and potential therapeutic
implications of excessive sleep need in TBI survivors have
not been characterized.
In the current literature, the deﬁnition of hypersomnia is
inconsistent–and is often used interchangeably or synony-
mous with daytime sleepiness. The word ‘hypersomnia’ is
composed of two different components: the Greek word
hyper, i.e. over, exceeding, above, and the Roman somnus,
i.e. sleep. Thus, in the narrower sense of the word,
hypersomnia stands for an abnormally increased amount of
sleep per 24 h rather than abnormally high sleep pressure.
However, the diagnostic criteria of the second edition of the
International Classiﬁcation of Sleep Disorders deﬁnes disor-
ders with predominant EDS as hypersomnia disorders
(American Academy of Sleep Medicine, 2005). Thus, for
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the sake of clarity, hypersomnia can not be used in patients
with excessive sleep need, because the emphasis lies
speciﬁcally on the quantitative increment of sleep amount
irrespective of the presence of absence of daytime sleepi-
ness. However, other terms, suchas longsleepers, canalsobe
misleading, because long sleepers are healthy subjects with a
sleep need above age-adjusted average values. We therefore
suggest introducing a new term for excessive sleep need
following TBI: in this study, we will use the term ‘post-traumatic
pleiosomnia’ in patients who need at least 2 h per 24 h more
sleep compared to their life prior to TBI, irrespective of the
presence of EDS (Baumann et al., 2007). The Greek word
pleio translates into more, most, full, excessive or multiple.
Our recent studies aimed at assessing the prevalence of
various sleep–wake disturbances among TBI patients rather
than giving detailed insights into the clinical characteristics of
post-traumatic pleiosomnia (Baumann et al., 2007; Kempf
et al., 2010). With this study, therefore, we aimed at
characterizing post-traumatic pleiosomnia more effectively
in a case control study of 36 consecutive and well-deﬁned
post-traumatic pleiosomnia patients from our outpatient sleep
clinic compared to 36 age- and sex-matched controls.
METHODS
Subjects
We included retrospectively consecutive TBI patients who
were examined in our tertiary sleep outpatient clinic and who
reported chronic post-traumatic pleiosomnia, i.e. an
increased sleep need of at least 2 h per 24 h compared to
pre-TBI conditions, which persisted at least 6 months after
trauma. Patients with sleep–wake disorders diagnosed prior
to TBI, or with neurological, psychiatric or systemic disorders,
were excluded from this study.
As controls, we included subjects without neurological or
psychiatric disorders, in whom sleep–wake disorders were
excluded by detailed history-taking and sleep laboratory
examinations. Subjects with Epworth Sleepiness Scale
(ESS) scores above 10, with objective EDS (abnormally
decreased mean sleep latencies on multiple sleep latency
tests, MSLT) or with apnea–hypopnea indices or periodic
limb movement indices above 15 were excluded. Subjects
with indices between 5 and 15 were included if history was
unremarkable regarding sleep apnea or restless legs syn-
drome, and if mean sleep latencies on MSLT were normal
(above 10 min).
All patients gave written informed consent for all study
examinations, and the study was approved by the local
ethical board.
General assessments
In our outpatient clinic and sleep laboratory all patients with
post-traumatic pleiosomnia underwent a complete diagnostic
workup, including the assessment of TBI severity according
to the Glasgow Coma Scale (13–15: mild; 9–12: moderate;
3–8: severe), and computed tomography images after trauma
were screened for intracranial bleedings. Every patient was
given a detailed neurological evaluation, and outcome after
TBI was assessed along the Glasgow Outcome Scale which
we used in our previous study (Baumann et al., 2007). The
scale classiﬁes outcome as follows: (1) dead, (2) vegetative
state, (3) severe disability, i.e. able to follow commands, but
unable to live independently, (4) moderate disability, i.e. able
to live independently, but unable to return to work or school,
and (5) good recovery, i.e. able to return to work or school.
Medical treatment need was ascertained.
In 15 TBI patients, we measured cerebrospinal ﬂuid
hypocretin-1 levels by radioimmunoassay. Cerebrospinal
ﬂuid was obtained by lumbar puncture as described earlier,
and according to our local reference samples, hypocretin-1
levels below 320 pg mL1 were considered as abnormally
low (Baumann et al., 2005).
Assessments of sleep and wakefulness
We applied subjective measurements of sleepiness by the
ESS (Bloch et al., 1999; Johns, 1991), and of fatigue by the
Fatigue Severity Scale (FSS) (Valko et al., 2008). Subjective
EDS was diagnosed when ESS scores were 10 or above,
and fatigue in patients with scores above 4.0. In addition, we
assessed recordings of sleep and wakefulness including
actigraphy, nocturnal polysomnography (PSG) and MSLT.
All sleep laboratory recordings were performed without
sleep–wake modulating drugs; i.e. after washout of drugs if
necessary. Prior to sleep laboratory tests, we recorded sleep
and physical activity levels over 14 days with sleep logs and
wrist actigraphy (on the non-dominant wrist; light sensor data
included; Actiwatch, Neurotechnology, Cambridge, UK)
(Morgenthaler et al., 2007). Actigraphy was used to deter-
mine periods of inactivity per 24 h to gain an estimate of
sleep duration, and to screen for circadian sleep–wake
disorders. In addition, we checked whether daytime naps
showed a circadian distribution; i.e. whether they occurred
more often in the morning, after lunch or in the afternoon.
Conventional nocturnal video-PSG (using a 16-channel
recording system: Embla A10; Embla, Colorado, CO, USA)
was performed overnight. Two patients underwent an addi-
tional PSG ad libitum; i.e. patients were not woken up in the
morning and thus given the opportunity to sleep as long as they
could. These additional PSGs were not followed by another
MSLT. Sleep stage scoring was performed along standard
criteria (Iber et al., 2007). Polysomnography was performed
as reported before, and scoring aswell as clinical classiﬁcation
was performed along actual guidelines (American Academy of
Sleep Medicine, 2005; Baumann et al., 2007).
The MSLT consisted of four sleep opportunities every 2 h,
measuring EDS objectively under standard conditions and in
the absence of external alerting factors (Littner et al., 2005).
Sleep latencies on MSLT were deﬁned as the time from
lights-off to the ﬁrst epoch of any sleep stage. Objective
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excessive daytime sleepiness was diagnosed when mean
sleep latency was <8 min.
Statistical analyses
Statistical analyses were performed using SPSS version 19.0
(IBM,Zurich,Switzerland).Groupdataaredescribedbymeans
and standard deviations (SD). For univariate analysis, we used
one-way analysis of variance (ANOVA) for numerical scale
variables and v2-test for nominal scale variables. For correla-
tion analysis we used a two-way Pearson’s product–moment
correlationcoefﬁcient.Multiple linear regressionanalyseswere
performed to assess the relationship between sleep/inactivity
times per 24 h (dependent variable) and age, sex, severity of
TBI and clinical outcome (Glasgow Coma Scale).
RESULTS
Demographic and clinical characterization
We identiﬁed 36 TBI patients who met the inclusion criteria
for post-traumatic pleiosomnia and 36 age- and sex-matched
controls (Tables 1 and 2). Fourteen TBI patients have been
reported before (Baumann et al., 2007). Twenty-four patients
returned to work after their trauma. An overview on TBI
characteristics and clinical outcomes is given in Table 1.
Mean levels of excessive daytime sleepiness and fatigue, as
assessed subjectively by questionnaires, were similar in both
groups. Thirteen TBI patients and no controls scored ESS
above 10, indicating subjective daytime sleepiness. Symp-
toms of restless legs syndrome were not reported by patients
or by controls. Epilepsy was not present in any TBI patient,
and no patient was treated with stimulants before or during
sleep recordings.
Actigraphy ﬁndings
All patients complained about increased sleep need of more
than 2 h after TBI (mean difference: 2.4 h, range 2.0–6.5 h).
According to sleep logs, mean time asleep after TBI was
9.4 h compared to 7.5 h in controls (P = 0.008, Table 2).
Interestingly, objective measures obtained by actigraphy
revealed a more pronounced increase of estimated sleep
need, as indicated by signiﬁcantly prolonged periods of
inactivity (mean 10.8 h) compared to controls (mean 7.3 h;
P < 0.001). The difference of mean time asleep/inactive
between sleep logs and actigraphy was signiﬁcant (P = 0.02)
in TBI patients, but not in controls. Estimated sleep duration
≥10 h per 24 h was observed in 21 patients (58%), but in no
controls (P < 0.001). Sleep logs and actigraphy recordings
revealed regular (at least ﬁve per week) daytime naps in 17
patients (47%) and in none of the controls (P < 0.001).
These daytime naps did not reveal a clear circadian
distribution.
Polysomnography and MLST
Sleep laboratory ﬁndings are summarized in Table 2. Sleep
duration and sleep efﬁciency were similar in both groups.
Slow-wave sleep [non-rapid eye movement (NREM) stage 3]
accounted for 20.4% of recorded sleep in patients and for
13.8% in controls (P = 0.009). The amount of other sleep
stages did not differ between patients and controls. Also,
wake after sleep onset in the percentage of sleep period time,
periodic limb movement indices and apnea–hypopnea indi-
ces were similar in TBI patients and in controls, and the latter
were not linked to arousals. Parasomnia disorders were not
observed.
During ad libitum PSG, two patients had sleep durations of
798 and 831 min; i.e. 13.3 and 13.9 h. Sleep efﬁciencies
were 90 and 84%, and slow-wave sleep accounted for 21 and
13%. Actigraphy recordings suggested that both patients
were sleep-satiated before PSG.
Multiple sleep latency tests revealed objective EDS in 15
patients (42%) and in no controls (0%, P < 0.001). In 10
patients with objective EDS, as deﬁned by a mean sleep
latency of ≤8 min, actigraphy revealed that nocturnal sleep
periods were at least 2 h shorter during weekdays than
during weekends. All 10 patients returned to work. This
actigraphy pattern was also found in two TBI patients without
objective EDS. Mean sleep latencies were 8.7 min in patients
and 12.4 min in controls (P < 0.001). Multiple sleep onset
REM periods were observed in three patients and in no
controls [not signiﬁcant (NS)]. In both groups, mean sleep
latencies on MSLT were not correlated with PSG ﬁndings,
such as sleep efﬁciency or total sleep time.
Clinical correlates of sleep ﬁndings
Longer intervals between TBI and sleep recordings were
associated with longer REM sleep latencies (r = 0.52,
P = 0.01). Other polysomnography parameters such as deep
sleep were not associated with time interval since injury.
Furthermore, severity of TBI or the presence of intracranial
bleedings were not associated with any sleep–wake ﬁnding,
Table 1 Characteristics of traumatic brain injury (TBI) and clinical
outcome in 36 patients
Characteristics of traumatic brain injury
Severity of TBI (mild–moderate–severe) 13–7–16
Intracranial bleedings 18 (50%)
Interval since TBI (months) 32  18
Outcome after traumatic brain injury
Glasgow Outcome Scale (1–2–3–4–5) 0–0–0–13–23
Headache since trauma 20 (56%)
Worse when not having slept enough 13 (65% of 20)
Report of cognitive problems since trauma 14 (39%)
Worse when not having slept enough 12 (86% of 14)
Motor deﬁcits since trauma 4 (11%)
Sensory deﬁcits since trauma 9 (25%)
Cranial nerve deﬁcits since trauma 5 (14%)
Pain other than headache since trauma 3 (8%)
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including sleep duration. Cerebrospinal ﬂuid hypocretin-1
determination was performed in 15 patients, but levels were
not associated with any actigraphy, PSG or MSLT ﬁndings.
However, three patients had a pathologically low hypocretin-
1 level (118/278/301 pg mL1). All three patients suffered
from severe TBI with intracranial haemorrhage. ESS scores
were normal in all of them, but MSLT revealed EDS in two
patients (hypocretin: 278 and 301 pg mL1, respectively).
Multiple sleep onset REM periods were found in two of these
patients (118 and 301 pg mL1). Actigraphic measures of
sleep per 24 h were not different from TBI patients with
normal hypocretin levels.
Regression analyses showed that age, sex, severity of TBI
and clinical outcome were not related to sleep times per 24 h.
Furthermore, we compared post-traumatic pleiosomnia
patients with sleep times over 10 h (n = 21) to those with
less than 10 h sleep per 24 h (n = 15). The two groups did
not differ in terms of age, sex, severity of TBI, clinical
outcome (Glasgow Outcome Scale), Epworth Sleepiness
Scale or fatigue severity scale scores, PSG measures such
as sleep efﬁciency, sleep latency, percentages of any sleep
stage or mean sleep latencies on MSLT.
DISCUSSION
Post-traumatic pleiosomnia is a common condition following
TBI, and persists for many years (Baumann et al., 2007;
Kempf et al., 2010). We deﬁne this condition as an increased
sleep need per 24 h of at least 2 h compared to the time
before trauma. Until now, however, there exists neither a
characterization of this neglected condition, nor do we know
how to treat it. Thus, this case–control study was designed to
shed some light into the clinical characteristics of post-
traumatic pleiosomnia.
Patients who suffered from TBI did not estimate their actual
sleep need correctly. In sleep logs, mean reported total sleep
time per day was more than 1 h shorter than the estimated
sleep duration calculated by duration of inactivity measured
in the actigraphy studies (10.8 h). Furthermore, 6 months
after trauma, we observed in our previous study on post-trau-
matic sleep–wake disturbances a tendency to underestimate
sleep propensity during daytime (Baumann et al., 2007). In
the present study, with an interval of 32  18 months after
trauma, we found subjective EDS–as assessed with ESS–in
13 patients and objective EDS–as assessed with MSLT–in
Table 2 Demographic data, sleep–wake measures and cerebrospinal ﬂuid hypocretin levels in 36 patients with traumatic brain injury,
compared to 36 controls
Patients (n = 36) Controls (n = 36) P
Demographic data
Sex (male) 26 (72%) 26 (72%) NS
Age (years) 36  12 36  10 NS
Hypocretin (orexin)
Cerebrospinal levels (pg mL1) 456  181 (n = 15) 497  63 (n = 20)† NS
Cerebrospinal levels low (<320 pg mL1) 3 (20%) 0 (0%) NS
Sleepiness and fatigue
Epworth sleepiness scale (ESS) 8.7  4.9 7.1  3.8 NS
ESS score ≥10 13 (36%) 0 (0%) <0.001
Fatigue severity scale 3.7  1.0 3.2  1.2 NS
Estimated sleep need per 24 h
Actigraphy: estimated sleep per 24h (h) 10.8 (8.0–15.6) 7.3 (5.7–9.2) <0.001
≥10 h estimated sleep per 24h (h) 21 (58%) 0 (0%) <0.001
Sleep logs: sleep per 24h (h) 9.4 (6.8–15.0) 7.5 (6.1–9.3) 0.008
Actigraphy/sleep log: regular daytime naps 17 (47%) 0 (0%) <0.001
Nocturnal video-polysomnography
Mean sleep duration (min) 379 (316–476) 375 (250–481) NS
Sleep efﬁciency (%) 90.2 (66.1–99.6) 86.9 (66.6–98.5) NS
Wake after sleep onset (% of SPT) 5.3 (0.3–29.5) 6.5 (1.1–30.3) NS
NREM1 (%) 5.0 (2.4–8.2) 5.9 (2.8–10.0) NS
NREM2 (%) 44.8 (31.5–64.2) 50.1 (38.6–65.8) NS
Slow-wave sleep (NREM3) (%) 20.4 (11.9–38.0) 13.8 (0–26.9) 0.009
REM sleep (%) 20.1 (4.5–34.8) 18.1 (7.1–26.1) NS
Sleep latency (min) 22.9 (3.6–68) 19.9 (3.5–87) NS
REM sleep latency (min) 88.9 (4.9–302.5) 112.6 (46.5–288.5) NS
Apnea–hypopnea index (h1) 4.5 (0–14.5) 3.2 (0–14.9) NS
PLMS index (h1) 3.2 (0–13.4) 1.9 (0–8.9) NS
Multiple sleep latency test
Mean sleep latency (min) 8.7 (2.9–17.2) 12.4 (8.1–18.1) <0.001
Mean sleep latency <8 min 15 (42%) 0 (0%) <0.001
≥2 sleep onset REM periods 3 (8%) 0 (0%) NS
NS, not signiﬁcant; PLMS, periodic limb movements during sleep; REM sleep, rapid eye movement sleep; SPT, sleep period time.
†Normative cerebrospinal ﬂuid levels from 20 previously published controls as measured in our laboratory (Baumann et al., 2005).
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15 patients. Altogether, these ﬁndings re-emphasize an
apparently common yet widely neglected phenomenon,
namely that underestimation or anosognosia of post-trau-
matic sleep–wake disturbances seems to be frequent among
TBI survivors. The present study conﬁrms our previous
observation that TBI patients may not be aware of their
increased sleep pressure, which is diagnosed only when
performing a multiple sleep latency test (Baumann et al.,
2007). In addition, a similar underestimation occurs also with
respect to sleep need per 24 h, as indicated by the
discrepancy between sleep logs and estimated sleep dura-
tion by actigraphy. Based on this novel observation, it
appears likely that our history-based screening method for
patient inclusion was not sensitive enough. Consequently,
post-traumatic pleiosomnia might be even more prevalent
than in 17% of TBI patients, as found in our previous study on
the prevalence of post-traumatic sleep–wake disturbances
(Baumann et al., 2007). This possibility must be considered
when counselling and treating TBI patients.
Objective EDS was present in only 42% (n = 15) of TBI
patients with post-traumatic pleiosomnia. Thus, EDS is not a
mandatory criterion for the diagnosis of post-traumatic
pleiosomnia. Conversely, in 10 of 15 post-traumatic pleio-
somnia patients with EDS, actigraphy studies displayed signs
of chronic sleep deprivation; i.e. the need to catch up sleep
during weekends. Such a pattern was found particularly in
young and middle-aged patients who are integrated in tight
work schedules or have families with young children. This
suggests that patients whose psychosocial environment
allows sleeping longer per 24 h could avoid increased sleep
propensity at daytime, whereas patients who cannot com-
pensate for the increased sleep need suffer consecutively
from EDS. Therefore, we might speculate that post-traumatic
pleiosomnia is a primary sleep–wake disturbance following
TBI, whereas EDS might be secondary to relative sleep
deprivation.
During polysomnography recordings we observed
increased slow-wave sleep in patients with post-traumatic
pleiosomnia, even many months after trauma. The reason
for increased deep sleep remains speculative: on one hand,
it might be caused by brain damage itself, or it might play a
role in regeneration and neuroplasticity. Early studies
revealed that damage to both the brainstem and the
hypothalamus–both important structures for arousal–are
common after TBI (Crompton, 1971a,b). Accordingly, we
found partial loss of hypocretin neurones in the hypothala-
mus of deceased TBI patients (Baumann et al., 2009). On
the other hand, the ﬁnding of low hypocretin-1 levels in the
cerebrospinal ﬂuid is rare in sleepy TBI patients. We know
that normal cerebrospinal ﬂuid hypocretin-1 levels might not
reﬂect partial hypocretin neuronal loss, but deﬁcient hypo-
cretin signalling is probably not the explanation for post-
traumatic pleiosomnia and increased slow-wave sleep
(Fronczek et al., 2007; Gerashchenko et al., 2003). It
appears more likely that increased sleep need is guided
by damage to several sleep–wake modulating neuronal
systems. TBI, with its focal impact and diffuse parenchyma-
tous damage, is disposed to affect widespread neuronal
systems in the brain.
In contrast, it is conceivable that increased sleep need and
particularly increased slow-wave sleep following TBI might
reﬂect recovery processes, particularly axonal sprouting,
synaptic remodelling and short-term plasticity processes
(Carmichael and Chesselet, 2002; Dijk, 2009; Stickgold
et al., 2001). The beneﬁcial effect of sleep and slow-wave
sleep on recovery has been shown in several studies on
rodents. Rats, which underwent sleep deprivation after
stroke, showed an increase in stroke size as well as delayed
motor recovery (Gao et al., 2010; Zunzunegui et al., 2011).
Conversely, the drug gamma-hydroxybutyrate, which is
known to enhance slow-wave sleep, accelerates functional
recovery after stroke (Gao et al., 2008). In this regard,
however, it would be somewhat surprising if these recovery
adaptation mechanisms lasted so long; i.e. for many years
after trauma. Finally, it is conceivable that increased slow-
wave sleep reﬂects, at least in some patients, a relative sleep
insufﬁciency.
Post-traumatic pleiosomnia can persist for many years. In
a recent study, we found post-traumatic pleiosomnia in 27%
of 51 consecutive TBI patients 3 years after trauma (Kempf
et al., 2010). In the present series, the longest follow-up time
was 93 months. Our society, however, demands full activity
at work–patients with an increased sleep need are disad-
vantaged and perhaps compensate for their increased sleep
time only during their leisure time. Thus, due to the chronic
course of post-traumatic pleiosomnia, medical treatment
would be necessary to allow patients returning to their
normal lives. Until now, however, medical treatment of post-
traumatic pleiosomnia remains an unsolved issue (Kaiser
et al., 2010).
This study has limitations. First, due to the retrospective
character of this study in consecutive patients, the age range
of TBI patients is high, and additional data such as psycho-
metric evaluation and neuroimaging results are not available.
Furthermore, the number of included patients is low, because
we aimed at including only well-described patients. There-
fore, we cannot exclude a selection bias in our study.
Narrowing the age range would have reduced the number of
patients too much, and regression analyses showed that age
was not associated with pleiosomnia. Secondly, we did not
control for concomitant depression which might impact
fatigue and even sleep need and inactivity, which is
measured by actigraphy. This should be conducted in future
studies. As actigraphy can only give an estimation of sleep
duration, future studies could also investigate electroenceph-
alographic sleep–wake measures and parameters of sleep
homeostasis across 24 h and over several days. Thus, it is
conceivable that novel diagnostic tools such as continuous
polysomnography during 24 h might provide additional
insights and lead ultimately to the better diagnosis of
hypersomnia disorders, including post-traumatic pleiosomnia
(Pizza et al., 2013).
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In conclusion, post-traumatic pleiosomnia is probably even
more frequent than reported previously, and can be associ-
ated with EDS, particularly in patients who cannot allow
themselves to sleep enough. Furthermore, post-traumatic
pleiosomnia patients exhibit an increase in slow-wave sleep,
which might reﬂect recovery mechanisms or intrinsic conse-
quences of diffuse brain damage. Whether or not it makes
sense to deﬁne post-traumatic pleiosomnia with and without
long sleep time (such as in idiopathic hypersomnia) will be
examined based on the study of larger numbers of patients.
The preliminary results of this study revealed no differences
between these two groups.
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Background: Short mean latencies to the ﬁrst epoch of non-rapid eye movement sleep stage 1 (NREM1)
and the presence ofP2 sleep onset REM (SOREM) periods on multiple sleep latency test (MSLT) occur in
both narcolepsy–cataplexy (NC) and behaviourally induced insufﬁcient sleep syndrome (BIISS). It is not
known whether speciﬁc MSLT ﬁndings help differentiate the two disorders.
Methods: We analyzed MSLT data including sleep latencies to and between different sleep stages of
60 age-, gender- and body mass index (BMI)-matched subjects (hypocretin-deﬁcient NC, actigraphy-
conﬁrmed BIISS, healthy controls: each 20).
Results: Mean latency (in minutes) to NREM1 sleep was signiﬁcantly shorter in NC (1.8 ± 1.5) than in
BIISS (4.7 ± 2.1, p < 0.001) and controls (11.4 ± 3.3, p < 0.001). Mean latency to NREM2 sleep was similar
in NC (8.6 ± 4.7) and BIISS (8.1 ± 2.7, p = 0.64); latency to either NREM2 or rapid eye movement (REM)
sleep (i.e., the sum of the sleep latency to NREM1 and the duration of the ﬁrst NREM1 sleep sequence),
however, was shorter in NC (4.4 ± 2.9) than in BIISS (7.9 ± 3.5, p < 0.001). Referring to all naps with
SOREM periods, the sequence NREM1–REM–NREM2 was more common (71%) in NC than in BIISS
(15%, p < 0.001), reﬂecting the shorter latency from NREM1 to NREM2 in BIISS (3.7 ± 2.5) than in NC
(6.1 ± 5.9, p < 0.001).
Conclusions: Our ﬁndings show that both sleepiness (as measured by NREM1 sleep latency) and REM
sleep propensity are higher in NC than in BIISS. Furthermore, our ﬁnding of frequent REM sleep prior
to NREM2 sleep in NC is in line with the recent assumption of an insufﬁcient NREM sleep intensity in
NC. Together with detailed clinical interviews, sleep logs, actigraphy, and nocturnal polysomnography,
mean sleep latencies to NREM1 62.5 min, the presence of multiple SOREM periods, and the sequence
NREM1–REM–NREM2 may be the best MSLT measures to discriminate NC from BIISS.
 2009 Elsevier B.V. All rights reserved.
1. Introduction
Excessive daytime sleepiness (EDS) represents the leading
symptom of narcolepsy, along with cataplexy, sleep paralysis,
and hypnagogic hallucinations. The pathophysiological hallmark
of narcolepsy with cataplexy (NC) is the loss of hypothalamic neu-
rons that produce wake-promoting neuropeptides, the hypocretins
(orexins). Besides the assessment of a detailed history, the multiple
sleep latency test (MSLT) is the most important ancillary test for
the diagnosis of NC, together with the measurement of cerebrospi-
nal ﬂuid hypocretin levels. The typical MSLT ﬁndings for narco-
lepsy include (1) a mean sleep latency of 68 min and (2) the
presence of P2 sleep onset rapid eye movement (SOREM) periods
as an indicator of high REM sleep propensity [1–3]. However, these
ﬁndings are not speciﬁc for narcolepsy since other sleep–wake
disorders with EDS such as sleep apnea syndrome or behaviourally
induced insufﬁcient sleep syndrome (BIISS; also referred to as
chronic sleep deprivation) may present with similar MSLT results
[2,4].
There is considerable evidence of a continuous reduction in
average sleep time by 20% over the past century [5]. Due to profes-
sional or social obligations, people often are not able or do not al-
low themselves to sleep enough. Besides EDS, BIISS may be
associated with decreased neurocognitive functioning, fatigue, in-
creased risk of motor vehicle crashes, negative mood states, and
decreased motivation [6]. Accordingly, BIISS is a frequent and
important differential diagnosis of NC in clinical practice: general
practitioners and neurologists often refer BIISS patients to sleep
laboratories with the suspicion of narcolepsy. For sleep specialists
who are familiar with NC patients, differentiating between NC and
BIISS is often possible on clinical grounds alone. First, clear-cut cat-
aplexy is pathognomonic for NC and does not occur in BIISS patients.
However, cataplexy-like symptoms, sleep paralysis, and hallucina-
tions are occasionally found in the setting of non-narcoleptic EDS
1389-9457/$ - see front matter  2009 Elsevier B.V. All rights reserved.
doi:10.1016/j.sleep.2009.03.008
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patients [7]. Second, BIISS-related EDS can be as irresistible as in
NC (e.g., microsleep during car driving), and short episodes of sleep
are also usually refreshing (e.g., power naps for sleep-deprived
hospital doctors). In terms of objective measures of EDS, very low
mean sleep latencies on MSLT and polysomnography recordings
are found in both BIISS and NC patients [8]. Last but not least,
NREM sleep is better preserved than REM sleep during sleep
restriction, possibly leading to high REM sleep propensity [9,10].
Indeed, SOREM periods are also observed in BIISS patients [2,4].
To better distinguish MSLT ﬁndings in NC and in BIISS, we
aimed at characterizing the sleep latencies to and between differ-
ent sleep stages in age-, gender- and BMI-matched patients with
deﬁnite NC, BIISS, and normal controls.
2. Patients and methods
2.1. Subjects
Among patients referred to the Sleep Disorder Centre of the
Neurology Department of the University Hospital of Zurich, we ret-
rospectively selected 3 groups (NC, BIISS, and controls), each con-
sisting of 20 age-, gender- and BMI-matched patients. EDS was
present in all patients and was estimated by the Epworth sleepi-
ness scale (ESS). In all NC patients, the diagnosis was conﬁrmed
by deﬁcient cerebrospinal ﬂuid hypocretin levels. In order to min-
imize concomitant BIISS, NC patients were instructed to pay regard
to an optimal sleep hygiene including sufﬁcient sleep amount, reg-
ular sleep–wake habits and repeated short daytime naps. Acti-
graphic recordings in NC patients conﬁrmed the absence of
chronic sleep restriction (i.e., reduced sleep time per 24 h). The
diagnosis of BIISS was made according to the international classiﬁ-
cation of sleep disorders, including improvement of subjective EDS
after sleep prolongation as documented by sleep logs and actigra-
phy [3]. Patients with additional sleep–wake disorders (e.g., sleep
apnea syndrome) were excluded. Control subjects did not report
EDS (normal ESS scores), nor did they suffer from any kind of
sleep–wake disorder. Patients and controls were free from drugs
affecting the central nervous system, except for two narcoleptic
patients (modaﬁnil and sodium valproate, respectively), one BIISS
patient (citalopram), and two controls (phenytoin/gabapentin
and citalopram, respectively).
2.2. Sleep studies
All patients underwent videopolysomnographic recording in
the night prior to the MSLT. MSLT was done according to standard
guidelines [11]. Brieﬂy, patients underwent four or ﬁve naps, each
lasting 20 min, at 2 h intervals over the day. If sleep occurred, tests
were run for another 15 min to assess SOREM periods. The MSLT
montage included central (C3 and C4) and occipital (O1 and O2)
electrodes with auricular reference electrodes, two electrooculo-
graphic channels, two submental electromyographic channels,
and electrocardiography (ECG). Sleep stages were scored using
30-second epochs according to standard criteria by Rechtschaffen
and Kales [12].
We measured sleep latencies from lights-off to the ﬁrst epoch of
non-rapid eye movement stage 1 (NREM1), NREM2, and REM sleep.
Furthermore, we assessed the duration of speciﬁc sleep stages. In
naps without sleep, mean sleep latency was deﬁned as 20 min.
2.3. Statistics
Statistical analyzes were performed using SPSS statistical anal-
ysis program (SPSS 12.0). Data are reported as means ± standard
deviation if not otherwise indicated. Comparisons between NC,
BIISS and controls were made using one-way ANOVA. For direct
comparisons between NC and BIISS, we used independent t-test
and Chi-square statistics. Signiﬁcance level was assumed for p
values <0.05. Signiﬁcant result on Chi-square and t-tests are
only presented when one-way ANOVA revealed differences
between the three groups (F-values and p levels of ANOVA are
not reported).
3. Results
3.1. Subjects
The demographic and clinical characteristics of the three groups
are summarized in Table 1. Subjective daytime sleepiness (esti-
mated by the ESS) was similar between NC and BIISS patients
(16 ± 4 and 15 ± 3, respectively, p = 0.2) and signiﬁcantly lower in
controls (7 ± 4, p < 0.001).
3.2. Sleep studies
On polysomnography, NC and BIISS had similar mean sleep
latencies to NREM2 (6.7 ± 4.7 and 9 ± 4.9 min, respectively,
p = 0.14) and REM sleep (44 ± 86 and 82.6 ± 48.3 min, respectively,
p = 0.09), but sleep efﬁciency was signiﬁcantly lower in NC than in
BIISS (86.8 ± 11.9% vs. 94.8 ± 4.7%, p = 0.008); other polysomno-
graphic data are presented in Table 2.
In BIISS patients, the actigraphy-based measure of sleep dura-
tion was 7 h 31 min ± 54 min, and 8 h 32 min ± 1 h 17 min after
sleep extension (p = 0.02).
On MSLT, mean sleep latencies to NREM1 were signiﬁcantly
shorter in NC (1.8 ± 1.5 min) compared to BIISS (4.7 ± 2.1 min,
p < 0.001) and controls (11.4 ± 3.3 min, p < 0.001) (Fig. 1). A mean
sleep latency 62.5 min was found in 16/20 (80%) NC patients com-
pared to 3/20 (15%) BIISS patients (p < 0.001). Mean sleep latencies
to NREM2 were similar in NC and BIISS (8.6 ± 4.7 and 8.1 ± 2.7 min,
respectively, p = 0.64), but signiﬁcantly shorter than in controls
(13.4 ± 3.3 min, p < 0.001). When measuring sleep latencies to
either NREM2 or REM (e.g., the sum of the sleep latency to NREM1
and the duration of the ﬁrst NREM1 sleep sequence), however, NC
revealed signiﬁcantly shorter latencies than BIISS (4.4 ± 2.9 and
7.9 ± 3.5 min, respectively, p < 0.001).
3.3. Subanalysis of MSLT naps with SOREM periods
SOREM periods occurred in 62/85 naps (73%) in NC patients,
compared to 13/89 naps (15%) in BIISS patients (p < 0.001). SOREM
periods were not observed in controls. Mean sleep latency below
8 min was found in each NC patient, but only 17 NC patients
(85%) had P2 SOREM periods. Three BIISS patients (15%) had a
mean sleep latency <8 min andP2 SOREM periods. When referring
only to naps with SOREM periods, mean sleep latency from lights
off to NREM1 did not differ between NC and BIISS (1.9 ± 2.3 and
1.8 ± 1.3 min, respectively; p = 0.96), but mean sleep latency from
lights off to REM sleep was signiﬁcantly shorter in NC than in BIISS
Table 1
Demographic and clinical characteristics of patients with narcolepsy and cataplexy
(NC) and behaviourally induced insufﬁcient sleep syndrome (BIISS), and normal
controls.
NC BIISS Controls p
Age (mean ± SD) [years] 39 ± 18 36 ± 13 40 ± 15 0.78
Gender (men/women) 11/9 10/10 11/9 0.94
BMI (mean ± SD) [kg] 25 ± 5 24 ± 5 23 ± 4 0.14
BMI: body mass index; SD: standard deviation.
I. Marti et al. / Sleep Medicine 10 (2009) 1146–1150 1147
(5.4 ± 3.8 and 10.0 ± 4.0 min, respectively; p < 0.001). Conversely,
mean sleep latency from lights off to NREM2 was signiﬁcantly
shorter in BIISS than in NC (6.5 ± 4.4 and 10.3 ± 6.4 min, respec-
tively; p < 0.001). In NC, no difference was found when comparing
mean sleep latencies to NREM1 in naps with and without SOREM
periods (1.9 ± 2.3 and 1.8 ± 1.3 min, respectively; p = 0.85). In BIISS
patients, on the other hand, mean sleep latency to NREM1 was sig-
niﬁcantly shorter in naps with than without SOREM periods
(1.8 ± 1.3 and 5.2 ± 3.4 min, respectively; p < 0.001) (Table 3). In
NC, we found no association between number of SOREMs and
mean sleep latencies.
3.4. Sleep stage sequencing in MSLT naps with SOREMs
In NC, REM sleep occurred immediately after NREM1 in 44/62
(71%) naps, and was followed in 20/44 (45%) naps by NREM2; in
24/44 (55%) naps NREM2 was not achieved. In the remaining 18/
62 (29%) naps the sequence NREM1–NREM2–REM was observed
(p < 0.001). In BIISS, REM sleep immediately after NREM1 was
found in only 2/13 (15%) naps, followed by NREM2 in one nap; in
11/13 (85%) naps the sequence NREM1–NREM2–REM was ob-
served (p < 0.001) (Fig. 2). Consecutively, NC had a signiﬁcantly
longer NREM1–NREM2 latency than BIISS (6.1 ± 5.8 and
3.5 ± 2.5 min, respectively; p = 0.001). However, when referring
only to naps without REM prior to NREM2, no difference in
NREM1–NREM2 latency was found between NC and BIISS
(2.4 ± 1.9 and 3.6 ± 2.1 min; p = 0.14).
4. Discussion
In our study, we found (1) shorter sleep latencies in MSLT to
NREM1 and REM in NC compared to BIISS, (2) but similar sleep
latencies to NREM2 in both disorders, which is explained by the
observation that (3) the sequence NREM1–REM–NREM2 is more
prevalent in NC (71% of all naps with REM sleep) compared to
BIISS, with NREM1–NREM2–REM as the most common sequence
(85%).
In general, sleepiness (as assessed with mean sleep latencies to
NREM1) and REM sleep propensity (as assessed with the number of
SOREM periods and the latency to REM sleep) were higher in NC
than in BIISS patients. However, considering only naps with SOREM
periods, mean sleep latencies to NREM1 were similar between the
two conditions. In other words, BIISS patients with SOREM periods
had signiﬁcantly shorter mean sleep latencies to NREM1 than BIISS
patients without SOREM periods, which is in line with other stud-
ies [13]. This ﬁnding suggests that the presence of SOREM periods
in BIISS is associated with a higher sleep pressure, leading to sleep
latencies not discernible from narcoleptic patients. In NC, however,
the occurrence of SOREM periods was not associated with shorter
sleep latencies on MSLT naps. Furthermore, we could not conﬁrm
previous ﬁndings of a signiﬁcant correlation between a higher
number of SOREM periods and lower mean sleep latencies in NC
[14].
The combination of P2 SOREM periods and short mean sleep
latency on MSLT has been shown to have limited sensitivity and
speciﬁcity for the diagnosis of NC [2,15]. Indeed, our ﬁnding of
Table 2
Polysomnographic data.
NC BIISS Controls pa
Total sleep time [min] 325 ± 54 406 ± 26 357 ± 50 0.03
Sleep efﬁciency [%] 87 ± 12 95 ± 5 91 ± 6 0.013
Sleep latency to NREM2 7 ± 5 9 ± 5 50 ± 49 <0.001
REM sleep latency 44 ± 86 83 ± 48 98 ± 39 0.02
NREM1 [%] 17 ± 10 7 ± 7 9 ± 7 0.001
NREM2 [%] 37 ± 11 51 ± 9 49 ± 9 <0.001
SWSb [%] 13 ± 7 17 ± 5 16 ± 6 0.11
REM [%] 20 ± 9 19 ± 5 16 ± 5 0.14
a One-way ANOVA.
b Slow wave sleep (NREM3 + NREM4).
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Fig. 1. Mean sleep latencies to NREM1, NREM2, and REM sleep in NC, BIISS, and
controls (including standard deviations). msl, Mean sleep latency.
Table 3
MSLT: mean sleep latencies (in minutes) to NREM1 in NC and BIISS.
n (naps) Mean sleep latency to NREM1
NC with SOREM 62 1.9 ± 2.3
NC without SOREM 23 1.8 ± 1.3
BIISS with SOREM 13 1.8 ± 1.3
BIISS without SOREM 76 5.2 ± 3.4
n = number of naps.
NREM1
NREM1
REM
NREM2
NREM2
REM
NC BIISS p
29% 85% <0.001
71% 15%    <0.001  
lights-off
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20
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Fig. 2. Different sleep stage sequencing in NC and BIISS patients in MSLT naps with SOREMs (NC: n = 62/85 naps, BIISS: n = 13/89 naps).
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61 SOREM period in 15% of NC patients corroborates the assump-
tion of suboptimal sensitivity of this particular test. On the other
hand, regarding speciﬁcity, P2 SOREM periods have also been re-
ported in other sleep–wake disturbances and even in healthy sub-
jects. Chervin et al. foundP2 SOREM periods in almost 5% of 1145
consecutive patients with suspected or conﬁrmed obstructive
sleep apnea [16]. Aldrich et al. reported a frequency ofP2 SOREM
periods in 7% of 1251 patients with sleep-related breathing disor-
ders [2]. Also, Guilleminault et al. observed multiple SOREM peri-
ods in patients suffering from upper airway resistance syndrome
[15]. Furthermore, P2 SOREM periods have been observed in a
high number of healthy controls. Bishop et al. observed a surpris-
ingly high frequency (17%) of P2 SOREM periods among 139
young, drug-free subjects without medical, psychiatric or sleep-re-
lated complaints [17]. However, as the same authors acknowledge,
no actigraphic recordings were performed in these subjects to con-
ﬁrm regular sleep schedules and to exclude BIISS as a potential
explanation of the high frequency of multiple SOREM periods. Sim-
ilarly, Mignot et al. found multiple SOREM periods in 13.1% of
males and 5.6% of females of the community-based Wisconsin
Sleep Cohort Study [4]. Conversely, in our healthy controls, in
whom BIISS was excluded by actigraphic recordings and sleep logs,
we could not ﬁnd any SOREM periods on MSLT. Other groups also
failed to demonstrate multiple SOREM periods in healthy controls
[18–21]. The reason for these discrepant ﬁndings is not clear at the
moment and will warrant further studies, as we believe (based on
our daily clinical work) that BIISS in the healthy population is
frequent.
Until now, there are no systematic studies on the frequency of
multiple SOREM periods in BIISS patients. In 1994, Rosenthal ﬁrst
suggested that P2 SOREM periods in patients without clinical
symptomatology for NC might reﬂect chronic sleep deprivation
[22]. We found a combination of P2 SOREM periods and a mean
sleep latency 62.5 min in 15% of BIISS patients. This ﬁnding ulti-
mately underscores the low speciﬁcity and limited reliability of
the MSLT in differentiating NC from BIISS, indicating that the clin-
ical interview remains most important in the diagnosis of these
sleep–wake disorders. Furthermore, sleep logs, actigraphy, and
nocturnal polysomnography are helpful in the distinction of the
two disorders.
Sleep stage sequencing is different in NC and BIISS, with
NREM1–REM–NREM2 being the most frequent pattern in NC, con-
trary to NREM1–NREM2–REM in BIISS. The ﬁnding of frequent REM
prior to NREM2 in NC may primarily indicate that REM sleep reg-
ulation is altered in NC. In this line, it has been hypothesized that
REM sleep propensity is enhanced in NC, consecutively leading to
phenomena which are believed to be fragments of REM sleep (ato-
nia, dream-like states) [23]. Recently, Lu and colleagues [24] iden-
tiﬁed REM-off neurons in the brainstem, which are densely
innervated by the hypocretin neurons. A loss of hypocretin neu-
rons, therefore, would weaken the REM-off side of a REM-on-off
ﬂip-ﬂop mechanism, giving way to enhanced REM pressure and ﬁ-
nally to REM sleep periods occurring prior to the constitution of
NREM2 sleep [25]. However, our ﬁnding also might indicate that
homeostatic NREM sleep regulation is altered in NC. In fact, little
is known about NREM sleep regulation in NC. A polysomnography
study suggested that NREM sleep intensity is insufﬁcient in NC,
with frequent interruptions and an impaired build-up of slow-
wake activity during nocturnal NREM sleep [26]. Thus, in accor-
dance with earlier reports, the frequent observation of SOREM epi-
sodes with the sequence NREM1–REM–NREM2might be explained
by a dysregulation involving both REM and NREM sleep in NC [14].
Although BIISS patients also often present with increased REM
sleep pressure and with SOREM periods, this abnormal NREM–
REM sleep interaction does not appear to be present in BIISS.
The main limitation of this study is the small sample size. How-
ever, our three groups have been strictly matched for age, gender,
and BMI. In addition, our study only analyzed narcolepsy patients
with clear-cut cataplexy. Hence, our ﬁndings cannot be generalized
to narcolepsy patients without cataplexy, although this subgroup
particularly needs objective features that allow differentiating it
from BIISS. Therefore, future studies will want to prospectively
compare MSLT ﬁndings between BIISS patients and narcolepsy pa-
tients with and without cataplexy. Furthermore, we included two
NC patients who were not free from drugs affecting the central ner-
vous system (modaﬁnil and sodium valproate, respectively). How-
ever, the clinical, polysomnographic and MSLT ﬁndings of these
two patients did not signiﬁcantly differ from the remaining NC pa-
tients, nor did the exclusion of these two patients alter the results
of this study.
In conclusion, we aimed at analyzing differences of MSLT char-
acteristics between NC and BIISS, two conditions whose clinical
presentation may show substantial overlap. The need of objective
parameters to differentiate between the two conditions is further
reﬂected by the almost equal degree of subjective EDS (estimated
by the ESS) in our study population. Nevertheless, the diagnosis
of NC cannot be made by means of the MSLT alone but still mostly
relies on a thorough clinical interview, together with sleep logs,
actigraphy, and nocturnal polysomnography. In cases with similar
clinical presentation, however, MSLT results can additionally help
differentiating between NC and BIISS. We found that several ﬁnd-
ings might serve as an indicator for NC and against BIISS: mean
sleep latencies to NREM1 62.5 min, the presence of multiple SOR-
EM periods, and the sequence NREM1–REM–NREM2 may be the
best discriminating factors.
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Loss of Hypocretin (Orexin)
Neurons With Traumatic
Brain Injury
Christian R. Baumann, MD,1,2 Claudio L. Bassetti, MD,1
Philipp O. Valko, MD, 1 Johannes Haybaeck, MD,3
Morten Keller, MD,4 Erika Clark,2 Reto Stocker, MD,5
Markus Tolnay, MD,3 and Thomas E. Scammell, MD2
Chronic, daytime sleepiness is a major, disabling symptom
for many patients with traumatic brain injury (TBI), but
thus far, its etiology is not well understood. Extensive loss of
the hypothalamic neurons that produce the wake-promoting
neuropeptide hypocretin (orexin) causes the severe sleepiness
of narcolepsy, and partial loss of these cells may contribute to
the sleepiness of Parkinson disease and other disorders. We
have found that the number of hypocretin neurons is signif-
icantly reduced in patients with severe TBI. This observation
highlights the often overlooked hypothalamic injury in TBI
and provides new insights into the causes of chronic sleepi-
ness in patients with TBI.
Ann Neurol 2009;66:555–559
Approximately 1.4 million people sustain traumatic
brain injury (TBI) each year in the United States.1
Coma and obtundation are common during the acute
period, but even after 6 months recovery, 43% of pa-
tients have symptoms of sleep disorders.2,3 In a pro-
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spective study of 65 TBI patients, 1 in 4 patients re-
ported excessive daytime sleepiness (EDS) irrespective
of the location or severity of the head trauma.2 An-
other study of 87 patients revealed similar results, with
sleepiness in 25% after TBI.3
Although chronic sleepiness is common after head
trauma, the cause remains unclear. Injury to ascending
arousal pathways from the brainstem may contribute,
but recent findings suggest a key role for the neuropep-
tides hypocretin-1 and -2 (also known as orexin-A and
-B).2,4,5 Hypocretins are made by a small cluster of
neurons in the lateral hypothalamus that play an essen-
tial role in promoting wakefulness. Selective loss of the
hypocretin-producing neurons causes sleepiness and
cataplexy in 90% of patients with narcolepsy,5–9 and
identical symptoms occur in mice genetically lacking
hypocretins.10 Injury to the hypothalamus is common
in patients with TBI,11 but its clinical impact remains
unclear. We recently found that TBI patients have a
marked reduction in cerebrospinal fluid (CSF)
hypocretin-1 levels in the first days after injury.4 Even
after 6 months recovery, many TBI patients with EDS
have persistently low hypocretin-1 levels.2 Thus, we
hypothesized that post-traumatic sleepiness is caused, at
least in part, by injury to the wake-promoting hypo-
cretin neurons.
Materials and Methods
Subjects
We collected brains at autopsy from 4 patients who died 7 to
42 (mean 19) days after severe TBI (Supplemental Table).
Causes of death were multiorgan failure (n  2), elevated
intracranial pressure (n  1), and brain death (n  1). We
obtained 4 additional brains from control subjects with no
clinical evidence of TBI or other neurological disorders.
Those subjects died from ruptured aortic aneurysm (n  1),
liver failure (n  1), drowning (n  1), and myocardial
infarction (n  1). First-degree relatives gave written in-
formed consent for autopsy and tissue research. This study
was approved by the human subjects committees of Kanto-
nale Ethikkommission Zurich and Beth Israel Deaconess
Medical Center.
Tissue Processing
We fixed whole hypothalami in 10% buffered formalin and
stored them at 4°C. After the tissue equilibrated for 2 to 3
days in phosphate-buffered saline with 20% sucrose, 10%
formalin, and 0.1% diethyl pyrocarbonate (pH 7.4), we
coronally sectioned the right and left halves of the hypothal-
amus at 40m in a 1:24 series. We stored sections at 20°C
in a cryoprotectant solution.9
Immunohistochemistry
We immunostained sections for hypocretin-1 (orexin A) as
described previously.9 Briefly, after treatment with 3% hy-
drogen peroxide and blocking in 3% normal horse serum, we
incubated sections overnight in goat anti–hypocretin-1 anti-
serum (1:5,000; Santa Cruz Biotechnology, Santa Cruz, CA)
and then in biotinylated donkey antigoat secondary anti-
serum at 1:500. We then exposed the sections to avidin-
biotin complex and diaminobenzidine to produce light
brown labeling of hypocretin-containing neurons. The spec-
ificity of the antiserum was tested and confirmed in hypo-
thalamic tissue from hypocretin-knockout mice.12
To test whether other neurons in the lateral hypothalamus
are lost with TBI, we immunostained adjacent sections for
melanin-concentrating hormone (MCH; rabbit primary an-
tiserum, 1:10,000; a kind gift from Eleftheria Maratos-Flier).
Finally, to test whether gliosis accompanies hypocretin
neuron loss, we double-labeled sections for hypocretin-1 (1:
5,000) and glial fibrillary acidic protein (GFAP), a marker
of astrocytes. Hypocretin was labeled using goat anti–
hypocretin-1 antiserum (1:5,000), biotinylated donkey an-
tigoat immunoglobulin (Ig) G (Jackson Laboratories, Bar
Harbor, ME), and Alexa 488-conjugated streptavidin (In-
vitrogen, Carlsbad, CA). GFAP was labeled using rabbit
anti-GFAP primary antiserum (1:2,000; Millipore, Bil-
lerica, MA) and Cy3-conjugated donkey antirabbit IgG sec-
ondary antiserum (Jackson ImmunoResearch Laboratories,
West Grove, PA).
Cell Counts
After immunostaining, we examined sections at 200 with a
Zeiss Axiophot microscope. We digitally superimposed a
counting grid on every section and counted all hypocretin-
and MCH-immunoreactive neurons across a 1:24 series of
the entire hypothalamus. To prevent miscounting, we used a
fine-scale counting grid that encompassed no more than 10
neurons per grid sector. Only clearly immunolabeled neu-
rons with neuronal morphology, outgoing axons and den-
drites, and a nuclear void were counted. To estimate accu-
rately the numbers of hypocretin and MCH neurons in each
section, we performed Abercrombie corrections based on the
size of the cell nuclei in each subject.13 We then calculated
the total numbers of hypocretin and MCH neurons by mul-
tiplying the cell counts per section by the section sampling
frequency (1:24). We also counted GFAP-immunolabeled as-
trocytes in 30 randomly selected 400  400m sites within
the lateral and posterior hypothalamus. Cell counts were
compared between groups using Student t tests.
Results
In this pilot study, the TBI patients were younger
(51  19 years) than the controls (69  18 years), and
all subjects were male except for 1 woman in the con-
trol group. Postmortem delays were similar in both
groups (TBI: 12  3 hours; controls: 13  3 hours)
(Supplemental Table).
The number of hypocretin neurons in TBI subjects
was 27% less than in controls (23,655  5,035 vs
32,318  3060 neurons; p  0.001) (Fig 1). Among
the TBI patients, the number of hypocretin neurons
differed moderately between the left and right sides of
the hypothalamus and between individuals, reflecting
the asymmetry and heterogeneity of TBI. Many hypo-
cretin neurons in TBI patients were small and py-
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knotic, and the density of hypocretin fibers appeared
reduced. Although TBI brains contained fewer hypo-
cretin neurons, the neurons were distributed in a nor-
mal pattern, thus demonstrating the reliability and
completeness of the cell counts (Fig 2). In all subjects,
the complete hypocretin neuron field was examined
(Supplemental Fig A). In controls, the total number of
hypocretin neurons and their distribution across the
lateral and posterior hypothalamus were similar to
prior reports.7,8,14,15
Hypothalami from TBI patients also contained in-
tense perivascular hypocretin immunoreactivity (Fig 3).
This amorphous staining was present around small ves-
sels in the posterior and lateral hypothalamus but not
elsewhere. The perivascular staining may represent
phagocytized hypocretin peptide following damage to
the hypocretin neurons.
TBI patients also had 31% fewer MCH neurons
than controls (39,540  10,900 vs 57,176  24,016),
but this reduction was not quite statistically significant
(p  0.06), probably because of variable numbers of
MCH neurons. If one excludes the female control sub-
ject with surprisingly low numbers of MCH neurons
(control subject 2), then the TBI subjects had 29%
fewer hypocretin neurons than controls (33,342 
2,785; p  0.002) and 40% fewer MCH neurons
(66,434  18,730; p  0.003).
The density of astrocytes as assessed by GFAP stain-
ing was significantly higher (21  12 vs 7  2 per
mm2; p  0.001) in TBI patients than in controls
(Supplemental Fig B). The pattern of gliosis differed
across the TBI patients; double immunofluorescence
staining showed that patients with more severe loss of
hypocretin neurons had more GFAP-labeled astrocytes
(r  0.46, p  0.01).
Discussion
In this pilot study, we found that patients with severe
TBI have a significant loss of hypocretin-producing
neurons. This injury was not limited to the hypocretin
neurons, as there was a partial loss of neurons produc-
ing MCH and patchy gliosis throughout the hypothal-
amus. These findings demonstrate that TBI can injure
the hypothalamus and suggest that reduced hypocretin
signaling may contribute to the persistent sleepiness of-
ten seen in TBI patients.
Descriptions of sub-cortical injury in TBI often focus
on the midbrain and subthalamus,16 but hypothalamic
injury is common. One early study showed damage to
the hypothalamus in 42% of deceased TBI patients.11
Other reports describe pituitary and hypothalamic dys-
Fig 2. Traumatic brain injury (TBI) patients and controls have similar caudal-rostral distributions of hypocretin neurons. The graphs
show the average number of hypocretin neurons per section (mean values across all cases). Overall, TBI patients have fewer neurons,
especially in the center of the hypocretin field. Level a: fornix touches the dorsal edge of the mammillary bodies; level b: fornix next to
the paraventricular nucleus. [Color figure can be viewed in the online issue, which is available at www.interscience.wiley.com]
Fig 1. Overview of hypocretin and melanin-concentrating hor-
mone (MCH) cell counts. Patients with traumatic brain in-
jury (TBI) have fewer hypocretin neurons. On average, TBI
patients have a total of 23,655 hypocretin neurons, whereas
controls have 32,318 neurons (p  0.001). The numbers of
hypocretin neurons on the left and right sides of the hypothal-
amus differ more in TBI patients, probably reflecting asymme-
try of the trauma. TBI patients also have fewer MCH neu-
rons than controls (39,540 in total vs 57,176; p  0.06).
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function,17,18 although to our knowledge, ours is the
first to describe injury to specific types of hypothalamic
neurons. In our patients, the loss of hypocretin neurons,
coupled with gliosis and intense perivascular hypocretin-
immunoreactive debris, strongly suggests that severe TBI
can directly or indirectly kill hypocretin neurons. Per-
haps the hypocretin neurons are injured by the same
shearing forces that often damage the midbrain, but va-
sospasm, or elevated intracranial pressure leading to
compression or reduced perfusion of the hypothalamus,
may also contribute.11,17,18
Chronic excessive daytime sleepiness is a major dis-
abling symptom for many TBI patients, but so far, its
etiology is not well understood.2 We believe that partial
loss of hypocretin neurons may contribute to chronic
sleepiness after TBI. Clearly, extensive loss of hypocretin
neurons is sufficient to cause the sleepiness of narcolepsy
with cataplexy,5–9 and some hypothesize that a partial
loss of these cells causes the generally milder sleepiness of
narcolepsy without cataplexy and Parkinson dis-
ease.14,15,19 This assumption is supported by our recent
finding of reduced CSF hypocretin-1 levels in sleepy
TBI patients who survived their injury.2 Although the
association between lumbar CSF hypocretin levels and
the number of intact hypocretin neurons is still poorly
understood, we hypothesize that reduced CSF levels of
hypocretin in TBI patients may reflect partial loss of the
hypocretin neurons and perhaps some reduction in the
activity of the surviving cells. However, it is likely that
reduced hypocretin signaling is not the only factor to
cause sleepiness after TBI. About 1
3
of TBI patients have
brainstem injuries, often near the midbrain tegmentum,
that may disrupt ascending monoaminergic or cholin-
ergic wake-promoting pathways.20 In addition, some
TBI patients have hypersomnolence, with excessively
large amounts of sleep each day. Hypersomnolence is
common with hypothalamic and rostral brainstem inju-
ries, but is uncommon with selective loss of the hypo-
cretin neurons.21 Loss of the MCH neurons may also
contribute to the pathophysiology of post-traumatic
sleep-wake disturbances, as these cells are hypothesized
to regulate rapid eye movement sleep.22,23 Overall, it
seems likely that the persistent sleepiness in some TBI
patients is due to a combination of reduced hypocretin
signaling and injury to other sleep-wake regulating sys-
tems.
This study has some limitations that should be ad-
dressed in future research. We examined a small number
of brains, and the control subjects were not fully
matched. However, our TBI patients had significantly
fewer hypocretin neurons, although they were younger
than the controls. In addition, we did not examine other
wake-promoting systems, and the extent of injury to
other arousal pathways should be further investigated in
larger human and animal studies. Last, we studied pa-
tients with fatal TBI, which probably introduced some
selection bias. It is possible that non-fatal TBI is associ-
ated with a less severe loss of hypocretin neurons.
TBI often results in chronic sleepiness, and the ob-
servation that wake-promoting hypocretin neurons are
lost with TBI provides new insights into the underly-
ing pathophysiology that may lead to novel treatment
options. For example, stimulants such as modafinil that
are helpful in narcolepsy and other hypocretin-deficient
disorders should be studied systematically in affected
TBI patients.24 Even better, hypocretin agonists could
become an elegant and tailored treatment option not
only for sleepy individuals with narcolepsy but also for
those with TBI.
This study was supported by the Foerderungskredit of the Univer-
sity of Zurich, Switzerland (Ch.B.), the Schweizerischer Ver-
sicherungsverband (SW), Switzerland (Ch.B.), and National Insti-
tutes of Health grant MH062589 (T.S.).
Fig 3. Traumatic brain injury patients have dense perivascular hypocretin immunoreactivity within the hypothalamic hypocretin
field (A, B), but not in adjacent areas (C).
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Brainstem 1H Nuclear
Magnetic Resonance (NMR)
Spectroscopy: Marker of
Demyelination and Repair
in Spinal Cord
Aleksandar Denic, MD,1 Allan Bieber, PhD,1
Arthur Warrington, PhD,1 Prasanna K. Mishra, PhD,2
Slobodan Macura, PhD,2 and Moses Rodriguez, MD1
Measuring in vivo spinal cord injury and repair remains elu-
sive. Using magnetic resonance spectroscopy (MRS) we ex-
amined brainstem N-acetyl-aspartate (NAA) as a surrogate
for spinal cord injury in two mouse strains with different
reparative phenotypes following virus-induced demyelina-
tion. Swiss Jim Lambert (SJL) and Friend Virus B (FVB)
mice progressively demyelinate with axonal loss. FVB mice
demyelinate similarly but eventually remyelinate coincident
with functional recovery. Brainstem NAA levels drop in both
but recover in FVB mice. Chronically infected SJL mice lost
30.5% of spinal cord axons compared to FVB mice (7.3%).
In remyelination-enhancing or axon-preserving clinical trials,
brainstem MRS may be a viable endpoint to represent overall
spinal cord dysfunction.
Ann Neurol 2009;66:559–564
New, noninvasive technologies to evaluate spinal cord
injury and repair are needed. Proton magnetic reso-
nance spectroscopy (1H-MRS) is one ideal method;
however, because the spinal cord is small and sur-
rounded by bone, direct spectroscopy has been limited.
During retrograde labeling studies of demyelinated spi-
nal cord axons, we observed a reduction in neuron cell
bodies in the brainstem labeled with fluorescent mark-
ers indicating death or dysfunction.1 This led to the
concept that neuron health measured at the brainstem
with MRS may reflect the integrity of many ascending
and descending spinal cord pathways. By following
virus-induced spinal cord disease in two strains of
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Increase of Histaminergic
Tuberomammillary Neurons in
Narcolepsy
Philipp O. Valko, MD,1,2 Yury V. Gavrilov, MD, PhD,1,2,3 Mihoko Yamamoto, MS,1
Hasini Reddy, MD, DPhil,4 Johannes Haybaeck, MD, PhD,5
Emmanuel Mignot, MD, PhD,6 Christian R. Baumann, MD,1,2 and
Thomas E. Scammell, MD1
Objective: Narcolepsy is caused by loss of the hypothalamic neurons producing the orexin/hypocretin neuropepti-
des. One key target of the orexin system is the histaminergic neurons of the tuberomammillary nucleus (TMN), an
essential wake-promoting system. As cerebrospinal fluid histamine levels may be low in patients with narcolepsy, we
examined histaminergic neurons in patients with narcolepsy and in 2 mouse models of narcolepsy.
Methods: We counted the number of hypothalamic neurons producing orexin, melanin-concentrating hormone, and
histamine in 7 narcolepsy patients and 12 control subjects using stereological techniques. We identified histaminergic
neurons using immunostaining for histidine decarboxylase. We also examined these systems in 6 wild-type mice, 6
orexin/ataxin-3 transgenic mice, and 5 orexin ligand knockout mice.
Results: Compared to controls, narcolepsy patients had 94% more histaminergic TMN neurons (233,572649,476 vs
120,455610,665, p< 0.001). This increase was higher in 5 narcolepsy patients with >90% orexin neuron loss than in
2 patients with 75% orexin neuron loss (252,2796 46,264 vs 186,8046 1,256, p5 0.03). Similarly, the number of
histaminergic TMN neurons was increased 53% in orexin ligand knockout mice compared to wild-type mice, whereas
orexin/ataxin-3 transgenic mice showed an intermediate 28% increase.
Interpretation: This surprising increase in histaminergic neurons in narcolepsy may be a compensatory response to
loss of excitatory drive from the orexin neurons and may contribute to some of the symptoms of narcolepsy such as
preserved consciousness during cataplexy and fragmented nighttime sleep. In addition, this finding may have thera-
peutic implications, as medications that enhance histamine signaling are now under development.
ANN NEUROL 2013;74:794–804
Narcolepsy is a common cause of chronic sleepinessthat is often accompanied by distinctive symptoms
including cataplexy, brief episodes of muscle weakness
triggered by strong emotions. Although narcolepsy has
been recognized by clinicians for >100 years, the under-
lying cause was a complete mystery until 13 years ago,
when 2 research groups discovered that narcolepsy is
caused by a loss of the hypothalamic neurons producing
the orexin (hypocretin) neuropeptides.1–3 These observa-
tions substantially advanced the field, but the cause and
consequences of orexin neuron loss remain unknown.
Among the targets of the orexin neurons, the hista-
minergic system plays an especially important role in
promoting wakefulness.4 The tuberomammillary nucleus
(TMN) in the posterior hypothalamus is the sole neuro-
nal source of histamine, and the orexin neurons heavily
innervate and excite the TMN neurons.5–8 Like other
monoaminergic systems, the histaminergic neurons are
View this article online at wileyonlinelibrary.com. DOI: 10.1002/ana.24019
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most active during wakefulness,9–11 and they are neces-
sary for generating normal wakefulness, as histamine
antagonists are sedating in humans and other species.12,13
In addition, the histaminergic system appears essential
for the wake-promoting effects of orexins, as mice lack-
ing histamine H1 receptors do not show an arousal
response to orexin.14 Furthermore, in mice globally lack-
ing orexin receptor-2 signaling, focal restoration of this
receptor in the TMN region rescues sleepiness by re-
establishing the normal excitatory signals from the orexin
neurons.8 Measuring histamine tone in humans is chal-
lenging, but as predicted from these observations, hista-
mine levels in lumbar cerebrospinal fluid (CSF) are low
in many patients with narcolepsy.15–17 Collectively, these
observations demonstrate the importance of the histami-
nergic system in the neurobiology of narcolepsy, but it
remains unknown if the reduction in histamine signaling
is caused by injury to the histaminergic neurons or
reduced activity in TMN neurons.
To assess these possibilities, we examined the histami-
nergic neurons in the brains of narcoleptic and control sub-
jects. We hypothesized that the number of histaminergic
neurons would be normal or possibly reduced if the neuro-
pathological process that kills the orexin neurons also
affects or injures the histaminergic neurons. We immuno-
stained hypothalamic sections for histidine decarboxylase
(HDC), the key enzyme for synthesizing histamine,18 and
counted neurons using unbiased stereological techniques.
To further examine this phenomenon, we then repeated
these experiments in 2 mouse models of narcolepsy.
Materials and Methods
Human Subjects
We studied hypothalamic tissue from 7 patients with narcolepsy
with cataplexy (NC) and from 12 control subjects with no clin-
ical evidence of neurological or psychiatric disease (Table). Con-
trol brains were provided by the Neuropathology Department
of Beth Israel Deaconess Medical Center (n5 7) and by the
Pathology Institute of the Medical University of Graz, Austria
(n5 5). Brains from NC patients were provided by Stanford
University (Subjects A, B, F), Beth Israel Deaconess Medical
Center (Subjects C, D, E), and Massachusetts General Hospital
(Subject G). Brain pH at the time of autopsy was not meas-
ured. The local ethics committees of all involved institutes
approved the study protocol.
All NC patients had a history of severe daytime sleepiness
and cataplexy for several decades. In Subject G, cataplexy had
decreased in frequency over the duration of his illness and was
rare during the 7 years prior to death. Subject C had Alzheimer
disease for the last 8 years of his life. We reported orexin neu-
ron counts from Subjects A, B, and C in prior studies.19,20
The mean age was similar in the control and NC groups
(67.46 13.6 years vs 69.36 13.1 years, respectively, p5 0.77).
Seven of the 12 controls were male, and all NC patients were
male (p5 0.07). All NC patients and 10 controls were Cauca-
sians; 2 controls were African American (Subjects 5 and 7).
Age, postmortem delay, and orexin A, melanin-concentrating
hormone (MCH), and HDC cell counts did not differ between
male and female controls. The numbers of neurons expressing
orexin A, MCH, or HDC in the control subjects did not corre-
late with age, fixation time, or postmortem delay.
Mice
We examined the hypothalami of 6 wild-type (WT) C57BL=6J
mice (5 males), 5 prepro-orexin ligand knockout (KO) mice (3
males), and 6 orexin/ataxin-3 (Atx) transgenic mice (4 males).
The orexin KO mice have a neomycin cassette inserted into the
prepro-orexin gene and lack the orexin A and B neuropepti-
des.21,22 In Atx mice, the human prepro-orexin promoter drives
expression of ataxin-3, a toxic transgene that selectively kills
most of the orexin neurons by around 12 weeks of age.23,24
Thus, these Atx mice are an excellent model of the severe loss
of the orexin-producing neurons that occurs in people with NC
and allow one to examine the roles of other neurotransmitters
(eg, dynorphin and glutamate) produced in the orexin neu-
rons.19,25,26 To maximize genetic homogeneity, we backcrossed
the Atx and orexin KO lines with C57BL=6J mice for 8 to 10
generations. We genotyped mice as described previously.24
None of the mice was treated with any medications or used in
other experiments. Mice were euthanized at similar ages: WT,
386 10 weeks; orexin KO, 366 17 weeks; and Atx, 236 1.3
weeks (p5 0.14). We also used MCH KO and HDC KO mice
to test the specificity of primary antisera. The Institutional Ani-
mal Care and Use Committees of Beth Israel Deaconess Medi-
cal Center and Harvard Medical School approved these animal
studies.
Human Brain Tissue
We studied both right and left halves of the hypothalami of all
control brains and of 2 NC brains (Subjects C and E), but
obtained only the right or left half of the hypothalamus in the
remaining 5 NC subjects. Postmortem delay of control brains
was 19.86 7.1 hours (range5 1–26 hours). Information on
postmortem delay of narcoleptic brains could be obtained in 5
subjects (11.86 6.9 hours, p5 0.07). The hypothalami were
fixed in 10% buffered formalin and stored at 4C. The fixation
times varied from 1 week to 2 years in control brains and from
2 months to 11 years in narcoleptic brains. After equilibration
in phosphate-buffered saline (PBS) with 20% sucrose, 10% for-
malin, and 0.1% diethyl pyrocarbonate (DEPC; pH 7.4) for 3
to 4 days, we coronally sectioned the hypothalamic blocks at
40lm on a freezing microtome into a 1:24 series. We stored
the sections at 220C in a cryoprotectant solution (25% glyc-
erol, 35% ethylene glycol, and 40% DEPC-PBS).
Mouse Brain Tissue
Under deep anesthesia, we perfused mice with saline followed
by 10% formalin. Brains were cryoprotected in PBS with 20%
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sucrose and 10% formalin. We then coronally sectioned the
brains at 30lm on a freezing microtome into a 1:3 series.
Immunohistochemistry on Human Tissue
We immunostained hypothalamic sections for orexin A (hypo-
cretin-1) as previously described.19 Briefly, free-floating sections
were washed 33 with PBS and then reacted for 30 minutes
with 0.3% hydrogen peroxide to block endogenous peroxidase
activity. After several PBS washes and blocking for 1 hour in
3% normal horse serum, we incubated sections overnight in
goat anti–orexin A antiserum (1:5,000; lot # B0309; Santa
Cruz Biotechnology, Santa Cruz, CA) and then for 1 hour in
biotinylated donkey antigoat secondary antiserum (1:500; Jack-
son ImmunoResearch, West Grove, PA). After washing with
PBS, we reacted sections for 1 hour with avidin/biotin complex
(ABC Kit; Vector Laboratories, Burlingame, CA), and finally
exposed them to nickel-enriched 3,30-diaminobenzidine and
0.1% hydrogen peroxide to produce dark blue–black labeling
of orexin neurons.
We used antigen retrieval to improve immunostaining for
MCH and HDC, a marker of the histaminergic neurons of the
tuberomammillary nucleus. After the initial reaction with
hydrogen peroxide, we put sections in Tris-buffered saline
(TBS; pH 7.6 for MCH, pH 11.0 for HDC immunostaining)
at 95C for 20 minutes. After cooling to room temperature, we
washed the sections twice in TBS for 10 minutes, and then
continued with the blocking step.
For MCH immunostaining, we used rabbit anti-MCH
primary antiserum (1:2,500; a kind gift from Dr. E. Maratos-
Flier27) followed by incubation with biotinylated donkey anti-
rabbit secondary antiserum (1:500; Jackson ImmunoResearch).
For HDC immunostaining, we used rabbit anti-HDC primary
antiserum (1:800; raised against amino acids 1–481 of the rat
HDC peptide, catalog # 03–16045, lot # 112078; American
Research Products, Waltham, MA), followed by incubation
with biotinylated donkey antirabbit secondary antiserum
(1:500; Jackson ImmunoResearch). The remaining steps for
MCH and HDC immunostaining were the same as for orexin
A immunostaining. We used the same lot of each primary anti-
serum for staining all control and narcoleptic brains.
Immunohistochemistry on Mouse Tissue
We used very similar immunohistochemical techniques for
staining mouse sections. Dilutions of primary antisera were
1:5,000 for orexin A, 1:10,000 for MCH, and 1:5,000 for
HDC. Antigen retrieval was not necessary, because fixation
time was short.
Immunohistochemistry Controls
The orexin and MCH antisera produced no staining in the
brains of orexin KO and MCH KO mice, respectively. The
HDC antiserum produced no staining in the TMN of HDC
KO mice, but it labeled monoamine neurons in the substantia
nigra, ventral tegmental area, and dorsal raphe, perhaps by
cross-reacting with aromatic L-amino acid decarboxylase.28 As
these other monoamine nuclei are outside the TMN region,T
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they did not affect TMN cell counts. In human hypothalami
and brainstem, the HDC antiserum did not produce any
ectopic labeling except for light labeling of occasional, small
neurons in the periventricular nucleus of the rostral hypothala-
mus of 3 control subjects and 1 narcolepsy patient. These neu-
rons do not produce HDC mRNA and they are well outside
the TMN region,29,30 so they were not included in cell counts.
Stereological Cell Counts
Estimation of the total number of orexin A, MCH, and HDC
labeled neurons was performed using a Zeiss (Oberkochen,
Germany) Axiophot microscope with a motorized stage inter-
faced with a Stereo Investigator system (MBF Biosciences, Will-
ston, VT). The same researcher (P.O.V.) did all counts to avoid
interindividual variations. The HDC cell counts were repeated
in a blinded fashion by Y.V.G. with very similar results; P.O.V.
found 94% more HDC neurons in the narcolepsy subjects
compared to the controls, compared to 86% more when
counted by Y.V.G. Intraclass correlation coefficient was 0.948,
indicating high inter-rater reliability (95% confidence inter-
val5 0.860–0.981, p< 0.001). In each section, a low-power
objective lens (32.5) was used to manually delineate the boun-
daries around all positively labeled neurons. Actual counting
was done using an oil immersed 3100 objective. We counted
neurons according to Gundersen’s unbiased counting rules, with
an optical dissector height of 10lm.31,32 To achieve accurate
cell counts as determined by a Gundersen’s coefficient of
error< 10%, we chose a small counting grid of 150 3 150lm
and 100 3 100lm in human and mouse tissue, respectively,
and a counting frame of 50 3 50lm. Finally, the optical frac-
tionator method provided the estimates of the total cell num-
ber, which was based on the abovementioned sampling
parameters, the measured section thickness, and the sample fre-
quency (1:24 series for human; 1:3 for mouse). For the human
tissue, the coefficients of error were 8% (orexin A), 6%
(MCH), and 5% (HDC). For the mouse tissue, the coefficients
of error were 7% (orexin A), 6% (MCH), and 6% (HDC).
In the 12 control brains, the right and left halves of the
hypothalamus contained similar numbers of orexin A neurons
(31,1266 6,240 vs 31,6286 4,084), MCH neurons
(41,6986 6,554 vs 41,8016 6,174), and histaminergic neurons
(60,5136 6,226 vs 59,9426 6,173; Supplementary Fig 1). There-
fore, to compare total neuron number between NC patients and
controls, we duplicated the cell count in those NC patients in
whom only 1 side of the hypothalamus was available. The mean
number of sections containing HDC-immunoreactive (IR) neurons
was similar in control and narcolepsy subjects (11.262.4 vs
11.06 2.2, p5 0.86).
We used the nucleator probe with 6 rays for calculation of
the mean cell area.33 We placed the origin of the rays in the cell
center and marked each intersecting point on the cell membrane.
Histogram analysis revealed a normal distribution of cell sizes.
Statistics
Group data are reported as means and standard deviations. We
compared cell counts between groups using Student t test or analy-
sis of variance (ANOVA) and performed correlation analyses using
the Pearson test. Statistical significance was accepted at p< 0.05.
Results
Cell Counts in NC and Control Hypothalami
NC patients had a substantial loss of orexin neurons. Specifi-
cally, the total number of orexin A–IR neurons in the NC
patients was 8,4926 10,515, whereas it was 62,7546 9,176
in the control subjects (p< 0.001; Fig 1). In 5 NC patients,
we found the characteristic, very severe orexin cell loss of 91
to 98%, but 2 NC patients had partial orexin cell loss of
only 75% and 53%. The severity of orexin cell loss was not
correlated with age at death or duration of NC.
Surprisingly, NC patients had almost twice as many
HDC-IR neurons as controls (233,5726 49,476 vs
120,4556 10,665, respectively, p< 0.001). Every NC
patient showed this increase, and there was no overlap
between the number of HDC-IR neurons in NC patients
and controls. Interestingly, the number of HDC-IR neu-
rons was highest in the 5 NC patients with >90% orexin
neuron loss compared to the 2 NC patients with less
severe orexin cell loss (252,2796 46,264 vs
186,8046 1,256, p5 0.03). This increase of HDC-IR
neurons was present across the entire tuberomammillary
nucleus with no bias toward the anterior or posterior
regions (Fig 2). The distribution and appearance of
HDC-IR neurons in the narcolepsy subjects was very
similar to that of controls and prior reports (Figs 3 and
4).29,30 The mean cell area of HDC-IR neurons was
slightly (7%) larger in NC patients than in controls
(7666 179lm2 vs 7156 180lm2, p< 0.001).
As expected from prior research,1,2 the number of
MCH-IR neurons did not differ between controls and NC
patients (83,4996 12,311 vs 79,7896 13,876, p5 0.57).
The quality of immunostaining for HDC, orexin
A, and MCH was excellent, with well-defined soma,
proximal dendrites, and axons (see Fig 4 and Supplemen-
tary Figs 2 and 3).
Cell Counts in Normal Mice and Mouse Models
of Narcolepsy
WTmice had 5,2646 456 orexin A neurons. As expected,
orexin KO mice had no orexin A–IR neurons (Fig 5). Atx
mice had only 7686 157 orexin A–IR neurons, reflecting an
80 to 88% reduction (p< 0.001); these remaining cells were
often small, with much less dendritic and axonal immuno-
labeling. Specifically, the mean cell area of orexin A–IR neu-
rons in Atx mice was smaller by 34% than in WT mice
(1336 37lm2 vs 2036 56lm2, respectively, p< 0.001).
Orexin KO mice had 53% more HDC-IR neurons
than WT mice (5,3526 977 vs 3,5086 703). Atx mice
showed an intermediate 28% increase (4,4786 1,143). The
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number of HDC-IR neurons differed significantly across
the 3 groups (p5 0.02 by ANOVA). Orexin KO mice had
significantly more HDC-IR neurons than WT mice (post
hoc adjustment with Bonferroni correction, p5 0.02), but
the increase in Atx mice did not reach statistical significance
perhaps because of variability in orexin neuron loss. Atx
mice with the greatest loss of orexin A–IR neurons tended
to have more HDC-IR neurons, but the correlation between
the numbers of orexin A–IR and HDC-IR neurons was not
statistically significant (rho520.40, p5 0.43). We did not
find any significant association between orexin A–IR cell
counts and the age at which the Atx mice were euthanized
(r520.51, p5 0.30). The mean cell area of HDC-IR neu-
rons was similar in the 3 mouse groups.
The numbers of MCH neurons were similar in
WT, orexin KO, and Atx mice (5,1856 612,
6,0636 1,052, and 6,0846 651, respectively, p5 0.13).
The quality of immunostaining for orexin A,
HDC, and MCH in mouse brains was excellent, with
well-defined soma, proximal dendrites, and axons (Sup-
plementary Figs 4–6).
Discussion
We found that patients with narcolepsy have almost twice
as many histaminergic neurons as controls, and this increase
was greatest in narcolepsy patients with severe loss of the
orexin neurons (>90%) compared to those with less severe
loss. Similarly, mice completely lacking the orexin peptides
had an increase in histaminergic neurons, and mice with a
partial loss of the orexin neurons had a small increase.
This increase in histaminergic neurons is surprising,
as loss of the orexin neurons was thought to be an
adequate explanation for the symptoms of narcolepsy.
This assumption was built on the hypothesis that the
neuropathologic process that kills the orexin neurons is
highly selective, with no involvement of adjacent cells
such as those producing MCH.1,2 In addition, loss of
orexin signaling in mice, rats, and dogs seemed sufficient
to produce the major symptoms of narcolepsy, including
sleepiness and cataplexy.34,35 Although simple loss of the
orexin neurons provides an explanation for many aspects
of narcolepsy, our new findings indicate that the neuro-
pathology of narcolepsy is more complicated, with unex-
pected involvement of another key arousal system.
Technical Considerations
The increase in histaminergic neurons appears robust, as
it occurs in both people and mice with narcolepsy, but
some methodological limitations should be kept in mind.
First, our antiserum targeting a fragment of the rat HDC
protein might also bind to an antigen other than HDC.
In human brains, we saw very little ectopic labeling. In
mouse brains, the HDC antisera labeled other monoa-
mine neurons, but these were outside the hypothalamus
and did not confound cell counts. In addition, the ana-
tomical distribution and morphology of histaminergic
neurons in narcoleptic subjects and mice are identical to
those previously reported in healthy humans and
rodents.29,30,36–38 Furthermore, John and colleagues have
FIGURE 1: Compared to control subjects, patients with narcolepsy with cataplexy have 86% fewer orexin neurons and 94%
more histaminergic tuberomammillary nucleus (TMN) neurons. The number of neurons producing melanin-concentrating hor-
mone (MCH) does not differ between the 2 groups. ***p<0.001.
FIGURE 2: Rostrocaudal distributions of histaminergic tuber-
omammillary nucleus (TMN) neurons in control subjects and
in narcolepsy patients. The distribution of histaminergic
TMN neurons in narcolepsy patients follows the same pat-
tern as in controls. HDC5histidine decarboxylase.
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independently found a similar increase in histaminergic
neurons in narcolepsy using antiserum targeting a short
fragment of the human HDC protein.39 Nonetheless,
future experiments should examine labeling for hista-
mine, HDC mRNA, and other markers to determine
additional neurochemical characteristics of these cells.
The postmortem delay before brain fixation tended
to be shorter in patients with narcolepsy, and this could
enhance HDC immunoreactivity. We think this is an
unlikely cause of the large differences in number of
HDC-IR neurons between groups, as there was no corre-
lation between postmortem interval and HDC cell num-
ber in controls. In addition, some control brains had
postmortem intervals similar to those of the narcolepsy
brains, yet the number of HDC neurons was much lower
than seen in any of the narcolepsy brains.
Potential Mechanisms Underlying the Increase
in Histaminergic Neurons
Several mechanisms could underlie the increase in hista-
minergic neurons. In narcolepsy, the histaminergic neu-
rons are distributed around the mammillary region in a
normal pattern, so it seems most likely that HDC
expression increases in narcolepsy, revealing some hista-
minergic neurons that may be difficult to detect in con-
trol subjects. Chronic loss of excitatory input from the
orexin neurons may cause an upregulation of HDC simi-
lar to the increased expression of choline acetyltransferase
reported in the laterodorsal tegmental nucleus of mice
lacking orexin receptors.40 The TMN is clearly capable
of plastic changes, as histamine levels and histaminergic
fiber density increase during hibernation in ground squir-
rels.41 Alternatively, the increase in HDC neurons could
be due to a change in neurochemical phenotype, as
occurs in histaminergic and other monoaminergic neu-
rons during development.42–44 The HDC gene is active
in parts of the thalamus and other neurons outside the
TMN early in development,45,46 and it will be important
to examine these regions in future studies, as this ectopic
expression could affect clinical symptoms. This neuro-
transmitter switching can occur even in adult animals
and may serve a function similar to homeostatic synaptic
FIGURE 3: Compared to the tuberomammillary nucleus (TMN) of a control subject (A–C), the TMN of a patient with narcolepsy
(D–F) has substantially more neurons expressing histidine decarboxylase (HDC). Each dot represents 1 HDC-immunoreactive
neuron. In these drawings, the narcolepsy subject has 51% more HDC neurons than the control subject. 3V5 third ventricle;
Arc5 arcuate nucleus; cp5 cerebral peduncle; f5 fornix; ic5 internal capsule; LM5 lateral mammillary nucleus; LTu5 lateral
tuberal nucleus; ML5medial mammillary nucleus, lateral part; MM5medial mammillary nucleus, medial part; mt5mammillo-
thalamic tract; mtg5mammillotegmental tract; MTu5medial tuberal nucleus; ot5optic tract; VMH5 ventromedial nucleus of
the hypothalamus.
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scaling.47 A third possibility is that chronic treatment
with stimulants could alter TMN neurons,48,49 but this
seems unlikely, as the untreated mice lacking orexin show
similar increases in HDC neurons.
An important remaining question is whether the
increase in HDC neurons occurs before or after the loss
of orexin neurons. Most likely, the increase occurs after
the loss of the orexin neurons, perhaps as a response to
FIGURE 4: Histidine decarboxylase (HDC) immunostaining in control and narcolepsy subjects. (A, B) Sections near the rostral
edge of the medial mammillary nucleus show approximately 60% more HDC-immunoreactive neurons in a subject with narco-
lepsy. In the section from a narcolepsy subject, some of the HDC neurons are scattered just anterior to the most rostral edge
of the mammillary body but are not present within the mammillary body in more caudal sections. (C, D) HDC labeling is robust
in neuronal soma, proximal dendrites, and axons. 3V5 third ventricle; MM5medial mammillary nucleus, medial part.
FIGURE 5: Numbers of orexin, histaminergic, and melanin-concentrating hormone (MCH) neurons in wild-type mice and 2
mouse models of narcolepsy. Orexin-ligand knockout mice have no orexin immunoreactivity and 53% more histaminergic neu-
rons than wild-type mice. Orexin/ataxin-3 transgenic mice have an 85% loss of orexin neurons and 28% more histaminergic
neurons than wild-type mice. The number of MCH neurons is similar in all groups. *p<0.05, ***p<0.001. TMN5 tuberomam-
millary nucleus.
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reduced excitatory inputs. However, if the increase in his-
taminergic neurons occurs earlier, it might play some
role in the destruction of the orexin neurons. In develop-
ing zebrafish, reduced histamine signaling decreases the
number of orexin neurons.50 Although the direction of
this response is different than in our study, it highlights
the important interactions between these systems, and
future studies examining the temporal relation between
orexin neuron loss and HDC neuron increase would be
very helpful to better understand the sequence of events.
Finally, one may speculate that orexin deficiency in
narcolepsy could improve survival of histaminergic TMN
neurons. Neurofibrillary tangles and plaques can occur in
the TMN region in Alzheimer disease,51–53 and an
orexin antagonist can reduce extracellular levels of amy-
loid beta.54 However, none of our control subjects had
clinical or neuropathological evidence of Alzheimer dis-
ease. Furthermore, HDC mRNA does not vary with
age,55 and the numbers of histaminergic neurons in our
subjects did not correlate with age. Considering these
findings and the nearly 2-fold difference in the number
of histaminergic neurons between control and narcolepsy
subjects, we think it is much more likely that histaminer-
gic neurons are increased in narcolepsy.
Potential Impact of the Increase in
Histaminergic Neurons
The increase in histaminergic neurons may help compen-
sate for reductions in orexin signaling. Hypersomnia
(sleeping for excessively long periods) is common around
the onset of narcolepsy, but over months to years, most
patients sleep normal amounts.56 Similarly, acute phar-
macologic antagonism of orexin signaling increases sleep
in people and rodents.57 Perhaps acute reductions in
orexin signaling reduce histamine signaling and cause
hypersomnia, but chronic orexin deficiency in narcolepsy
triggers increased expression of HDC that helps restore
histamine signaling and normal amounts of wakefulness.
How this actually affects synaptic concentrations of hista-
mine remains unclear, as some studies report low CSF
levels of histamine in narcolepsy,14–16 whereas others
report that histamine levels are normal.58,59 In future
research, it will be very useful to examine whether CSF
histamine levels are low close to the onset of narcolepsy
but increase at later times. Drugs to enhance histamine
signaling (eg, tiprolisant) are now under development as
a new class of wake-promoting medications,60 and if the
number of histaminergic neurons increases slowly, then
these drugs might be most effective in patients with long-
standing narcolepsy.
The increase in histaminergic neurons may also
shed light on some clinical aspects of narcolepsy. For
example, TMN neurons remain active during cataplexy,61
and altered histaminergic signaling could explain the par-
adoxical preservation of consciousness during rapid eye
movement (REM) sleep–like states such as cataplexy and
sleep paralysis. In support of this perspective, Atx mice
have a partial loss of orexin neurons and a smaller
increase in histaminergic neurons than orexin KO mice,
and behaviorally, they have less cataplexy and more REM
sleep during the active period.24 Perhaps treatment of a
narcolepsy patient with a histamine antagonist would
reduce cataplexy and other intermediate states and
increase transitions into full REM sleep. In addition,
although all patients with narcolepsy have daytime sleepi-
ness, many also have fragmented sleep at night. This
could be caused by excessive histaminergic signaling dur-
ing the sleep period that could lower the threshold to
transition from sleep to wake.22
Conclusions and Future Directions
We found that the number of histaminergic TMN neu-
rons is substantially increased in subjects with narcolepsy
when compared with controls, especially in those with
the most severe loss of the orexin neurons. Orexin KO
mice also showed an increase in histaminergic neurons,
and increased histaminergic signaling may influence the
symptoms and clinical management of narcolepsy.
These observations raise many new questions and
opportunities. For example, what mechanism triggers the
increase in histaminergic neurons? When does the
increase occur? Is the effect limited to only the histami-
nergic neurons or are there changes in other arousal sys-
tems? Research shedding light on these questions could
easily lead to novel and more effective therapies for treat-
ing narcolepsy.
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Introduction
The etiology of the selective loss of hypocretin (orexin) 
neurons in the posterolateral hypothalamus in sporadic 
narcolepsy with cataplexy (NC) is not known. Because of 
the tight association of narcolepsy with certain human 
leukocyte antigen (HLA) alleles, an autoimmune mech-
anism is considered [1, 2]. Two groups recently reported 
on hypocretin-deficient NC patients, who experienced a 
significant and sustained reduction of frequency and 
severity of cataplexy after administration of high-dose 
intravenous immunoglobulins (IVIg), in particular 
when treated early after disease onset [3, 4, 8]. These 
findings seemed to corroborate the autoimmune hypo-
thesis and suggested that early IVIg treatment in NC 
might favorably modify the course of disease. 
In this report we describe four hypocretin-deficient 
NC patients without or with uncertain benefit from IVIg 
therapy.
Case 1
This 43-year-old woman noticed in summer 2004 the 
gradual appearance of daytime sleepiness with daily 
 irresistible and restorative naps. In December 2004 she 
experienced the first cataplectic attacks involving the 
head and both lower limbs, triggered by strong emo-
tions (mainly laughter), and occurring up to several 
times per day. Her night-time sleep was increasingly dis-
turbed by frequent awakenings, and dreams became 
more vivid and realistic. She also had rare episodes of 
(hypnagogic) hallucinations and sleep paralysis. Ep-
worth Sleepiness Scale (ESS) was 19/24, Ullanlinna Nar-
colepsy Score (UNS) 16/44, and Swiss Narcolepsy Scale 
(SNS) 36 [7, 10]. Clinical examination was unremark-
able. Magnetic resonance imaging (MRI) scan of the 
brain showed few, nonspecific, small (< 1 cm) hyperin-
tense signal alterations of the subcortical/white matter 
without gadolinium enhancement. Cerebrospinal fluid 
(CSF) examination revealed normal glucose and protein 
content, 5 mononuclear cells/μl, and no oligoclonal 
bands. CSF hypocretin-1 was undetectable (< 40 pg/ml). 
HLA typing was positive for DQB1*0602, DQA1*01, 
DRB1*15 and DRB5*. Polysomnography (PSG), multiple 
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■ Abstract  We report on four 
 patients with narcolepsy with 
 cataplexy (NC), who were treated 
with high-dose intravenous 
 immunoglobulins (IVIg). Although 
in some patients transient effects 
were seen of both objective (multi-
ple sleep  latency test and mainte-
nance of wakefulness test) and 
 subjective symptoms (Epworth 
Sleepiness Scale and frequency of 
cataplexy), these effects lasted at 
the most for a few weeks and did 
not persist. Our report challenges 
the recent observations of a favor-
able and persistent effect of IVIg in 
NC patients.
■ Key words  narcolepsy · 
 cataplexy · intravenous 
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 daytime sleepiness
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sleep latency tests (MSLT; showing 4 sleep onset REM 
periods [SOREMP] in 5 tests) and maintenance of wake-
fulness tests (MWT; showing 2/4 SOREMPs) were con-
sistent with narcolepsy (Fig. 1). 
Methylprednisolone 1000 mg/d was administered in-
travenously for 3 consecutive days and then orally ta-
pered over 8 days. During the first 3 weeks after steroid 
treatment the patient reported a mild (10–20 % better as 
estimated by the patient) but only transient reduction of 
EDS and cataplexy. This prompted a trial with IVIg at a 
dose of 1 g/kg/day over 2 days, repeated three times at 
5-week intervals (latency from cataplexy onset: 4 
months). After the first two IVIg infusions, the patient 
reported a gradual improvement of EDS (decrease of 
ESS from 15–19/24 at baseline to 11/24 after the second 
IVIg trial) and a mild reduction of frequency of self-re-
ported cataplexy (measured by a cataplexy diary). How-
ever, after the third IVIg infusion, cataplexy and severity 
of EDS (ESS = 17/24) returned to pre-treatment levels. 
No effects were noted on hallucinations, sleep paralysis 
and MSLT/MWT results during and after IVIg (Fig. 2).
Case 2
This 59-year-old woman developed EDS and cataplectic 
attacks after a flu-like infection in 1987. She had 3–4 
short irresistible and restorative naps per day, her 
 cataplectic attacks affected mainly the head and neck, 
triggered by laughter, but also by negative emotions, oc-
curring up to 1–3 times/day. Acoustic (hypnagogic) hal-
lucinations occurred once a month, and a few years later 
she also developed rare episodes of sleep paralysis. Most 
drugs, including modafinil, methylphenidate, dexam-
phetamine and mazindol, were not tolerated. Fluoxetine 
had a moderate effect on cataplexy. 
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In August 2003 a common variable immunodefi-
ciency syndrome (deficiency of IgG subclasses II and IV, 
[9]) was diagnosed and a treatment with IVIg infusions 
of 20 g every 3 weeks was started.
In September 2004 we first saw the patient. ESS was 
20/24, UNS 30/44, and SNS –66. Clinical examination 
and brain MRI were unremarkable. Routine CSF exami-
nations were normal. CSF hypocretin-1 was undetect-
able. HLA-typing was positive for DQB1*0602, DQA1*01, 
DRB1*15 and DRB5*. Sleep-wake tests (PSG, MSLT with 
2/4 SOREMPs, MWT without SOREMPs) were typical 
for narcolepsy (Fig. 1).
Considering the failure of all previous medications 
and the diagnosis of a common-variable immunodefi-
ciency syndrome, additional treatment with high-dose 
IVIg infusions was started (latency from narcolepsy 
 onset: 17 years). Because of allergic reactions the usual 
dose (2 g/kg) was distributed over 5 days (and not as 
usual over 2 days). No effects were noted on EDS, cata-
plexy, hallucinations, sleep paralysis, and MSLT/MWT 
results during and after IVIg (which was stopped after 
the second administration because of recrudescence of 
allergy) (Fig. 1).
Case 3
This 41-year-old man developed EDS with irresistible 
naps within a few days in August 2004 while mastering 
an unusually stressful family situation. In the following 
months he experienced few generalized and several par-
tial clear-cut cataplectic attacks per day which were trig-
gered by laughing and other positive emotions, as well 
as occasional sleep paralysis and hypnagogic and hyp-
nopompic hallucinations. Night-time sleep became 
more fragmentary and his dreams intense and threaten-
ing. ESS was 22/24, UNS 29/44, and SNS –95. Clinical ex-
amination and brain MRI were unremarkable. Sleep-
wake tests were typical for narcolepsy, including 4/4 
SOREMPs in MSLT and 3/4 SOREMPs in MWT (Fig. 1). 
Repeated CSF examination showed a mild pleocytosis 
(4–10 mononuclear cells/μl), without oligoclonal bands. 
CSF hypocretin-1 was undetectable. HLA-typing was 
positive for DQB1*0602, DQA1*01, DRB1*15 and DRB5*. 
Extensive serologic and immunologic tests were nega-
tive. 
The combination of modafinil 100–200 mg b.i.d. with 
venlafaxine 75 mg completely controlled cataplectic at-
tacks, hallucinations and sleep paralysis and signifi-
cantly improved EDS (the ESS went from 22 to 15). He 
was able to return to work in full time position for 2.5 
years. In association with an increased psychosocial 
stress (divorce) and weight gain his narcoleptic symp-
toms exacerbated and became disabled despite several 
modifications of his medical therapy. This prompted 
treatment with IVIg infusions at a dose of 1 g/kg/day 
over 2 days, repeated three times at 5-week intervals (la-
tency disease onset: 4 years).
The patient reported a significant reduction in num-
ber and severity of cataplectic attacks from 3–4/d at 
baseline to 1–2/week after the second and 0–1/week 
 after the third IVIg infusion. The overall improvement 
of cataplexy was estimated to be around 80–90 %. How-
ever, during the short hospitalizations on occasion of the 
IVIg trials, the persistent occurrence of daily cataplectic 
attacks could be witnessed by several of us (POV, RK, 
CLB). There was also a strong improvement of subjec-
tive EDS, which the patient reported to recognize already 
within the first hour of the first IVIg infusion (reduction 
of ESS from 15–19/24 at baseline to 11/24 after the first 
IVIg). Objective parameters (MSLT, MWT), however, re-
mained unchanged. In the following weeks, the patient 
experienced also a progressive reappearance of narco-
leptic symptoms. Eight weeks after the last IVIg trial 
severity of EDS, cataplexy and sleep paralysis and hal-
lucinations were comparable to pre-treatment levels. 
Case 4
In June 2006 this 52-year-old woman developed EDS 
with irresistible need of 2–3 restorative naps/day and 
severe cataplectic attacks with falls, triggered by both 
positive and negative emotions, and occurring up to ten 
times per day. She did not notice any change of her 
night-time sleep, but her dreams became more intensive. 
She has never experienced any hypnagogic hallucina-
tions or sleep paralysis. ESS was 17/24, UNS 39/44, and 
SNS –92. Clinical examination and brain MRI were un-
remarkable. Routine CSF examination was normal. CSF 
hypocretin-1 was undetectable. HLA-typing was posi-
tive for DQB1*0602, DQA1*01, DRB1*15 and DRB5*. 
Sleep-wake tests were typical for narcolepsy, including 
2/4 SOREMPs in MSLT tests and 3/4 SOREMPs in MWT 
(Fig. 1). 
Treatment with modafinil 50 mg/d and fluoxetine 20 
mg/d was started, leading only to a mild improvement of 
both subjective EDS and cataplexy. Treatment with 
modafinil and fluoxetine was gradually tapered, and af-
ter a drug-free period of 3 weeks a trial with IVIg was 
started at a dose of 1 g/kg/day over 2 days, repeated three 
times at 5-week intervals (latency from cataplexy onset: 
11 months). No effects were noted on EDS, cataplexy, 
and MSLT/MWT results during and after IVIg treat-
ment.
Discussion
We report the absence of persistent improvements of 
narcoleptic symptoms in four patients treated with IVIg 
infusions. Although transient effects were seen concern-
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ing MSLT in patients 1 and 4, MWT in patient 3, cata-
plectic attacks in patient 3, and ESS in patients 1 and 3, 
these effects lasted at the most for a few weeks and did 
not persist. This observation is in contrast with the re-
cent reports by Dauvilliers, Lecendreux, and collegues, 
on five narcolepsy patients [3, 4, 8] in whom a sustained 
reduction in number and severity of cataplexy and a 
moderate effect on EDS (in all five patients) were 
achieved. The lack of a significant and persistent effect 
of intravenous steroids given early after onset of symp-
toms in one of our four patients also confirms the report 
of Mignot [6].
Four factors may account for the lack of significant 
effects of IVIg in our patients. First, only two of our pa-
tients were treated early after onset of cataplexy (four 
and eleven months, respectively, after the first appear-
ance of cataplectic attacks). However, one patient de-
scribed by Dauvilliers et al. was treated with IVIg with a 
delay of 9 years from disease onset, but reported im-
provement on both cataplexy and EDS with persistence 
of efficacy after 22 months without any anticataplectic 
or stimulant treatment. Second, in all of our patients CSF 
hypocretin-1 was already undetectable, suggesting that 
(presumed) autoimmune destruction of hypocretin 
neurons was already complete when IVIg therapy was 
started. However, all patients reported by Dauvilliers et 
al. had also undetectable CSF hypocretin-levels before 
IVIg treatment was started. Third, the treatment proto-
col was not identical in each patient, with patient 1 re-
ceiving corticosteroids and patient 2 receiving IVIg in 
lower dosages prior to the three IVIg trials. Fourth, our 
patients were older at disease onset (39, 40, 41 and 51 
years) than those reported by Dauvilliers et al. (10, 12, 21 
and 43 years). Both the efficacy of IVIg and the suscep-
tibility to placebo effects may significantly depend on 
the patient’s age at disease onset. 
The discrepancy between lack of objective improve-
ment (of EDS) and strong subjective improvement (of 
both cataplexy and EDS) in patient 1 and 3 suggest that 
a placebo effect might explain, at least in some cases, the 
improvement of narcoleptic symptoms (and particu-
larly cataplexy) after IVIg. Indeed, a similar observation 
was recently reported in a narcoleptic patient who un-
derwent a double-blind placebo-controlled administra-
tion of IVIg [5]. The authors could not find a difference 
between placebo and IVIg treatment. Furthermore, a re-
cent trial with sodium oxybate has proven the existence 
of a placebo effect on cataplexy [11].
Our report challenges the first, very optimistic obser-
vations on the favorable effects of IVIg in patients with 
narcolepsy with cataplexy [3, 4, 8], without proving the 
absence of any effect of IVIg (particularly on cataplexy). 
Only a randomized, double-blind and placebo-con-
trolled study with narcolepsy patients with both early 
and late disease onset could determine the “true” value 
of IVIg in the treatment of narcolepsy and the ideal in-
terval after onset of symptoms for this expensive and 
possibly harmful therapeutic intervention. 
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lack of efficiency (n = 1) and side effects (n = 1). These data 
confirm and expand previous reports on the good effects 
and tolerability of SO as a treatment for narcolepsy with cat-
aplexy.  Copyright © 2011 S. Karger AG, Basel 
 Introduction 
 Narcolepsy with cataplexy (NC) is a disabling life-long 
sleep-wake disorder, characterized by excessive daytime 
sleepiness (EDS) and sudden loss of muscle tone triggered 
by emotions (cataplexy)  [1] . Additional symptoms in-
clude sleep paralysis, hypnagogic hallucinations and 
fragmented nighttime sleep. Cataplexy is specific for nar-
colepsy and its presence allows diagnosing NC on clinical 
grounds. Typical paraclinical findings with diagnostic 
significance include the occurrence of two or more sleep-
onset REM periods (SOREMPs) in the multiple sleep la-
tency test (MSLT)  [2] , association to the HLA-DQB1 * 0602 
(found in 98% of NC compared to 35% of healthy con-
trols)  [3] and decrease of CSF hypocretin (levels  ! 110 pg/
ml are considered low or undetectable, between 110 and 
200 pg/ml intermediate and levels  1 200 pg/ml are con-
 Key Words 
 Narcolepsy   Cataplexy   Excessive daytime sleepiness   
Sleep paralysis   Hallucinations   Sodium oxybate 
 Abstract 
 Sodium oxybate (SO; Xyrem) has been approved in most 
countries for treatment of narcolepsy and cataplexy. In this 
study, we present a single-center experience of a series of 18 
patients with narcolepsy with cataplexy (18/18 DQB1*0602 
positive, 17/17 with low/absent cerebrospinal fluid hypocre-
tin) in whom SO was prescribed. After 26 ± 13 months, 13/18 
patients were still on SO at a mean dosage of 6.1 ± 1.2 g (in 8 
of them in combination with stimulants). The following sig-
nificant effects were observed: improved subjective sleepi-
ness (12/13), cataplexy (13/13; median number of attacks 
from 20 to 1/month), hallucinations (8/10) and sleep paralysis 
(8/8); increase in mean sleep latency on the Maintenance of 
Wakefulness Test (from 5.5 to 17.4 min) and sleep/rest effi-
ciency on actigraphy (from 61 to 76%); decrease in Epworth 
Sleepiness Scale score (from 18 to 14), sleep onset REM peri-
ods on the Multiple Sleep Latency Test (from 3.6 to 2.4) and 
errors in the Steer-Clear Test (from 11 to 2%). Five patients 
discontinued SO because of insufficient compliance (n = 2), 
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sidered normal)  [4] . The conventional treatment is symp-
tomatic and includes stimulant drugs (amphetamine an-
alogs and modafinil) targeting EDS and antidepressants 
to treat cataplexy  [5] . Sodium oxybate (SO), also known 
as   -hydroxybutyrate (GHB), is a new approach to treat 
all symptoms of the disease. It has been suggested that 
GHB has a role as a neurotransmitter or neuromodulator 
in the mammalian brain  [6] and specific high-affinity 
binding sites have been identified in hippocampus, ven-
trolateral thalamus and the frontoparietal and entorhinal 
cortex of the rat brain  [7] .
 GHB was first synthesized in 1960 and was shown to 
cross the blood-brain barrier rapidly to induce a sleep-
like state with cardiovascular stability. In 1964, the sub-
stance was introduced as an intravenous anesthetic but 
was never largely accepted because of the high incidence 
of side effects (vomiting, seizures). In 1967, it was hy-
pothesized that GHB might be beneficial for the treat-
ment of sleep disorders  [8] . Broughton and Mamelak  [9, 
10] decided to use GHB to normalize nighttime sleep in 
narcolepsy patients and thus to improve the daytime 
symptoms of the disease. These and following studies 
 [11–13] demonstrated that the bedtime administration of 
GHB improved nighttime sleep but also daytime sleepi-
ness, cataplexy, hypnagogic hallucinations and sleep pa-
ralysis. Parallel to these studies, reports appeared that 
GHB enhanced the effect of steroids and the release of 
growth hormone  [14] . As a consequence, the drug was 
used by bodybuilders and for strength training. After the 
reports of a few fatal overdose cases in bodybuilders, 
GHB was banned by the American Food and Drug Ad-
ministration (FDA) in 1990. This was followed by illicit 
use of GHB as a recreational drug because of its euphor-
ic effects, disinhibition and sexual arousal. It was also 
implicated in a number of sexual assault cases and was 
labeled as ‘date rape drug’. Especially in combination 
with alcohol GHB, causes anterograde amnesia and the 
victims are unable to recall any details of the event. In 
Switzerland, mainly cases with acute GHB intoxication 
have been reported  [15–17] . According to the GHB fact-
sheet, issued by the Swiss National Health Organization 
(Bundesamt für Gesundheit, BAG) between 1997 und 
2005, 334 cases with GHB intoxication were reported to 
the Swiss Toxicological Information Centre, of which 
only 1 was fatal  [18] . Recently, 3 fatal cases in patients 
with NC (n = 2) and sleep apnea (n = 1) treated with SO 
were reported  [19] , but the link with SO was not clear in 
any of them  [20] .
 In 1994, Orphan Medical began the development of 
SO oral solution and after the safety and the efficacy of 
the drug for the treatment of narcolepsy were estab-
lished in two multicenter, double-blind, placebo-con-
trolled, randomized trials  [21, 22] , the FDA approved it 
for the treatment of cataplexy in narcolepsy in 2002 and 
for the treatment of EDS in 2005. In 2005, SO was also 
approved by the European Medicines Agency (EMEA). 
Swissmedic approved it in Switzerland in 2006. In the 
mean time, the long-term efficacy  [23] and the effect of 
SO on daytime alertness have been shown  [24–27] . 
Based on A-level evidence, SO has been recommended 
as a first-line treatment for cataplexy in NC by the Eu-
ropean Federation of Neurological Societies (EFNS) 
Task Force  [28] .
 In this study, we present our own experience in the 
treatment of NC patients with SO.
 Patients and Methods 
 Eighteen HLA-DQB1 * 0602-positive (18/18), hypocretin-defi-
cient (17/17) NC patients (9 men), mean age 43 years  8 16 (SD), 
mean disease duration 14  8 14 years, were treated with SO be-
cause of persistent/severe cataplexy (n = 18/18) and EDS (n = 
18/18). Disturbed nighttime sleep was reported in 17/18 patients. 
The Epworth sleepiness score (ESS), frequency of cataplexy, sleep 
paralysis, hallucinations and nightmares were assessed before 
and after treatment. Video-polysomnography (PSG) was per-
formed in 17/18 patients before treatment and in 6/18 patients af-
ter treatment, MSLT in 16/18, respectively in 10/18, maintenance 
of wakefulness test (MWT) and actigraphy in 15/18, respectively 
in 10/18, and steer-clear vigilance test (SCVT) in 14/18, respec-
tively in 10/18 patients.
 PSG consisted of four-channel EEG (C3/A2, C4/A1, O1/A2, 
O2/A1), left and right electrooculography (EOG), submental elec-
tromyography (EMG), electrocardiography (ECG), respiratory 
flow and effort, pulse oximetry and left and right anterior tibialis 
EMG. All recordings were done on Embla Somnologica TM Studio. 
Sleep stages, apneas/hypopneas, periodic limb movements and 
arousals were scored manually according to international criteria 
 [2, 29–31] . Sleep onset was defined as the first epoch of either 
NREM-2 or REM sleep.
 Standard MSLT  [32] was performed on the day following the 
nocturnal recording, starting 2 h after waking up. For each pa-
tient, four or five naps with a duration of 20 min in 2-hour inter-
vals were recorded. The naps were terminated after 20 min. MWT 
was performed at daytime, for each patient four naps, each with a 
maximal duration of 40 min in 2-hour intervals were recorded. In 
case the patient fell asleep, the recording was interrupted after 
three consecutive epochs of NREM-1 or after one epoch of any 
other sleep stage. Sleep onset for both MSLT and MWT was de-
fined as the first epoch of sleep.
 Fourteen-day actigraphy was performed using Actiwatch  
(Cambridge Neurotechnology); the main parameter of interest 
was the sleep/rest efficiency in percent. Vigilance during a mo-
notonous task was assessed using the steer-clear vigilance test 
(SCVT) computer program  [33] . For SCVT an arbitrary cut-off of 
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3% has been accepted in different sleep laboratories as normal 
controls usually lie clearly below this value  [33] .
 Statistical analysis was performed using SPSS 15 software.   2 , 
paired t tests and Wilcoxon signed rank tests were used to analyze 
categorical and continuous variables, respectively. Significance 
level was set at p  ! 0.05.
 Results 
 All patients were HLA-DQB1 * 0602-positive and in 
17/18, CSF levels of hypocretin-1 were measured. It was 
undetectable in 13, low in 3, and intermediate in 1 patient. 
ESS was assessed in all patients at baseline. All patients 
reported cataplexy with a monthly frequency ranging 
form 1 to 600 (median 16, mean 101). Sleep paralysis was 
reported in 11/18 patients, hypnagogic hallucinations in 
14/18, nightmares in 4/18 and disturbed nighttime sleep 
in 17/18 patients. The demographics, ESS, PSG, MSLT, 
MWT, actigraphy and SCVT data for all patients prior to 
treatment are shown in  table 1 .
 Patients on Sodium Oxybate 
 Thirteen out of 18 patients are still treated with SO (7 
men, mean dosage 6.4  8 1.2 g, mean treatment duration 
26  8 13 months). Additional therapies include modafinil 
(n = 5), fluoxetine (n = 1) and methylphenidate (n = 1). 
One patient stopped modafinil after the initiation of SO, 
in all the others the additional therapies remained stable.
 One patient reported overall improvement of the nar-
colepsy symptoms of about 80% with one single bedtime 
dose of 5 g SO. Another 2 patients admitted skipping the 
second dose occasionally but in spite of that did not no-
tice any significant difference in their symptoms. The 
remaining 10 patients reported taking SO regularly
twice – at bedtime and between 2.5 and 4 h later.
 Nearly all patients (12/13) reported subjective im-
provement in EDS (from 20 to 80%, mean 33  8 23%). ESS 
significantly improved (from 17.9 to 13.9, p = 0.001). After 
treatment, 6/13 patients were free of cataplexy, in 7/13 pa-
tients a marked reduction in cataplexy frequency, dura-
tion and severity was observed. Cataplexy under SO usu-
ally occurred later in the day, when the patients were 
tired. In general the improvement of cataplexy was high-
ly significant (median before treatment 20 per month, af-
ter treatment 1, p = 0.001). The reduction in percent was 
between 50 and 100%, mean  8 SD, 88  8 19%. Sleep pa-
ralyses disappeared in 8/8 patients after initiation of SO. 
Under SO treatment, 8/10 patients were free of hallucina-
tions, 2 patients reported significant reduction in the fre-
quency of hallucinations. Nightmares disappeared in 3 
Table 1.  Characteristics of the patients prior to treatment with SO
Variable Mean 8 SD Range
Age, years 43816 18–69
Male gender 9
Disease duration, years 14814 2–50
ESS 1784 9–24
Cataplexy frequency per month, median 16 1–600
Sleep paralysis per month 589 0–30
Hallucination frequency per month 788 0–30
Sleep/rest efficiency in actigraphy, % 62819 16–81
Rest/sleep for 24 h, % 37812 10–72
Sleep latency, min 8810 0–38
Sleep efficiency, % 8889 71–98
REM latency, min 35862 0–232
Apnea/hypopnea index/h 11818 0–68
PLMS index/h 15824 0–70
NREM-1, % 1886 9–31
NREM-2, % 36810 19–54
Slow wave sleep, % 1287 0–22
REM, % 2188 12–38
Arousal index/h 1687 7–32
Mean sleep latency in MSLT 1.881.2 0.4–4.6
Number of SOREM in MSLT 3.680.7 2–4
Mean sleep latency in MWT 6.384.1 0.5–15.8
Number of SOREM in MWT 1.181.2 0–3
Error % in SCVT 8.589.7 0.6–37.8
E SS = Epworth sleepiness score; MSLT = multiple sleep la-
tency test; MWT = maintenance of wakefulness test; SOREM = 
sleep-onset REM period; SCVT = steer-clear vigilance test.
0
%
EDS
20
40
60
80
100
67
33
Cataplexy Sleep
paralyses
Hallucinations
12
88
100 98
Improvement
Residual symptoms
2
 Fig. 1. Improvement of clinical symptoms after treatment, in per-
cent. 
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and persisted in 1 of 4 patients. All patients experienced 
a subjective improvement of their nighttime sleep. The 
improvement of the clinical symptoms of NC is presented 
in  figure 1 .
 Rest/sleep efficiency in the actigraphy improved (from 
61 to 76%, p = 0.017), the mean sleep latency in MSLT did 
not differ significantly, the mean sleep latency in MWT 
increased clearly (from 5.5 to 17.4 min, p  ! 0.001) and the 
error quotient in SCVT decreased (from 10.7 to 2.1%, p = 
0.017). In PSG a decrease in sleep latency, REM sleep la-
tency, apnea/hypopnea index, NREM-1, REM and arous-
al index and an increase in slow wave sleep was observed, 
although as PSG was available before and after treatment 
in only 5 patients, the results did not reach statistical sig-
nificance. The results of the different tests are presented 
in  table 2 . An actigraphy and a PSG hypnogram example 
before and after treatment are shown in  figure 2 .
 Dropouts 
 In 5 patients the drug was discontinued shortly after 
initiation due to insufficient compliance (n = 2), lack of 
efficiency (n = 2) or side effects (n = 1), including nausea 
and worsening of sleepiness and cataplexy. This patient 
did not tolerate modafinil and fluoxetine either and did 
not wish further treatment. Four of these patients had 
rare cataplexy (once or twice a month); 3 were treated 
with modafinil (as monotherapy 400–600 mg/day, or to-
gether (200 mg/day) with venlafaxine 75 mg/day or fluox-
etine 20 mg/day). One patient was treated with clomip-
ramine 100 mg/day. In these patients no follow-up assess-
ment under SO was possible as they discontinued the 
medication shortly after initiation (1 week in most cases).
 Adverse Events 
 The most common adverse event (considering all 18 
patients) was nighttime confusion (n = 6). Others includ-
ed nausea (n = 2), enuresis (n = 2, in 1 of the cases only 
once over 1.5 years), diffuse muscle pain, headache, flat-
ulence, disturbance in attention and forgetfulness (n = 
1). The patient with diffuse muscle pain also had enure-
sis; after a dose reduction from 6 to 4.5 g/day the adverse 
events decreased and the patient insisted on taking the 
medication. Only 1 patient discontinued treatment be-
cause of adverse events. This patient reported pro-
Table 2. E ffect of SO on different subjective and objective parameters
Variable Cases, n Before SO treatment
mean 8 SD
After SO treatment
mean 8 SD
p value
ESS 13 17.881 13.981.2 0.001
Number of cataplexies/month, median 13 20 1 0.001
Number of sleep paralyses/month 13 4.188.3 0 0.011
Number of hallucinations/month 13 7.689.5 0.481.1 0.005
Nightmares/month 13 6.5810.3 1.585.5 NS
Sleep/rest efficiency in actigraphy 8 60.5819.7 7684 0.017
Mean sleep latency in MSLT, min 8 281.5 2.482.6 NS
Number of SOREM in MSLT 8 3.680.5 2.481.4 0.038
Mean sleep latency in MWT, min 9 5.584.5 17.488.9 <0.001
Number of SOREM in MWT 9 181.1 0.481.1 NS
Error % in SCVT 8 10.8 812.5 2.182.1 0.017
Total sleep time in PSG, min 5 390850 398842 NS
Sleep latency in PSG, min 5 11.7816 5.687.5 NS
Sleep efficiency in PSG, % 5 88.587.9 92.185.7 NS
REM latency, min 5 76.68109.4 21.6841.9 NS
NREM-1, % 5 19.185.5 8.282.8 0.071
NREM-2, % 5 38.3810.2 37.589.3 NS
Slow wave sleep, % 5 10.587.7 33.1814.7 0.074
Apnea/hypopnea index/h 5 22.4827.8 16.2816.7 NS
PLMS index/h 5 7.187.2 8.3814.8 NS
Arousal index 5 20.586.3 9.282.3 0.067
E SS = Epworth sleepiness score; MSLT = multiple sleep latency test; MWT = maintenance of wakefulness 
test; SOREM = sleep-onset REM period; SCVT = steer-clear vigilance test.
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nounced nausea and worsening of nighttime sleep and 
cataplexy. 
 There was 1 patient who over time voluntarily in-
creased the dose of SO from 2  ! 4.5 g to 3  ! 4.5 g per 
night because of nighttime sleep disturbance.
 Discussion 
 Efficacy: Clinical Findings 
 SO led to significant improvement of cataplexy, day-
time sleepiness and alertness, sleep paralysis, hallucina-
tions, nightmares and nighttime sleep. Actigraphy and 
SCVT were used for the first time to assess the treatment 
effects of SO.
 Cataplexy improvement regarding its frequency, dura-
tion and severity has been shown in a number of studies 
 [10–12, 21–27, 34] . As already reported by Mamelak et al. 
 [34] , cataplexy under SO occurred later in the day, when 
the patients were tired. Consistent with previous studies 
 [11, 21, 24, 26, 27, 34] , improvement of daytime sleepiness 
and alertness was demonstrated. As 5 patients were treat-
ed with modafinil (in 1 in alternation with methylpheni-
date) and 1 with fluoxetine, the effects on EDS cannot 
only be attributed to SO. Sleep paralysis and hallucina-
tions improved too, as previously reported  [11–13, 34] . In 
more recent studies  [21, 23–25] , a decrease in the frequen-
cy of sleep paralyses and hallucinations was observed, but 
the results did not reach statistical significance. Night-
mares disappeared in 3 of our patients, 1 of them report-
ed that she continued dreaming but the dreams were no 
longer frightening. This phenomenon has also been de-
scribed by Mamelak et al.  [34] . A literature overview of 
different studies, assessing the effects of SO, is presented 
in table 3.
 Efficacy: Actigraphy, MSLT, MWT, SCVT and PSG 
 Actigraphy showed a marked improvement in the 
nighttime rest/sleep efficiency, consistent with the sub-
jectively reported improvement of nighttime sleep. Simi-
23:00
Arousal
MT
Wake
REM
S1
S2
S3
S4
Arousal
MT
Wake
REM
S1
S2
S3
S4
00:00 01:00 02:00 03:00 04:00 05:00 06:00
23:00 00:00 01:00 02:00 03:00 04:00 05:00 06:00
a b
c
d
 Fig. 2. Actigraphy and PSG hypnogram examples before and after treatment with SO:  a actigraphy before,
 b actigraphy after,  c hypnogram before, and  d hypnogram after treatment. 
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larly, a significant subjective nighttime sleep improve-
ment  [11–13, 34] and a significant decrease in the number 
of nighttime awakenings have been reported  [21, 25] . To 
our knowledge, actigraphy data has not been previously 
used to assess the treatment effects of SO. Actigraphy al-
lows the assessment of sleep-wake patterns over longer 
periods of time. As seen in  figure 2 , the results are com-
parable with the hypnogram, obtained after an overnight 
PSG. We suggest that the method can be a useful, far less 
expensive and less complex tool in the evaluation of the 
treatment effects of SO, especially concerning nighttime 
sleep improvement.
 There were no significant differences in daytime sleep 
latency in MSLT as already reported in the literature  [34] . 
Concordant with previous studies, a significant improve-
ment of the mean sleep latency in MWT was observed 
 [24, 26, 27] . The SCVT demonstrated an improvement in 
sustained attention. This result can be compared to the 
Table 3.  Literature overview
Reference
(first author)
Design Patients
n
Methods EDS/sleep
attacks
Cataplexy Sleep
paralyses
Hallucina-
tions
Nighttime 
sleep quality
Broughton
1979 [10]
case series, open 16 clinical assessment improved improved NA NA improved
Scharf
1985 [11]
case series, open 30 clinical assessment, 
PSG
improved improved improved improved improved
Mamelak
1986 [34]
case series, open 48 clinical assessment, 
PSG, MSLT
improved improved improved improved improved
Scrima
1989 [12]
double-blind,
counter-balanced
crossover design
20 clinical assessment, 
daily diary
not 
significantly 
different
improved NA NA improved
Lammers
1993 [13]
randomized, 
double-blind 
placebo-controlled 
crossover design
24 daily diary, 
questionnaires, 
PSG, MSLT
improved improved, 
but not 
significantly
low 
incidence, 
not accessible
improved improved, 
but not 
significantly
US Xyrem 
Multicenter
Study Group
2002 [21]
multicenter, 
double-blind 
placebo-controlled 
136 daily diary, 
questionnaires
improved, 
dose-
dependent
improved, 
dose-
dependent
improved, 
but not 
significantly
improved, 
but not 
significantly
improved, 
dose-
dependent
US Xyrem 
Multicenter Study 
Group 2003 [23]
open-label 118 daily diary, 
questionnaires
long-term 
improvement
long-term 
improve-
ment
improved, 
but not 
significantly
improved, 
but not 
significantly
improved, 
but not 
significantly
Mamelak
2004 [24]
open-label study 25 PSG, MWT, 
questionnaire
improved improved improved improved improved
Xyrem 
International
Study Group
2005 [25]
double-blind 
placebo-controlled 
228 daily diary NA improved, 
dose-
dependent
improved, 
but not 
significantly
improved, 
but not 
significantly
NA
Xyrem 
International
Study Group
2005 [27]
double-blind 
placebo-controlled 
228 daily diary, 
questionnaires, 
MWT
improved, 
dose-
dependent
NA NA NA NA
Black
2006 [26]
multicenter, 
double-blind 
placebo-controlled 
270 daily diary, 
questionnaires, 
MWT
improved NA NA NA NA
Black
2009 [36]
double-blind 
placebo-controlled 
278 daily diary, 
questionnaires, 
PSG, MWT
improved NA NA NA improved
M SLT = Multiple sleep latency test; MWT = maintenance of wakefulness test; NA = not available; PSG = polysomnography.
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improved ability to stay awake in MWT, but whereas 
MWT requires a whole day of testing, SCVT is completed 
in 30 min. Additionally, it is in a way closer to some ev-
eryday life situations, where patients are involved in mo-
notonous tasks, but their active participation is still re-
quired. We suggest that the test is used complementary 
to MWT.
 SO also leads to changes in nighttime sleep architec-
ture, such as decrease of NREM-1  [24] , increase of slow 
wave sleep  [24, 34] and decrease in nighttime awakenings 
 [21, 24] . As PSG was available in only 5 patients before 
and after treatment, we could not find significant differ-
ences in nighttime sleep parameters. Nevertheless, a 
trend for a decrease in NREM-1 and in the arousal index 
and a trend for increase in slow wave sleep were observed. 
Although not significant, there was a decrease in apnea/
hypopnea index after SO treatment. This finding is in 
line with a recent report in which the use of SO 4.5 g/
night over 2 weeks did not generate respiratory depres-
sant effects in obstructive sleep apnea patients as mea-
sured by the apnea/hypopnea index, obstructive apnea 
events, central apneas, and oxygen saturation  [35] .
 Safety 
 SO was well tolerated in most patients. Consistent with 
the literature  [21, 23, 25] , adverse events primarily affect-
ed the central nervous system and digestive system. In 
most patients, there was no dose relationship for the most 
common adverse events and the majority were mild to 
moderate in severity. In 1 patient, dose reduction led to 
improvement of the adverse events. Only 1 patient dis-
continued the medication because of nausea and worsen-
ing of the narcolepsy symptoms.
 Conclusion 
 SO is effective not only for cataplexy but also for EDS, 
sleep paralyses, hallucinations and nighttime sleep quality 
in NC. The drug is generally well tolerated in spite of the 
occurrence of mild-to-moderate adverse events. Actigra-
phy offers a cheaper and less complex alternative to PSG 
for assessment of SO treatment effects, especially in every-
day practice, and vigilance tests should be used comple-
mentary to MWT in order to assess sustained attention.
 
 References 
 1 Bassetti C, Aldrich MS: Narcolepsy. Neurol 
Clin 1996; 14: 545–571. 
 2 American Academy of Sleep Medicine 
(AASM): International Classification of 
Sleep Disorders. Diagnostic and Coding 
Manual, ed 2. Westchester/IL, AASM, 
2005.  
 3 Lin L, Hungs M, Mignot E: Narcolepsy and 
the HLA region. J Neuroimmunol 2001; 117: 
 9–20. 
 4 Mignot E, Lammers GJ, Ripley B, et al: The 
role of cerebrospinal f luid hypocretin mea-
surement in the diagnosis of narcolepsy and 
other hypersomnias. Arch Neurol 2002; 59: 
 1553–1562. 
 5 Billiard M: Narcolepsy: current treatment 
options and future approaches. Neuropsy-
chiatr Dis Treat 2008; 4: 557–666. 
 6 Vayer P, Mandel P, Maitre M:   -Hydroxybu-
tyrate, a possible neurotransmitter. Life Sci 
1987; 41: 1547–1557. 
 7 Snead OC, Liu C:   -Hydroxybutyric acid 
binding sites in rat and human brain synap-
tosomal membranes. Biochem Pharmacol 
1984; 33: 2587–2590. 
 8 Yamada Y, Yamamoto J, Fujiki A, Hishakawa 
Y, Kaneko Z: Effect of butyrolactone and   -
hydroxybutyrate on the EEG and sleep cycle 
in man. Electroencephalogr Clin Neuro-
physiol 1967; 22: 558–562. 
 9 Broughton R, Mamelak M: In Guilleminault 
C, Dement WC, Passousant P (eds): Advanc-
es in Sleep Research. New York, Spectrum, 
1976, pp 659–667. 
 10 Broughton R, Mamelak M: The treatment of 
narcolepsy-cataplexy with nocturnal   -hy-
droxybutyrate. Can J Neurol Sci 1979; 6: 1–6. 
 11 Scharf M, Brown D, Woods M, et al: The ef-
fects and effectiveness of   -hydroxybutyrate 
in patients with narcolepsy. J Clin Psychiatry 
1985; 46: 222–225. 
 12 Scrima L, Hartman PG, Johnson FH Jr, Hill-
er FC: Efficacy of   -hydroxybutyrate versus 
placebo in treating narcolepsy-cataplexy: 
double-blind subjective measures. Biol Psy-
chiatry 1989; 26: 331–343. 
 13 Lammers GJ, Arends J, Declerck AC, et al: 
  -Hydroxybutyrate and narcolepsy: a dou-
ble-blind placebo-controlled study. Sleep 
1993; 6: 216–220. 
 14 Takahara J, Younuki S, Yakushiji W: Stimu-
latory effects of   -hydroxybutyric acid on 
growth hormone and prolactin release in hu-
mans. J Clin Endocrinol Metab 1977; 44: 
 1014–1016. 
 15 Herbrand R, Greminger P, Schurter G, 
Pletscher W, Kupferschmidt H: Sudden 
coma in a 20-year-old man (in German). 
Praxis (Bern 1994) 2000; 89: 1326–1330. 
 16 Liechti ME, Kupferschmidt H:   -Hydroxy-
butyrate (GHB) and   -butyrolactone (GBL): 
analysis of overdose cases reported to the 
Swiss Toxicological Information Centre. 
Swiss Med Wkly 2004; 134: 534–537. 
 17 Iten PX, Oestreich A, Lips R, Brabetz M: A 
new drug reaches Switzerland: coma after in-
take of   -hydroxybutyrate (GHB) (in Ger-
man). Schweiz Med Wochenschr 2000; 130: 
 356–361. 
 18 Bundesamt für Gesundheit BAG. Factsheet 
GHB 2009. 
 19 Zvosec DL, Smith SW, Hall BJ: Three deaths 
associated with use of Xyrem  . Sleep Med 
2009; 10: 490–493. 
 20 Lammers GJ, Bassetti C, Billiard M et al: So-
dium oxybate is an effective and safe treat-
ment for narcolepsy. Sleep Med 2010; 11: 105–
106. 
 21 US Xyrem  Multicenter Study Group: A ran-
domized, double-blind, placebo-controlled 
multi-center trial comparing the effects of 
three doses of orally administered sodium 
oxybate with placebo for the treatment of 
narcolepsy. Sleep 2002; 25: 42–49. 
 22 US Xyrem  Multicenter Study Group: Sodi-
um oxybate demonstrates long-term efficacy 
for the treatment of cataplexy in patients 
with narcolepsy. Sleep Med 2004; 5: 119–123. 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
14
4.
20
0.
17
.3
8 
- 2
/2
7/
20
14
 1
2:
36
:3
7 
PM
 Poryazova et al. Eur Neurol 2011;65:175–182182
 23 US Xyrem  Multicenter Study Group: A 
12-month, open-label, multicenter extension 
trial of orally administered sodium oxybate 
for the treatment of narcolepsy. Sleep 2003; 1: 
 31–35. 
 24 Mamelak M, Black J, Montplaisir J, Rista-
novic R: A pilot study on the effects of sodi-
um oxybate on sleep architecture and day-
time alertness in narcolepsy. Sleep 2004; 27: 
 1327–1334. 
 25 Xyrem  International Study Group: Further 
evidence supporting the use of sodium oxy-
bate for the treatment of cataplexy: a double-
blind, placebo-controlled study in 228 pa-
tients. Sleep Med 2005; 6: 415–421. 
 26 Black J, Houghton WC: Sodium oxybate im-
proves excessive daytime sleepiness in nar-
colepsy. Sleep 2006; 29: 939–946. 
 27 Xyrem International Study Group: A double-
blind, placebo-controlled study demon-
strates sodium oxybate is effective for the 
treatment of excessive daytime sleepiness in 
narcolepsy. J Clin Sleep Med 2005; 1: 391–397. 
 28 Billiard M, Bassetti C, Dauvilliers Y, et al: 
EFNS guidelines on management of narco-
lepsy. Eur J Neurol 2006; 13: 1035–1048. 
 29 Rechtschaffen A, Kales A: A Manual of Stan-
dardized Terminology, Techniques and 
Scoring System for Sleep Stages of human 
Subjects. Los Angeles, UCLA Brain Informa-
tion Service/Brain Research Institute, 1968. 
 30 American Sleep Disorders Association: EEG 
arousals: scoring rules and examples. A pre-
liminary report from the Sleep Disorders At-
las Task Force of the American Sleep Disor-
ders Association. Sleep 1992; 15: 174–184. 
 31 American Academy of Sleep Medicine Task 
Force: Sleep-disordered breathing disorders 
in adults: recommendations for syndrome 
definition and measurement techniques in 
clinical research. Sleep 1999; 22; 667–688. 
 32 Carskadon MA, Dement WC, Mitler MM, 
Roth T, Westbrook PR, Keenan S: Guidelines 
for the multiple sleep latency test (MSLT): a 
standard measure of sleepiness. Sleep 1986; 
 9: 519–524. 
 33 Findley L, Unverzagt M, Guchu R, Fabrizio 
M, Buckner J, Suratt P: Vigilance and auto-
mobile accidents in patients with sleep apnea 
or narcolepsy. Chest 1995; 108: 619–624. 
 34 Mamelak M, Scharf MB, Woods M: Treat-
ment of narcolepsy with   -hydroxybutyrate. 
A review of clinical and sleep laboratory 
findings. Sleep 1986; 9: 285–289. 
 35 George CF, Feldman N, Zheng Y, Steininger 
TL, Grzeschik SM, Lai C, Inhaber N: A 
2-week, polysomnographic, safety study of 
sodium oxybate in obstructive sleep apnea 
syndrome. Sleep Breath (in press). 
 36 Black J, Pardi D, Hornfeldt CS, Inhaber N: 
The nightly administration of sodium oxy-
bate results in significant reduction in the 
nocturnal sleep disruption of patients with 
narcolepsy. Sleep Med 2009; 10: 829–835. 
 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
14
4.
20
0.
17
.3
8 
- 2
/2
7/
20
14
 1
2:
36
:3
7 
PM
DOI 10.1212/WNL.0b013e3181fd62a2
2010;75;1780-1785 Neurology 
P.R. Kaiser, P.O. Valko, E. Werth, et al. 
brain injury
Modafinil ameliorates excessive daytime sleepiness after traumatic
This information is current as of November 15, 2010
 http://www.neurology.org/content/75/20/1780.full.html
located on the World Wide Web at: 
The online version of this article, along with updated information and services, is
Enterprises, Inc.. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.
since 1951, it is now a weekly with 48 issues per year. Copyright Copyright © 2010 by AAN 
® is the official journal of the American Academy of Neurology. Published continuouslyNeurology 
Modafinil ameliorates excessive daytime
sleepiness after traumatic brain injury
P.R. Kaiser, MSc*
P.O. Valko, MD*
E. Werth, PhD
J. Thomann, MSc
J. Meier
R. Stocker, MD
C.L. Bassetti, MD
C.R. Baumann, MD
ABSTRACT
Background: Excessive daytime sleepiness (EDS) and fatigue are common symptoms after trau-
matic brain injury (TBI), but there is no specific treatment for affected patients. With this pilot
study, we aimed at studying the effect of daily modafinil on posttraumatic EDS and fatigue.
Methods: We conducted a prospective, double-blind, randomized, placebo-controlled pilot study
in 20 patients with TBI who had fatigue or EDS or both. After baseline examinations (question-
naires including the Epworth Sleepiness Scale to assess EDS and the Fatigue Severity Scale to
assess fatigue, actigraphy, polysomnography, maintenance of wakefulness test, and psychomo-
tor vigilance test), 10 patients received 100 to 200 mg modafinil every morning, and 10 patients
were treated with placebo. After a 6-week treatment period, all examinations were repeated.
Results: EDS improved significantly in patients with TBI who were treated with modafinil, com-
pared with the placebo group. Similarly, the ability to stay awake on the maintenance of wakeful-
ness test improved only in the modafinil group. Modafinil, however, had no impact on
posttraumatic fatigue. Clinically relevant side effects were not observed.
Conclusion: This study indicates that modafinil is effective and well tolerated in the treatment of
posttraumatic EDS but not of fatigue.
Classification of evidence: This study provides Class I evidence that modafinil (100–200 mg daily)
improves posttraumatic EDS compared with placebo. This study provides Class I evidence that
modafinil (100–200 mg daily) does not improve posttraumatic fatigue compared with placebo.
Neurology® 2010;75:1780–1785
GLOSSARY
EDS  excessive daytime sleepiness; ESS  Epworth Sleepiness Scale; FSS  Fatigue Severity Scale; GCS  Glasgow
Coma Scale; MWTmaintenance of wakefulness test; TBI traumatic brain injury.
Traumatic brain injury (TBI) occurs in about 1.4 million people in the United States each year,
corresponding to an incidence of 460 per 100,000 per year.1 Another study estimated that 3.17
million US citizens (more than 1% of the total US population) have long-term neurologic
disability that resulted from TBI.2 Thus, TBI causes the largest number of disability-adjusted
life-years lost to death and to varying degrees of disability, including posttraumatic sleep-wake
disturbances.3
Excessive daytime sleepiness (EDS) and fatigue are frequent symptoms after TBI. In our
prospective study on posttraumatic sleep-wake disturbances, we studied 65 consecutive pa-
tients by means of questionnaires and sleep laboratory examinations 6 months after trauma.4
We found EDS in 38% and fatigue in 17% of our patients. Our findings are in line with other
reports on posttraumatic sleep-wake disturbances.5-7 The etiology of posttraumatic EDS is not
known. Recently, we found a partial loss of wake-promoting hypothalamic hypocretin (orexin)
neurons after fatal TBI.8 EDS and fatigue significantly impair quality of life and daytime
functioning, including professional performances and social activities.4 Despite their high inci-
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dences, posttraumatic EDS and fatigue are
still underestimated, and there is no treatment
for affected patients.
Thus, with this pilot study, we aimed at
studying the effect of daily modafinil on post-
traumatic EDS and fatigue. Modafinil (2-
[(diphenylmethyl) sulfinyl] acetamide) has
wake-promoting properties and is approved
by the US Food and Drug Administration for
the treatment of EDS in patients with narco-
lepsy, obstructive sleep apnea syndrome, and
shift work sleep disorder.
METHODS This prospective study was conducted at the De-
partment of Neurology of the University Hospital of Zurich,
Switzerland, between January 2007 and June 2009.
Subjects. In this prospective, double-blind, randomized,
placebo-controlled pilot study, we included 20 consecutive pa-
tients from our first study on posttraumatic sleep-wake distur-
bances.4 All patients were admitted for closed mild to severe TBI
to our surgical intensive care unit, where they were recruited for
this study. TBI severity was quantified with the initial Glasgow
Coma Scale (GCS) examination, which was performed immedi-
ately after trauma (mild TBI: GCS 13–15, moderate TBI: GCS
9–12, severe TBI: GCS 3–8). Admission to the surgical inten-
sive care unit was for mild to severe TBI. The mandatory inclu-
sion criterion was the presence of fatigue or EDS or both since
TBI. Patients with neurologic, psychiatric, or other disorders
and medication that might cause sleep-wake disturbances were
not included. Furthermore, we excluded patients who revealed
significant sleep-wake disturbances other than posttraumatic vig-
ilance impairment at baseline examinations. Patients with
chronic sleep deprivation were also excluded. The latter was di-
agnosed in patients with EDS who slept 2 hours more on
weekends or during holidays than during weekdays. All exclu-
sions were made before randomization.
Fatigue was assessed with the Fatigue Severity Scale (FSS),
and EDS was assessed with the Epworth Sleepiness Scale (ESS).
Both scales have been validated in German.9,10 Fatigue is diag-
nosed in patients with FSS values above 4.0, and EDS is diag-
nosed in those with ESS scores 10. Before randomization,
written informed consent was obtained from all patients.
Baseline examinations. At baseline, patients were adminis-
tered the Beck Depression and Anxiety Inventory, a standard
questionnaire to assess depression and anxiety symptoms.11 To
rule out chronic sleep deprivation, patients were examined by 2
weeks of actigraphy studies. Actigraphy is a noninvasive method
to monitor activity/rest cycles over a defined period of time.
Sleep and physical activity levels were recorded by wrist actigra-
phy. The actimeter includes a light sensor and is worn on the
nondominant wrist (Actiwatch, CamNtech Ltd., Cambridge,
UK).12 With this software, the determination of time asleep
and time awake relies on an algorithm using the activity data
recorded by the Actiwatch in a series of linked calculations.
During actigraphy recordings, all patients simultaneously
filled in sleep logs.
Immediately after actigraphy, conventional nocturnal poly-
somnography was recorded from 11 PM to 7 AM. We used a
16-channel recording system (Embla A10, Embla, Broomfield,
CO). Sleep-stage scoring was performed visually by the first au-
thors according to standard criteria.13 Patients with significant
sleep-wake disturbances, such as obstructive sleep apnea, de-
tected during polysomnographic recordings were excluded from
the study. The day after polysomnography, all patients were ex-
amined by a maintenance of wakefulness test (MWT).14 This test
measures the ability to stay awake for 40 minutes while sitting
quietly in a dark room and is performed every 2 hours, in total 4
times a day. Mean sleep latency in the MWT was defined as the
time from lights off to the first epoch of any sleep stage. At the
same day, before every MWT test, we examined the patients’
vigilance with the psychomotor vigilance test. This test measures
reaction times of patients to the sudden appearance of a time-
keeper on a black computer screen.15 The test lasts 10 minutes
and assesses the number of lapses, defined as times the subject
does not respond to the signal in time, and calculates reaction
times. Intake of caffeine and medication with known effects on
vigilance and sleepiness were not allowed during days and nights
with sleep recordings and vigilance tests.
Randomization and follow-up examinations. After com-
pletion and evaluation of all tests, included patients were ran-
domly assigned to either the modafinil group or the placebo
group. All study procedures were performed in a strict double-
blind manner. For allocation concealment, labeling of masked
study medication (modafinil or placebo) by manufacturing of
numbered containers was performed centrally by the Pharmacy
of the University Hospital of Zurich. All patients in the treat-
ment group started with 1 oral capsule (corresponding to 100
mg modafinil per day in the treatment group), administered in
the morning. Every 2 weeks, a phone call from the first author
evaluated the subjective response to treatment, including efficacy
and side effects. In patients without clear efficacy and without
side effects, the dose was doubled: 1 oral capsule in the morning
and 1 at noon. In patients with troublesome side effects with 2
capsules, there was a possibility to reduce the dose again. Fur-
thermore, all patients were asked whether they estimated their
vigilance impairment to be ameliorated by treatment.
After 6 treatment weeks, all examinations, including ques-
tionnaires, actigraphy, conventional nocturnal polysomnogra-
phy, MWTs, and psychomotor vigilance tests, were repeated.
Primary outcome measures included improvements in FSS and
ESS values, and in mean sleep latencies on MWT.
Standard protocol approvals, registrations, and patient
consents. The study was approved by the local ethical stan-
dards committee on human experimentation (Ethikkommission
des Kantons Zurich) and by Swissmedic, the Swiss agency for
therapeutic products. All study participants gave oral and written
consent to all study procedures.
Statistics. Statistical analyses were performed by using corre-
lation analyses (Pearson and Spearman), Student t tests,
Mann–Whitney U tests, and multivariate regression analyses.
Parametric tests were 2-tailed.
RESULTS Demographic data and baseline charac-
teristics of both the treatment and the placebo group
can be found in table 1. Patients in both groups did
not differ in age, sex distribution, severity of TBI, or
duration since trauma. At study inclusion, the dura-
tion since trauma was 1 to 3 years in all patients.
After baseline examinations, we excluded 4 patients
because of obstructive sleep apnea and 1 patient be-
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cause of chronic sleep deprivation. A flow diagram
depicting the passage of participants through this
study is given in figure 1.
At baseline, 8 patients in every group were diag-
nosed with fatigue. FSS values at baseline did not
differ between the 2 groups: mean FSS values were
5.0  1.4 in the modafinil group and 4.6  0.8 in
the placebo group. Five patients in the placebo group
and 6 in the modafinil group were diagnosed with
EDS. Again, ESS values at baseline did not differ
between the 2 groups (modafinil: 8.2 3.7, placebo:
10.0  4.2). Relevant sleep-related breathing or
movement disorders were not present in either
group. The respective measures such as the apnea-
hypopnea index or the periodic limb movement in-
dex were similar in the 2 groups. Also, actigraphy
measures did not differ between groups. Beck De-
pression and Anxiety Inventories revealed similar re-
sults in the 2 groups. In both treatment groups, the
dose of study medication was doubled in 8 patients.
It was not necessary in any of these patients to reduce
the dose again because of side effects. None of our
patients discontinued treatment.
After 6 weeks of treatment, the decrease in FSS
scores was higher in the modafinil group (0.8 
1.0) than in the placebo group (0.0  0.6), but this
finding was not significant after correction for the
independent variables sex, age, TBI severity, and
Beck Depression and Anxiety scale values (figure 2).
Fatigue was still present in all 8 patients in the
placebo group and in 4 patients in the modafinil
group. When selecting only patients with fatigue
(FSS  4.0) at baseline, decreases in FSS scores
were not higher in the modafinil group.
After 6 treatment weeks and compared with the
placebo group, the decrease in ESS scores was higher
in the modafinil group (2.3  2.3 compared with
0.7  1.8, p  0.005; figure 2). This finding re-
mained significant after correction for the same inde-
pendent variables, and also when selecting only those
patients with EDS (ESS 10) at baseline. Under treat-
ment, EDS was still present in 3 patients in each group.
The objective measurement of the ability to re-
main awake at daytime under nonstimulating condi-
tions revealed a significant increase compared with
baseline of the mean sleep latency on MWT in the
treatment group (8.4 9.6 minutes) compared with
the placebo group (0.4  6.2 minutes) (p  0.04;
figure 2). Patients under placebo treatment fell asleep
quicker at nocturnal polysomnography than at base-
line (13.6  16.4 minutes) after 6 treatment
weeks, which probably reflects habituation to the
sleep laboratory environment. Patients treated with
modafinil, however, had no change in sleep latencies
compared with baseline (2.7 14.7 minutes), which
again indicates decreased sleep pressure compared
with the placebo group (p  0.03). Conversely, the
psychomotor vigilance test did not reveal differences
between the groups: both reaction times and number
of lapses were similar. Actigraphy revealed an in-
crease of time awake per 24 hours in the modafinil
group by 1.9 hours, whereas time awake decreased
mildly (0.3 hours) in the placebo group (p 
0.33).
Table 1 Baseline characteristics and changes from baseline in 20 patients
with traumatic brain injury, 10 treated with placebo and 10
treated with modafinila
Placebo Modafinil p Value
General findings
Age, y 43 19 37 9
Sex,%male 90 80
Glasgow Coma Scale 8 4 7 4
Pathologic CT findings,% 60 50
Interval after trauma, y 2.0 1.2 1.8 0.9
High dosage (modafinil group: 200mg),% 80 80
Side effects,% 10 20
Baseline findings
ESS 8.2 3.7 10.0 4.2
FSS 5.0 1.4 4.6 0.8
Beck Depression Inventory 11 9 9 6
Beck Anxiety Inventory 10 11 10 9
PSG: sleep efficiency,% 87 5 88 11
PSG: sleep latency to NREM2, min 20 16 16 18
PSG: apnea-hypopnea index 4.3 3.8 2.6 3.3
PSG: periodic limbmovements index 0.8 0.9 2.1 4.4
MWT: mean sleep latency, min 18.7 9.3 15.6 11.4
Actigraphy: awake per 24 h,% 39 13 41 11
Actigraphy: sleep elongation weekend, h 0.5 0.7 0.8 1.0
PVT: velocity, s 3.7 0.6 3.8 0.5
PVT: no. of lapses 3.7 4.3 2.8 1.9
Changes from baseline
ESS 0.7 1.8 2.3 2.3 0.005b
FSS 0.0 0.6 0.8 1.0 0.07b
Beck Depression Inventory 0.4 3.5 1.1 3.2 NS
Beck Anxiety Inventory 0.5 5.2 0.1 1.8 NS
PSG: sleep efficiency,% 0.8 5.7 0.05.1 NS
PSG: sleep latency to NREM2, min 13.6 16.4 2.7 14.7 0.03b
MWT: mean sleep latency, min 0.4 6.2 8.4 9.6 0.04b
Actigraphy: awake per 24 h,% 0.3 4.7 1.9 3.8 NS
PVT: velocity, s 0.0 0.2 0.2 0.4 NS
PVT: no. of lapses 0.8 2.9 1.3 2.6 NS
Abbreviations: ESS  Epworth Sleepiness Scale; FSS  Fatigue Severity Scale; MWT 
maintenance of wakefulness test; NS  not significant; PSG  polysomnography; PVT 
psychomotor vigilance test.
a Mean values are given with SDs.
b Mann-WhitneyU test.
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The overall subjective estimation of patients on
vigilance impairment amelioration was similar in the
2 groups (table 2). These subjective self-estimations
did not correlate with the FSS, the ESS, or MWT
results. Depression and anxiety scale values did not
change from baseline in either group. Thus, treat-
ment—although improving objective measures of
sleepiness—had no impact on quality of life. This
may not be surprising, because 2.3 points on the ESS
is not clinically significant, although 8.4 minutes on
the MWT might be.
Side effects were similar in the 2 groups. One pla-
cebo patient reported a reduction in appetite, 1
modafinil patient reported nausea and mild and tran-
sient stomachache, and 1 modafinil patient reported
mild arthralgia in the shoulders.
DISCUSSION The main outcome of this first
double-blind, randomized, placebo-controlled study
that included electrophysiologic sleep laboratory tests
in 20 patients with TBI indicates that 100 to 200 mg
modafinil is effective and well tolerated in the treat-
ment of posttraumatic EDS but not of fatigue. ESS
values decreased by 2.3 points and mean sleep laten-
cies on MWT increased by 8.4 minutes under treat-
ment. Furthermore, patients with TBI who were
treated with modafinil stayed awake 1.9 hours longer
per day, whereas placebo-treated patients did not re-
veal an increase of their time awake. This potentially
important difference, however, remained nonsignifi-
cant in this small trial.
Several studies observed an improvement of EDS
with modafinil in a variety of disorders, including
narcolepsy, obstructive sleep apnea, and chronic shift
work.16-18 After TBI, EDS and fatigue are frequent
complications.4 Earlier studies showed a potential
benefit of modafinil for the treatment of posttrau-
matic vigilance impairment.19,20 Under treatment
with 100 to 400 mg modafinil (once every morning),
Teitelman reported increased wakefulness and atten-
tion of posttraumatic hypersomnia in 10 patients
who had closed TBI.19 Unfortunately, objective mea-
Figure 1 Flow diagram depicting the passage of participants through this randomized controlled trial
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sures such as MWT or mean sleep latency tests were
not performed, and study results were not controlled.
Our findings contrast with a recent randomized
questionnaire-based trial in more than 50 patients
with TBI who had posttraumatic EDS.20 These au-
thors did not find a beneficial effect of 400 mg
modafinil on fatigue and EDS. However, in this
study, electrophysiologic sleep laboratory studies in-
cluding polysomnography and vigilance tests have
not been performed, and other possible causes of vig-
ilance impairment have not been excluded by actig-
raphy. Furthermore, increased FSS or ESS scores at
baseline were not mandatory for inclusion in the
study. Because of these methodologic differences, it
is not possible to compare this study with our own
trial. In our trial as much as in this cited study, how-
ever, there is the possibility of a ceiling effect, where
no higher dose of modafinil would further improve
vigilance in our patients. However, because we only
administered 100 to 200 mg, we cannot rule out that
higher doses might add benefit for our patients.
In our study, the subjective estimation of treated
patients regarding an improvement of vigilance dur-
ing medication was not different from those who re-
ceived placebo. This may have 2 reasons: First, based
on findings in our earlier studies and in accordance
with other authors, we believe that many patients
with TBI tend to underestimate their sleep prob-
lems.4,21 In our first study on posttraumatic sleep-
wake disturbances, we found very low mean sleep
latencies on multiple sleep latency tests in patients
with TBI who reported that they would not be sleepy
at daytime.4 Likewise, in the present study, the effect
of modafinil on ESS values is smaller than in trials
examining patients with narcolepsy or sleep apnea,
whereas the improvement on the MWT is similar to
the findings in these disorders.16,17 Therefore, the
question whether patients with TBI develop a spe-
cific type of anosognosia toward sleep-wake distur-
bances remains to be elucidated in systematic studies.
Second, in this pilot study, we administered only 100
to 200 mg modafinil. We assume that higher doses
might have a higher and clinically more significant
impact on vigilance.
The lacking effect of modafinil on fatigue is re-
markable. Recently, a similar outcome was observed
in patients with Parkinson disease, with an improve-
ment of EDS but not of fatigue with modafinil treat-
ment.22 In fatigue related to multiple sclerosis or
diencephalic stroke, however, modafinil was effec-
tive.23 In general, fatigue is an ill-defined symptom
that probably is influenced by several factors, includ-
ing physical exhaustibility, sleep-wake disturbances,
and disorders of mood. Furthermore, it is not clear
whether fatigue and EDS belong to the same clinical
spectrum. Our result of effectiveness of modafinil for
EDS but not fatigue indicates that the 2 symptoms
are distinct entities, probably with different patho-
physiologic pathways.
AUTHOR CONTRIBUTIONS
Statistical analyses were performed by Christian R. Baumann.
DISCLOSURE
Dr. Kaiser, Dr. Valko, Dr. Werth, Ms. Thomann, and Ms. Meier report
no disclosures. Prof. Stocker has served on scientific advisory boards for
KCI Europe Holding BV and Baxter International Inc.; has received
funding for travel or speaker honoraria from Fresenius Medical Care and
Bio-Synthesis Inc.; and receives research support from the Swiss National
Foundation, SUVA Foundation, the Swiss Academy for Medical Sciences,
and Swisstransplant. Prof. Bassetti serves as Chief Editor of the Swiss
Archives of Neurology and Psychiatry and on the editorial boards of the
Journal of Sleep Research, Sleep Medicine, Somnology, and the Belgian Neu-
rological Journal; has served on scientific advisory boards for and received
speaker honoraria from Boehringer Ingelheim, Lundbeck Inc., Novartis,
Pfizer Inc, ResMed Inc., and UCB; receives research support from Lund-
beck Inc., Respironics, Inc., ResMed Inc., Vifor Pharma, and UCB; and
receives institutional research support from the Zurich Center for Integra-
tive Human Physiology and the Swiss National Science Foundation. Dr.
Baumann has served on scientific advisory boards for and received speaker
honoraria from Boehringer Ingelheim, UCB, and GlaxoSmithKline; re-
ceives research support from UCB, Cephalon, and Novartis; and receives
institutional research support from the Swiss National Foundation.
Figure 2 Changes from baseline in ESS and FSS values, and in mean sleep
latencies onMWT (in minutes)
ESS  Epworth Sleepiness Scale; FSS  Fatigue Severity Scale; MWT  maintenance of
wakefulness test.
Table 2 Overall subjective estimation
of vigilance impairment
(fatigue, excessive daytime
sleepiness) amelioration
Placebo Modafinil p Value (2)
Much better 1 0 0.23
Better 1 3
Somewhat better 1 3
Unchanged 7 3
Worse 0 1
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Background. Fatigue in patients with multiple sclerosis (MS) is highly prevalent and severely impacts quality of life. Recent
studies suggested that sleep-disordered breathing (SDB) significantly contributes to fatigue in MS. Study Objective. To evaluate
the importance of routine respirography in MS patients with severe fatigue and to explore the effects of treatment with continuous
positive airway pressure (CPAP). Patients and Methods. We prospectively assessed the presence of severe fatigue, as defined by a
score of ≥5.0 on the Fatigue Severity Scale (FSS), in 258 consecutive MS patients. Ninety-seven patients (38%) suffered from severe
fatigue, whereof 69 underwent overnight respirography. Results. We diagnosed SDB in 28 patients (41%). Male sex was the only
independent associate of SDB severity (𝑃 = 0.003). CPAP therapy in 6 patients was associated with a significant reduction of FSS
scores (5.8±0.5 versus 4.8±0.6, 𝑃 = 0.04), but the scores remained pathological (≥4.0) in all patients.Conclusion. Respirography in
MS patients with severe fatigue should be considered in daily medical practice, because SDB frequency is high and CPAP therapy
reduces fatigue severity. However, future work is needed to understand the real impact of CPAP therapy on quality of life in this
patient group.
1. Introduction
Although fatigue has been increasingly recognized over the
past two decades as one of the most frequent and most
debilitating symptoms in patients with MS, there are still
no insights into its neurobiological mechanisms, and current
treatment options are highly frustrating [1–4]. In clinical
practice, MS patients complaining about fatigue are usu-
ally first scrutinized for additional and potentially treatable
comorbidities, such as depression, pain, anemia, or sleep-
wake disturbances [5]. If there is no such cause of fatigue, the
patient is considered to suffer from “MS-related fatigue,” that
is, a disease-inherent symptom related to the underlying neu-
roimmunological and neurodegenerative processes, and off-
label symptomatic treatment with stimulants of the central
nervous system may be recommended [3].
Recently, the need to search for sleep-wake disorders
in MS patients has been reemphasized, as several groups
observed a significant correlation with fatigue [6–10]. Specif-
ically, sleep-disordered breathing (SDB) has been proposed
as a potential risk factor for fatigue in MS. In the last year, a
cross-sectional study in 48MS patients suggested a predispo-
sition for SDB [11], and two studies found that severe fatigue
in MS was significantly associated with SDB and respiratory-
related arousals [9, 12]. Furthermore, Coˆte´ et al. conducted
the first controlled, nonrandomized clinical treatment study
and reported a significant improvement of fatigue follow-
ing treatment of SDB and other sleep disorders [13]. Very
recently, Veauthier et al. were able to identify treatment of
sleep disorders in MS patients as independent predictor of
fatigue reduction [14].
Taken together, there is increasing amount of data sug-
gesting that SDB should be routinely screened for in all
MS patients with severe fatigue. We therefore prospectively
assessed the presence and severity of fatigue in consecutive,
unselectedMS patients seen in a tertiary center and suggested
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overnight respirography to MS patients with severe fatigue.
Patients with SDB were offered CPAP therapy. The main
purpose was to elucidate whether routine respirography can
be recommended as a screening method in MS patients with
severe fatigue and whether long-term CPAP therapy leads to
a clinically meaningful improvement of fatigue. In addition,
we aimed at examining potential predictive factors of SDB in
MS patients with fatigue.
2. Patients and Methods
This prospective study was conducted at the Neurological
Department of the Kamillus-Klinik in Asbach, Germany,
from October 2010 until March 2011. The study protocol has
been reviewed and approved by the local Institutional Review
Boards, and all patients gave written informed consent before
inclusion.
2.1. Subjects and Clinical Assessment. During the above-
mentioned period, we prospectively evaluated 258 consecu-
tive patients with multiple sclerosis (MS). The diagnosis of
MS was definite in each patient and was made according
to standard criteria [15]. The majority of patients suffered
from secondary progressive MS (87%) (SPMS), and 13% had
a relapsing remitting (RRMS) form. We measured fatigue
severity with the Fatigue Severity Scale (FSS), a self-
administered questionnaire with nine items which has been
validated for various neurological disorders including MS
[16, 17]. A final score greater than 4.0 is widely accepted
to indicate the presence of fatigue. For the purpose of
our study, we included only patients with severe fatigue
defined by a FSS score ≥5.0. The rationale for including only
patients with severe fatigue is given by the observation that
beneficial treatment effects of CPAP therapy are usually most
pronounced in patients with high levels of fatigue [18]. We
identified 97 MS patients with severe fatigue. Sixty-nine of
them agreed to undergo overnight respirography. We used
the Epworth Sleepiness Scale (ESS) to assess sleepiness, with
scores ≥10 indicating excessive daytime sleepiness (EDS) [19,
20]. Information on disease duration was taken from the
patients’ medical history.We estimated the severity of disease
disability using the Kurtzke Expanded Disability Status Scale
(EDSS) [21].
2.2. Sleep Studies. Overnight (from 10 p.m. to 6 a.m.) respi-
rography was performed using a portable device (EasyScreen
4.0, Respironixs, Germany), which measured nasal airflow,
pulse rate, arterial oxygen saturation (finger pulse oximetry),
and thoracic and abdominal movements. Respirography has
been validated previously in patients with ischemic stroke
[22]. Apnea was defined by a cessation of nasal airflow ≥10
seconds and hypopnea by a reduction of nasal airflow by
≥50% or ≥30%, when associated with an oxygen desaturation
≥4% [23]. Apnea-hypopnea index (AHI) was defined by
the mean number of apneas and hypopneas per hour. SDB
was diagnosed in patients with an AHI ≥ 5/h. SDB was
classified as mild (AHI 5–15/h), moderate (AHI 15–30/h),
and severe (AHI ≥ 30/h). Apneas were differentiated in
obstructive, mixed, and central apneas according to standard
criteria [23]. Apneas were obstructive if accompanied with
continuous respiratory effort, central if unaccompanied by
evidence of respiratory effort, and mixed if a central apnea
developed respiratory effort with evidence of obstruction
later in the apneic interval. A diagnosis of central sleep
apnea was made in patients, in whom >50% of all respiratory
events were central. In addition, calculation of the oxygen
desaturation index (ODI) was performed. The magnitude
of the oxygen desaturation considered for ODI was ≥4%.
The analysis was made automatically and corrected visually.
Titration of CPAP was performed during overnight video-
polysomnography. The optimal therapeutic pressure was
determined to eliminate snoring, apneic events with arousals,
and oxyhemoglobin desaturations in all body positions and
sleep stages. Patients received conventional CPAP therapy
(REMstar M series, Philips Respironics or SOMNOcom-
fort2, Weinmann). Reevaluation of FSS and ESS scores was
scheduled after a 6-month period of CPAP therapy, although
significant short-term relief of both fatigue and sleepiness can
be expected already after 3–6 weeks of CPAP therapy [18].
2.3. Statistics. Continuous data were expressed as means and
standard deviation (SD) and categorical variables as numbers
and percentage. All analyses were performed with the Sta-
tistical Package for the Social Sciences (SPSS, version 17.0).
For univariate analysis we used Student’s t-test (for numerical
scale variables) and 𝜒2-test (for nominal scale variables). To
identify predictors of SDB severity, we performed stepwise
multiple linear regression analysis for multivariate analysis,
with AHI as dependent variable and the following indepen-
dent variables: age, sex, disease duration, disease subtype,
EDSS, BMI, FSS, and ESS scores. Correlation analyses were
performed using the Spearman’s coefficient. Significance was
accepted at 𝑃 < 0.05.
3. Results
3.1. Demographic and Clinical Characteristics. Sixty-nine MS
patients with severe fatigue consented to overnight respirog-
raphy. The majority were female (70%); mean age was 49.8 ±
9.2 years (range: 21–75 years). BMI was 26.0 ± 4.9 (range:
17–40). Most patients were severely affected by the disease,
as reflected by a mean EDSS of 5.8 ± 1.4 (range: 1.0–8.5)
and mean disease duration of 13.7 ± 8.8 years (range: 1–33
years). The patient group that declined respirography (𝑛 =
28) showed similar demographic and clinical characteristics
(data not shown).
3.2. Sleep-Disordered Breathing. Overnight respirography
revealed a mean AHI of 9.3 ± 16.9/h and a mean ODI of
10.5 ± 14.7%. SDB was found in 28 MS patients (41%) and
was mild in 18 patients (26%), moderate in 3 patients (4%),
and severe in 7 patients (10%). SDB was obstructive in all but
one patient. MS patients with SDB were significantly older
(𝑃 = 0.01) and tended to be more often male (𝑃 = 0.06).
Likewise, AHI correlated with age (rho = 0.33, 𝑃 = 0.006) but
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Table 1: Demographic and clinical characteristics in severely
fatigued MS patients with and without sleep-disordered breathing.
No SDB (AHI < 5/h) SDB (AHI ≥ 5/h) P
n (%) 41 (59%) 28 (41%)
Female sex, n (%) 32 (78%) 16 (57%) 0.06
Age (y) 47.4 ± 8.3 53.3 ± 9.5 0.01
BMI 25.4 ± 5.2 26.8 ± 4.2 0.27
Disease duration (y) 13.8 ± 8.9 13.6 ± 8.8 0.92
Disease subtype 0.73
RRMS 3 6
SPMS 25 35
EDSS 5.9 ± 1.5 5.8 ± 1.3 0.79
FSS 5.7 ± 0.7 5.5 ± 0.9 0.36
ESS 9.4 ± 4.7 9.7 ± 3.8 0.79
EDS (ESS ≥ 10) 18 (44%) 17 (61%) 0.13
BMI: body mass index (kg/m2), EDS: excessive daytime sleepiness, EDSS:
Expanded Disability Status Scale, ESS: Epworth Sleepiness Scale, FSS:
Fatigue Severity Scale, RRMS: relapsing-remitting multiple sclerosis, SPMS:
secondary progressive multiple sclerosis.
not with EDSS, disease duration, or BMI. Table 1 provides the
remaining demographic and clinical characteristics (Table 1).
3.3. Excessive Daytime Sleepiness. The overall prevalence of
excessive daytime sleepiness in our patient group was high
(51%).The presence of excessive daytime sleepiness, however,
was similar between patients with and without SDB (61%
versus 44%, 𝑃 = 0.13). Even when comparing patients with
moderate-severe SDB and those without SDB, we did not
detect any differences in the prevalence of SDB (70% versus
44%, 𝑃 = 0.30). Similarly, there was no correlation between
ESS scores and AHI (𝑟 = −0.05, 𝑃 = 0.66).
3.4. Sex-Related Differences. The gender ratio (f : m) was
3.6 : 1 in patients without SDB, but the male proportion
significantly increased with more severe SDB (𝑃 = 0.005):
the ratio was 2.6 : 1 in mild SDB, 0.5 : 1 in moderate SDB, and
0.4 : 1 in severe SDB. BMIwas similar in bothmale and female
patients (25.3 ± 3.8 versus 26.3 ± 5.2, 𝑃 = 0.12), but AHI
was significantly higher in male patients (18.5 ± 24.7 versus
5.2 ± 9.9, 𝑃 < 0.001). Multiple regression analysis confirmed
that male sex was an independent associate of SDB severity
(𝑃 = 0.003). Figure 1 shows the different relative distribution
of SDB in male and female patients. Otherwise, the clinical
characteristics were similar in both sex groups (Table 2).
3.5. Evolution of FSS and ESS under CPAP Therapy. We
recommended CPAP therapy to all patients with an AHI ≥
10/h (𝑛 = 14). Nine patients agreed, but 3 of them did not
tolerate the device. The remaining 6 patients (2 with RRMS,
4 with SPMS) revealed a CPAP daily average adherence of
≥5 hours per night during the 6-month treatment. In these
patients, AHI decreased during CPAP therapy from 39.2 ±
26.3/h to 5.2 ± 3.6/h (𝑃 = 0.02), and the minimal SaO
2
improved from 71.5 ± 11.7% to 88.2 ± 1.9% (𝑃 = 0.02). EDSS
remained stable (6.3 ± 1.3 versus 6.3 ± 1.2). At followup after
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Figure 1:MaleMS patients with severe fatigueweremore frequently
affected by SDB than female MS patients with severe fatigue.
Table 2: Gender-related differences in MS patients with severe
fatigue.
Female Male P
n (%) 48 (70%) 21 (30%)
Age (y) 49 ± 9.3 51 ± 9.2 0.73
Disease duration (y) 14.4 ± 9.1 11.9 ± 7.7 0.16
Disease subtype 0.71
RRMS 7 2
SPMS 41 19
EDSS 5.9 ± 1.4 5.8 ± 1.4 0.78
ESS 9.7 ± 4.5 9.2 ± 3.8 0.65
EDS (ESS ≥ 10) 25 (52%) 10 (48%) 0.49
BMI 26.3 ± 5.2 25.3 ± 3.8 0.12
No SDB (AHI < 5/h) 32 (67%) 9 (43%) 0.06
AHI 5.2 ± 9.9 18.5 ± 24.7 <0.001
ODI 7.1 ± 7.9 18.1 ± 22.4 <0.001
SaO2 min (%) 78.9 ± 14.6 75.5 ± 19.1 0.58
AHI: apnea-hypopnea index, BMI: bodymass index, EDS: excessive daytime
sleepiness, EDSS: Extended Disability Status Scale, ESS: Epworth Sleepiness
Scale, ODI: oxygen-desaturation index, RRMS: relapsing-remitting multiple
sclerosis, SaO2 min: minimal O2 saturation, SDB: sleep-disordered breath-
ing, SPMS: secondary progressive multiple sclerosis.
6 months, CPAP therapy was associated with a significant
decrease of FSS scores (5.8 ± 0.5 versus 4.8 ± 0.6, 𝑃 = 0.04),
whereas ESS scores did not change (9.8 ± 3.5 versus 9.5 ±
3.0, 𝑃 = 0.61) (Figure 2). However, despite the significant
reduction of fatigue severity during CPAP therapy, FSS scores
remained pathologic (≥4.0) in all treated patients.
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Figure 2: Follow-up under long-term treatment with continuous positive air pressure (CPAP) reveals significant reduction of FSS scores but
not of ESS scores.
4. Discussion
Considering the increasing interest in SDB as a potential risk
factor for fatigue in MS, the primary goal of this prospective
investigation—so far the largest respirography study on
SDB in MS—was to understand whether routine overnight
respirography should be done in all MS patients with severe
fatigue.We found a SDB frequency of 41% amongMSpatients
with severe fatigue and demonstrated that CPAP therapy was
associated with a significant improvement of fatigue severity,
while sleepiness remained unchanged. Furthermore, only
male sex could be identified as an sindependent predictor
of SDB in MS patients with severe fatigue. Taken together,
these findings indicate that routine respirography should be
considered in this specific patient group, but future work is
needed to confirm our results and establish the exact benefit
of SDB treatment also in terms of quality of life.
Although the observed SDB frequency was rather high,
our study was not designed to estimate the prevalence of SDB
inMS or to compare its prevalence betweenMS patients with
and without fatigue, as we did not perform respirography in
MSpatientswith FSS scores<5.0 anddid not include a control
group.Moreover, comparison to other studies is hampered by
disparities of included patient cohorts, methodological and
technical differences, and heterogeneous definitions of SDB.
In this line, two recent studies on SDB and fatigue in MS
differedwith regard to the applied polysomnographic scoring
criteria: one group used the Rechtschaffen and Kales criteria
and the other study scored according to the 1999 American
Academy of Sleep Medicine Task Force [9, 12, 24]. The two
methods use different placement of EEG electrodes, which
may affect the scoring of respiratory arousals. Thus, several
reasons may account for the large discrepancy of reported
prevalence of SDB inMS patients with or without fatigue. For
instance, two earlier studies did not find any cases with SDB,
as defined by an AHI ≥ 5/h, among 37 and 10 MS patients,
respectively, although the majority of these patients suffered
from fatigue [25, 26]. On the other hand, Kaminska et al.
performed polysomnography in 37 MS patients with severe
fatigue, as defined by the same criteria as in our study, and
found severe SDB (AHI > 30/h) in 32%, relative to 8% among
25 MS patients without severe fatigue [12]. Using another
fatigue questionnaire, Veauthier et al. reported a SDB preva-
lence of 27% and 2.5% in 26 MS patients with fatigue and 40
MS patients without fatigue, respectively [9]. Finally, Braley
et al. reported a mean AHI of 17.0±18.8/h in 48MS patients,
a much higher number than in our study [11]. Overall, these
studies illustrate our uncertainty regarding prevalence and
severity of SDB in MS and its relationship to fatigue.
Six MS patients with SDB and severe fatigue showed
significant reduction of fatigue severity after 6 months of
CPAP therapy: FSS scores decreased from 5.8 ± 0.5 to 4.8 ±
0.6. In otherwords, long-termCPAP therapy resulted in a 17%
fatigue reduction. Our results are in line with the recent study
of Coˆte´ et al. who treated 17MSpatients with SDB and fatigue,
reporting a decrease of FSS scores from 5.0 ± 1.7 to 4.3 ± 1.7,
corresponding to a 13% amelioration [13]. In addition, the
reduction of mean FSS scores in both studies was >0.6, which
has been suggested by Putzki et al. as a “clinical significant”
improvement [27]. On the other hand, however, the final
FSS score was still above 4.0, which is a widely accepted
cut-off for fatigue [17]. Considering the high burden of MS-
related fatigue, any alleviation would certainly be desirable,
even if only marginal. However, by now we do not really
know to what extent the observed reductions of the FSS score
represent a benefit to affected patients, especially in terms of
quality of life. Worthy of mention, a multivariate analysis in
the study of Coˆte´ et al. failed to detect any improvement of
quality of life after CPAP therapy, as examined by the Physical
and Mental Component Summary Scale of the Short Form
(36) Health Survey (SF-36) [13]. The number of studies on
health-related quality of life in MS patients is very large, and
fatigue has been identified as an independent predictor [28–
30].Thus, the lack of improvement in quality of life challenges
the significance of CPAP therapy in MS-related fatigue. A
possible explanation could be that the level of depression,
which is an ever stronger predictor of quality of life in MS,
did not improve during CPAP therapy, thereby obscuring a
potential benefit [28–30].
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Additional considerations highlight the ambiguous rela-
tionship between fatigue and SDB in MS patients. First, we
currently lack any objective tool that enables us to quantify
fatigue. Thus, rating of treatment outcomes regarding fatigue
relies solely on subjective estimation. Second, and closely
related to the first point, a possible placebo effect cannot be
ruled out. As evidenced by a recent randomized, double-blind
controlled trial, the placebo effect of shamCPAP therapymay
be quite considerable: ESS scores decreased in the placebo
group from 15.2±4.0 to 11.9±5.9 (𝑃 = 0.001), corresponding
to an effect size of 0.82, but results of the Osler test did
not change [31]. Furthermore, the placebo group showed
also a significant improvement of several items of the SF-
36 [31]. Other groups confirmed this substantial placebo
effect of CPAP therapy on sleepiness and quality of life [32].
A few groups studied fatigue response to CPAP therapy
in SDB patients without underlying neurological disease,
generating similar results [33–35]. While most groups uni-
formly reported a significant improvement of fatigue during
CPAP therapy, the findings from 2 double-blind, randomized
controlled trials observed significant reductions of fatigue
scores also during placebo CPAP therapy [34, 35]. Recently,
Tomfohr et al. confirmed that long-term CPAP therapy
leads to a benefit on fatigue beyond placebo effects [18]. In
summary, these studies clearly illustrate the importance of a
randomized, placebo controlled trial in order to demonstrate
that the observed improvement of fatigue in MS after CPAP
therapy is more than a mere placebo effect.
An intriguing finding of our study is the lack of cor-
relation between sleepiness and SDB. Other groups made
similar observations in MS patients, regarding both subjec-
tive and objective measures of sleepiness [12, 36]. In general,
sleepiness is regarded as the main daytime consequence
of SDB, caused by repeated apnea-induced arousals, sleep
fragmentation, and reduced slow-wave sleep, and a marked
reduction of sleepiness has been demonstrated following
CPAP therapy [37]. The high prevalence of sleepiness in our
cohort and its persistence under CPAP therapy suggest that
SDB is not the main etiology of sleepiness in MS patients
with fatigue.The prevalence of most sleep-wake disturbances
in MS has been shown to be increased in MS compared
to the general population and may thus account for the
observed high prevalence of sleepiness [7]. On the other
hand, sleepiness and fatigue in MS—generally regarded as
two distinct symptoms—may share a common pathophysi-
ology. The observation that the correlation between FSS and
ESS scores in MS is much stronger than in subjects with
various sleep disorders is also supportive of this hypothesis
[38, 39].
Finally, our study demonstrates that sleepiness, BMI, and
disease severity are not useful predictors of SDB in MS
patients with severe fatigue. Conversely, male and elder MS
patients aremore likely to presentmoderate-severe SDB.This
illustrates that the presence of SDB among MS patients with
severe fatigue may clinically not appear as obvious as it is in
subjects with “classical” SDB.
We have to acknowledge several limitations. First of all,
the number of treated patients was small, making general
conclusions difficult. Second, we did not assess possible con-
founders, such as mood disorders, and did not measure the
effects of CPAP therapy on quality of life. Third, we did not
include a control group. Furthermore, the additional presence
of other sleep-wake disturbances has not been assessed.
The prevalence of most sleep disorders is increased in MS
patients [7], and effective improvement of fatigue in MS
patients may require tailored therapies of more than only one
sleep disorder [13, 14]. In particular, a recent meta-analysis
indicated that restless-legs syndrome is frequent in MS, with
reported prevalence of 12–58%, and restless-legs syndrome
appears to be associated with fatigue in MS [40]. Finally,
future studies should prefer polysomnography instead of
respirography, as the latter does not allow detecting apnea-
induced EEG arousals, and they might use additional fatigue
scales such as the Modified Fatigue Impact Scale (MFIS),
which has been shown to assess cognitive and psychosocial
functioning more accurately than the FSS [41]. Nevertheless,
we believe that our study provides an additional piece of
clinical experience to the current discussion on the role of
SDB in MS patients with fatigue.
In conclusion, our study confirms that SDB and fatigue
are associated features in MS and that SDB treatment leads
to a small yet statistically significant reduction of fatigue.
However, well-designed studies are needed to substantiate the
clinical relevance of this association, by proving that fatigue
reduction following CPAP therapy has a meaningful impact
on quality of life that goes beyond a mere placebo effect.
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